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This Supplement contains the abstracts of the invited speakers and oral pre-
sentations of the XVIII National Congress of the Italian  Society for the
Study of Headaches (SISC) “Prevention of headache suffering: from early
diagnosis to effective measures” – Taormina, Sicily, 7-10 October 2004.
Specific factors have prompted the SISC in preparing this Supplement at
this time: SISC is growing well, therefore, English abstracts can encourage
diffusion of the Society’s best scientific results in the field of headaches in
the last year. In addition, since the younger generations of Italian headache
researchers have greater international relationships, the Supplement seemed a
choice in line with their scientific life.
Finally, to publish the abstracts of the Congress in the SISC’s official
journal, now in its fifth year, represented a moment of pride and an opportu-
nity that had to be seized.
The main topics of the Congress centre on early headache diagnosis and
appropriate treatment as the targets in preventing headache chronicization.
The prevention of chronic headaches, in fact, represents the modern, impera-
tive task for both SISC and other multidisciplinary national and international
headache societies.
As President of the Congress it is a privilege to present this Supplement
and I sincerely hope that it will be received favourably by the headache com-
munity. I hope that it will stimulate headache research findings and con-
tribute to a greater visibility of the Society.
This volume is dedicated to the SISCs’ Past Presidents, Prof. Virgilio
Gallai and Prof. Franco Michele Puca, who had in common one characteris-
tic: the continuous search of new horizons towards which the Society could
work.
Lastly, I wish all the participants a pleasant and productive Congress.
Marcello Fanciullacci
President
Italian Society for the Study of Headaches
LECTURERS
THE SCIENCE OF MIGRAINE THERAPY FIVE YEARS AFTER
RECOGNIZING THE ROLE CENTRAL SENSITIZATION AND
CUTANEOUS ALLODYNIA PLAY IN THE PATHOPHYSIOLO-
GY OF THIS MALADY
R. Burstein
Departments of Anesthesia and Critical Care, Beth Israel Deaconess
Medical Center; Department of Neurobiology and the Program in
Neuroscience, Harvard Medical School, Boston, U.S.A.; e-mail:
rburstei@bidmc.harvard.edu
In recent years, we discovered that the network of neurons that sense pain
signals from the dura, changes rapidly during the course of a single
migraine attack and that the treatment of an attack is a moving target. We
found that if the pain is not stopped within 10–20 minutes after it starts,
the first set of neurons in the network, those located in the trigeminal gan-
glion, undergo molecular changes that make them hypersensitive to the
changing pressure inside the head which explains why migraine
headache throbs and is worsen by bending over and sneezing. We found
that if the pain is not stopped within 60–120 minutes, the second group
of neurons in the network, those located in the spinal trigeminal nucleus,
undergoes molecular changes that convert them from being dependent on
sensory signals they receive from the dura by the first set of neurons, into
an independent state in which they themselves become the pain genera-
tor of the headache. When this happens, patients notice that brushing
their hair, taking a shower, touching their periorbital skin, shaving, wear-
ing earrings, etc become painful, a condition called cutaneous allodynia.
Based on this scenario, we showed recently that the success rate of ren-
dering migraine patients pain-free increased dramatically if given before
the establishment of cutaneous allodynia and central sensitization. The
molecular shift from activity-dependent to activity-independent central
sensitization together with our recent conclusion that triptans ability to
disrupt communications between peripheral and central trigeminovascu-
lar neurons (rather than inhibiting directly peripheral or central neurons)
explain their clinical effects. Both our clinical and pre-clinical findings of
the last 5 years point to possible short- and long-term advantages in using
early-treatment approach in the treatment of acute migraine attacks.
MIGRAINE: A HISTORICAL AND ARTISTIC PERSPECTIVE
G. Zanchin
Headache Centre, Department of Neurosciences, University of Padua,
Padua, Italy; e-mail: giorgio.zanchin@unipd.it
This widely experienced ailment has possibly inspired artistic creative-
ness in some instances; much more frequently, it has been the subject
of written or pictorial representations by patients, sharing with us in
this way their peculiar suffering through a non verbal language.
What are the more interesting, although somewhat debated instances, in
which migraine has influenced art in its figurative but also written
expressions? Who were the main artists who were known, or presumed
to be migraineurs? Is this form of recurring ailment, eminently subjec-
tive and so intimately perceived, with its emotional as well as physical
involvement, teaching us emblematically about the comprehensive atti-
tude that should be adopted toward the patient in all his human aspects;
showing in our daily practice the relevance of caring along with curing?
CLINICAL AND PHARMACOLOGICAL IMPLICATIONS OF
THE NEW CLASSIFICATION OF HEADACHE
1,2G. Nappi, 1P. Giacomini, 1P. Marchione, 2C. Tassorelli
1Department of Neurology and Otorhinolaryngology, University of
Rome “La Sapienza”, Rome, Italy; 2IRCCS Institute of Neurology “C.
Mondino” Foundation, University Centre for the Study of Adaptive
Disorders and Headache (UCADH), Pavia, Italy; e-mail:
giuseppe.nappi@mondino.it
With the recent publication of the second edition of the Classification
of Headache Disorders (ICHD-II), the International Headache
Society (IHS) has accomplished the second act of a tremendous effort
in systematizing the clinical approach to headaches that started back
in 1988, with the realization of the first edition of the classification.
The 1988 IHS classification represented an absolute novelty in the
headache field, which, being based on a limited amount of evidence,
was expected to undergo a short-term revision. The revision was, in
fact, postponed for several years because it took the headache spe-
cialists a long time to become familiar with the new system and to
field-test it.
When the scientific community finally felt that enough evidence had
been collected for a second edition, the ICHD-II Subcommittee worked
intensively collecting and debating data, elaborating and discussing
proposals. The main body of the newly published ICHD-II is formed
by 4 parts: (1) Primary Headaches (Migraine; Tension-type Headache;
Cluster Headache and Other Trigeminal Autonomic Cephalalgias;
Other Primary Headaches); (2) Secondary Headaches (Groups V-XII);
(3) Cranial Neuralgias, Central and Primary Facial Pain and Other
Headaches (Groups XIII and XIV); (4) Appendix. 
The classification of primary headaches is descriptive (symptom-
based), while secondary headaches are classified according to the etio-
logical process. Based on the hierarchical model, already adopted in
the first edition, ICHD-II is equally intended for research and clinical
practice, for the headache specialist, and for the general practitioner.
All headache disorders are classified into major groups, and each group
is then subdivided one or more times, the desired detail of the diagno-
sis depending on the purpose and on the “user”.
As the first edition, ICHD-II diagnoses attacks, not patients, and it is
scarcely focused on the evolution of the disease. This may seem a lim-
itation in the usefulness of this taxonomic system in the clinical field,
however, the restriction was necessary because of the lack of evidence
on the evolution of the various forms of headache. The impact of genet-
ics upon ICHD-II was limited because available evidence does not
allow as yet the identification of monogenic entities within the present
clinically-defined heterogeneous phenotypes.
In order to fuel the virtuous circle represented by evidence-based tax-
onomic criteria that are improved by research findings and, in turn,
stimulate research advances, the ICHD-II committee has created the
Appendix, which describes a number of orphan disorders or proposals
of new forms that need validation.
CGRP ANTAGONISTS FOR THE TREATMENT OF MIGRAINE
H. Doods
Boehringer Ingelheim Pharma GmbH & Co. KG, Department of CNS
Research, Biberach, Germany; e-mail: henri.doods@bc.boehringer-
ingelheim.com
During migraine attacks, plasma levels of the potent vasodilator calci-
tonin gene-related peptide (CGRP) are elevated in migraine patients.
Preclinical data with the first non-peptide high affinity CGRP antago-
nist BIBN4096BS in animal models related to migraine will be
reviewed and discussed.
For instance, in the animal model, hemodynamic changes were
induced by either CGRP injection or electrical stimulation of the
trigeminal ganglion and facial blood flow changes (FBF) were moni-
tored [1]. Here, BIBN4096BS fully reversed the evoked vasodilation
with ED50s of 0.003 and 0.05 mg/kg in marmoset monkeys and rats,
respectively.
In healthy volunteers, a 2.5 mg dose of BIBN4096BS significantly
attenuated human α-CGRP-induced increase in cerebral blood flow.
The same dose relieved headache pain 2 hrs after the start of treat-
ment in 65.6% of migraine patients (versus 26.8% of placebo) in a
multicenter, double blind, placebo-controlled, randomized clinical
trial [2]. Together, the data demonstrate that counteracting CGRP
function during a migraine attack is a novel approach to treat
migraine headache.




1. Doods H, Hallermayer G, Wu D et al (2000) Pharmacological pro-
file of BIBN4096BS, the first selective small molecule CGRP
antagonist. Br J Pharmacol 129(3):420–423
2. Olesen J, Diener HC, Husstedt IW et al BIBN 4096 BS Clinical
Proof of Concept Study Group (2004) Calcitonin gene-related pep-
tide receptor antagonist BIBN 4096 BS for the acute treatment of
migraine. N Engl J Med 350(11):1104–1110
MIGRAINE IS A RISK FACTOR FOR SUB-CLINICAL BRAIN
LESIONS
M.D. Ferrari
Department of Neurology, Leiden University Medical Centre, Leiden,
The Netherlands; e-mail: m.d.ferrari@lumc.nl
Clinical series suggest an increased prevalence of cerebral infarction
and white matter lesions (WML) in migraine patients. Not known is
whether these lesions are prevalent in the general migraine population.
We conducted a population-based MRI study to determine the prevalence
of cerebral infarcts and WML in migraine cases from the general popula-
tion and to identify migraine characteristics associated with these lesions.
We randomly selected migraineurs with aura (MA, n=161), migraineurs
without aura (MO, n=134), and controls (n=140) who were frequency
matched to cases for age, sex, and place of residence, from a large pop-
ulation-based sample of Dutch adults aged 30 to 60 years. Brain MR
scans were evaluated for infarcts, by location and vascular supply terri-
tory, and for periventricular and deep WML (DWML). The risk (odds
ratio (OR)) of these brain lesions was examined by migraine sub-type
(with or without aura) and monthly attack frequency (<1 attack, ≥1
attack), controlling for cardiovascular risk factors and use of vasocon-
strictor migraine agents. All participants underwent a standard neuro-
logical examination; no abnormalities were found.
Compared to controls, migraine cases were at increased risk for
infarcts in the cerebellar region of the posterior circulation territory.
The adjusted risk varied by migraine sub-type and attack frequency:
the highest risk was in MA with ≥1 attack/month. Among women, the
risk for high-DWML-load was increased in migraineurs; this risk
increased with attack frequency (highest in those with ≥1
attack/month), but was similar in migraine with or without aura.
These population-based findings suggest that migraineurs with and
without aura are at increased risk for sub-clinical brain lesions. The
more attacks, the greater the risk. Given the high prevalence of
migraine, these findings are of potential public-health importance and
may have implications for management guidelines for migraine.
ADVANCES IN NEUROIMAGING OF PRIMARY HEADACHES
P.J. Goadsby
Institute of Neurology, The National Hospital for Neurology and
Neurosurgery, London, UK; e-mail: peterg@ion.ucl.ac.uk
Headache is perhaps the most common of medical problems and may
be considered as either primary, where headache and the associated
symptoms are the key problem, such as migraine and cluster headache,
or secondary, where headache is due to some clear pathological process
[1]. Both clinical problems share an underlying anatomy and pain pro-
cessing physiology that is concentrated around the projections to the
trigeminal nucleus. Modern neuroimaging is shedding considerable
light on the age-old neurological question for primary headache: where
is the lesion?
Pain from intracranial sources arises from the dura mater and the large
blood vessels with the brain substance being insensate for the most
part. Pain-producing intracranial structures are innervated by the first,
ophthalmic, division of the trigeminal nerve and much of the dural
innervation sweeps back gathering together in the middle cranial fossa
to form the tentorial nerve which joins the ophthalmic division shortly
before it enters the trigeminal ganglion. Intracranial structures below
the tentorium cerebelli are innervated by branches of the C2 root. It has
now been shown clearly in experimental animals that both supratento-
rial and infratentorial pain projections end up synapsing on second
order neurons in the trigeminal nucleus caudalis and the superficial
dorsal horns of C1 and C2, a functional group of neurons collectively
called the trigeminocervical complex [2]. This pattern of innervation
leads to the well-known referral patterns of the many headache syn-
dromes that do not respect the cutaneous innervation patterns of the
head. An important concept in the context of the innervation of the
pain-producing intracranial structures is that vascular change is sec-
ondary to neural activation so that migraine and cluster headache
should properly be referred to as neurovascular headaches not as vas-
cular headaches [3].
Positron emission tomography (PET) during acute migraine has shown
activations, increases in regional cerebral blood flow, in regions known
to be involved in pain, such as anterior cingulate cortex and insula cor-
tex. Furthermore, PET studies demonstrate activations in the brainstem
in the dorsal midbrain and dorsolateral pons [4, 5] that are not seen in
other primary headaches, such as cluster headache [6]. These data sug-
gest that brainstem areas are either fundamental to the attack onset or
to its resolution; certainly they are particular to migraine. Brain imag-
ing offers insights into migraine pathophysiology by studying the prob-
lem in humans. An understanding of the pathophysiology of migraine
must ultimately result in better patient management.
References
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INVITED SPEAKERS
HEADACHE MANAGEMENT IN PUBLIC HEALTH CARE OF
THE CALABRIA REGION PSR 2004/2006
R. Iannacchero, E. De Caro
Regional Headache Study Centre, “Pugliese-Ciaccio” Hospital,
Catanzaro, Italy; e-mail: rosarioiann@tiscali.it
Introduction Headache is the most common symptom that patients
complain of to neurologists. Headache specialists play an important
role in patient referral, physician education, improving headache diag-
nosis and optimizing treatment within primary care. Primary care plays
an important role and contributes to improve headache management.
Materials and methods During the period October to December 2002,
a survey was conducted on a random sample of 500 general practition-
ers’ (GPs) in Calabria. The questionnaire included questions focusing
on GPs demographics and practice characteristics.
Results Of 500 questionnaires distributed, 455 responses were
received for a response rate of 91%. Results of logistic regression
analysis, performed on the responses given by GPs who knew that the
cost-benefits analysis examined the costs and benefits of treatments on
patients’ health status, indicated who had a fewer number of years in
practice (OR=0.96; 95% C.I.=0.93–0.99; p<0.019), who attended
courses on epidemiology or evidence-based medicine (OR=1.66; 95%
C.I.=1.03–2.69; p=0.038), and who would not modify the patient’s
treatment when scientific evidence indicated that it was more expen-
sive than the new treatment (OR=0.72; 95% C.I.=0.58–0.89; p=0.003).
Two-thirds of those samples (65%) thought that disability in headache
patients was of significance to illness diagnosis and regression analy-
sis showed that GPs who disagreed that the clinical approach to
migraine required a clinical effectiveness evaluation by performing
controlled clinical trials (OR=0.51; 95% C.I.=0.32–0.82; p=0.0005),
who were older (OR=1.63; 95% C.I.=1.14–2.31; p=0.007), and who
were female (OR=0.52; 95% C.I.=0.28–0.97; p=0.039), were signifi-
cantly more likely to believe that disability is a prominent diagnostic
feature in headache patients.
Discussion Despite a number of important advances in the diagnosis
classification, and treatment of headaches over the past decade, there is
still widespread under-consultation, under-diagnosis, and under-treat-
ment of headaches in primary care. In our survey, 70% of GPs per-
formed preventive treatments for headache patients in their practice
and the results of regression analysis showed that this took place in a
primary-practice setting. Patients in a primary-practice setting may
therefore be more likely to benefit from behavioural interventions than
patients seen in subspeciality headache clinics. This pattern reflects 3
important and persistent barriers to improved headache care: failure to
consult, failure to appreciate disease severity, and failure to recognize
and assess the impact of headache on the sufferer’s quality of life.
Conclusions Improving communication between patients, physicians
and headache specialists will help achieve better outcome in terms of
recognition of headache severity and treatment needs. Continuing edu-
cation and raising awareness of the impact of headache will help over-
come barriers to migraine care and improve migraine management.
ORGANIZATIONAL EVOLUTION OF THE HEADACHE CEN-
TRES: FROM EARLY DIAGNOSIS TO EFFICACY MEASURES
A. Rodio, S. De Filippis, P. Santi, G. Coloprisco, P. Martelletti
Regional Referral Headache Centre, II School of Medicine,
Sant’Andrea Hospital, University of Rome “La Sapienza”, Rome,
Italy; e-mail: paolo.martelletti@uniroma1.it
The history of public assistance in the multidisciplinary field of
headache disorders began in Italy in the 1950s, with the opening of the
Headache Centre in Florence, where the first theoretical-practical edu-
cational courses took place for many of us. After this staging post,
many headache centres were born, and today they are regarded as the
“driving force” for the diffusion of the assistance standards: Pavia,
Turin, Rome, Milan, Parma, Vicenza, etc.
At the end of the 1970s (SISC headache educational course, Belgirate,
1977), we began discussing the definition of assistance standards for a
correct Headache Centre organization. 
Afterwards, it came to an often indiscriminate use of inpatient admis-
sion and neuroimaging examinations, to effectuate a screening of
headache patients, who often bring the “indulgent” doctor to create a
diagnostic, frustrating loop, resorting to the umpteenth diagnostic test,
which is more or less useful and reliable, and always returning to the
therapeutic starting line. Nunc, quid agendum?
In this sea of diagnostics according to the criteria suggested by the dif-
ferent IHS classifications, the creation of Headache Centres of excel-
lence, of I, II, III level (SISC 1980s), put an efficacious and useful
brake on the expenditure of resources.
The Regional Reference Centres for Headaches – those operative at a
national level are here alphabetically listed – L’Aquila, Pavia, Milan,
Rome, Vicenza, seem now to be able to offer an organizational model
integrated with structures which are merely ambulatory, with day
hospital admission only for weaning therapies, rehabilitation proce-
dures, or targeted diagnostics. We have to offer a comprehensive
response to the increasing health requirements in the headache disor-
ders area, yet respecting the mandatory and sometimes unwelcome
rules of both the DRG and LEA (Essential Levels of Assistance).
Both the appropriateness of admission for headache disorders and
their payment will become the operative challenges, to allow the
extension to every region, of a complete public assistance for chron-
ic headache patients.
Further information
To consult and examine in detail DRG, LEA and Headache Disorders,
visit online the official sites of the Ministry of Health, dedicated to the





INTERUNIVERSITY CENTRES AND SCIENTIFIC RESEARCH:
EXPERIENCE OF THE PAVIA CENTRE
1G. Sandrini, 2F. Facchinetti, 3G.C. Manzoni, 4E. Sternieri, 1,5G. Nappi
1Department of Neurological Sciences, IRCCS, “C. Mondino”
Foundation, University Centre for Headache and Adaptive Disorders,
University of Pavia, Pavia, Italy; 2Mother-Child Department,
University of Modena and Reggio Emilia, Modena, Italy; 3Neurologic
Clinic, University of Parma, Parma, Italy; 4Headache Centre,
Toxicology and Clinical Pharmacology Section, University of Modena
and Reggio Emilia, Modena, Italy; 5Department of Neurology and
Otorhinolaryngology, University of Rome “La Sapienza”, Rome, Italy;
e-mail: giorgio.sandrini@unipv.it
SOCIAL BURDEN OF MIGRAINE: A HEADACHE CENTRE
EXPERIENCE
R. Cerbo, C. Mostardini, G. Bruti, F. Di Stani, V. Villani, V. Rondelli
Pain Centre “Enzo Borzomati”, Headache Unit, Department of
Neurological Sciences, University of Rome “La Sapienza”, Rome,
Italy; e-mail: rosanna.cerbo@uniroma1.it
Migraine is a common and debilitating condition that affects 8% to
12% of the general population. Epidemiologic studies show that
migraine affects 28 million Americans, approximately 18% of women
and 6% of men, with a higher prevalence in those who are white.
Migraine is a major cause of absenteeism from and decreased produc-
tivity at work, exerting also a significant burden on the individual in
terms of disability and reduced quality of life [1–3].
J Headache Pain (2004) 5:S5–S26
DOI 10.1007/s10194-004-0093-6 P R E F A C E
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In addition to the impact on an individual’s life, the cost of migraine is
also high. The cost of a disease derives from the burden of illness on
the patient, their family, and society. The cost of migraine is high for
both patients and society. The annual direct cost of migraine, including
all medical care and possible economic repercussions for the patient (in
the case of private health care) or the state (public health care), is about
$1 billion; some studies have estimated the indirect costs as high as
$9.6 billion in the United States [3–6].
Even if triptans are more expensive than NSAIDs, Lofland showed that
in the 6 months after sumatriptan therapy was initiated, health care
resource use and time lost from workplace productivity and nonwork-
place activity were reduced, while health-related quality of life and
patient satisfaction scores improved for the managed care migraineurs
enrolled in this study [3].
Otherwise, triptan administration is not the only solution for knocking
down the burden of migraine. It is indispensable to reduce the misdi-
agnosed and under-treated migraine. Our group, working in the
Emergency Department, found that in 90% of patients migraine was
misdiagnosed and under-treated; a correct diagnosis reduced the direct
costs (-50% neuroimages required) and improved the health-related
quality of life of patients.
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THE EXPERIENCE OF A TERRITORIAL HEADACHE CENTRE
IN A NEUROSCIENCE DEPARTMENT: THE SYNERGY WITH
GENERAL MEDICINE
1G.B. La Pegna, 1E. Cumbo, 2V. Saporito, 3C. Morreale, 4A. D’Agati
1Neuroscience Department, A.S.S. 2, Caltanissetta, Italy; 2Neurology
Service, District of Bagheria, A.S.L. 6, Palermo, Italy; 3Neurological
Unit, “Enrico Albanese” Hospital, A.S.L. 6, Palermo, Italy; 4N.P.I.
Department, A.U.S.L. n. 3, Catania, Italy; e-mail: g.lapegna@libero.it
Introduction Headaches are disabling and very diffuse pathologies with
a remarkable socio-economic burden. On the basis of statistical data
from the major industrialized countries, most patients do not consult a
physician, but resort to self-medication or tolerate the headache; when
they consult a physician, they generally consult a General Practitioner
(GP). For this reason, GPs serve a basic role and frequently are the first
stage in the route of medical care, especially in Italy, where they control
the patient’s admittance to the specialized health-care system.
Unfortunately, in agreement with the literature, our experience confirms
that GPs do not always, adequately, play their role of “filter”, because of
their diagnostic-therapeutic mistakes with inappropriate investigations
and inefficacious therapies. In contrast, GPs sometimes do not get the
consistent support of the specialist and they often judge Guidelines as too
difficult to apply. To improve relations between the GP and Specialist, we
think it is convenient to make more frequent professional contacts to
transform the GP into an active element in the management of the patient,
through the activation of different instruments of communication.
Methods We identified the following instruments: (1) A report about
our patient’s management, to send to the GP with the object of sharing
diagnostic-therapeutic decisions, avoiding unnecessary diagnostic
assessments, and limiting, as far as possible, pharmacological compli-
cations deriving from the interactions with drugs taken for associated
pathologies; (2) Meetings for information and professional training on
Headaches and Guidelines to assure a very good and lasting support of
the GP to the clinical statement suggested by our Centre; (3) The real-
ization of screening by means of a few “key” questions, according to
Lipton’s experience [1], that GPs will address to their own headache
patients to identify the migraineurs.
Discussion The collaboration between a Territorial-Specialist and GP
is the basis of a medical net care system that is as valid as it is able to
identify patients and to take them through a reliable and efficacious
clinical course. The sensitization and the involvement of the GP aims
at identifying patients on the basis of IHS criteria and the methods
specifically selected for the GP. In this way they will be not only the
first examiners but, thanks to their increased efficiency, also the only
filter of the patients referred to the territorial headache centre, which is
recognized as the main structure of diagnostic investigation. 
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THE GENOMEUTWIN-MIGRAINE PROJECT
1P. Barbanti, 2L. Nisticò, 2A. Stazi
1Department of Neurological Sciences, University of Rome “La
Sapienza”, Rome, Italy; 2National Centre of Epidemiology, Surveillance
and Health Promotion, Section of Genetic Epidemiology, National
Institute of Health, Rome, Italy; e-mail: piero.barbanti@uniroma1.it
European populations and epidemiological cohorts are of special
interest in the current era of genomic research aiming to characterize
the background of common human diseases. The genome sequence,
detailed information of genetic variations between individuals, high-
throughput molecular technologies, and novel statistical strategies
create new possibilities to define genetic and life-style risk factors
behind common health problems. Studies of large population cohorts
are needed to transform the genetic information into a detailed under-
standing of the predisposing factors in diseases affecting most human
populations. 
European twin cohorts provide a unique competitive advantage for
investigations of the role of genetics and environment or life style in
the etiology of common diseases. The GenomEUtwin applies and
develops new molecular and statistical strategies to analyse unique
European twin and other population cohorts to define and characterize
the genetic and environmental components underlying diseases like
obesity, migraine, coronary heart disease, and stroke, representing
major health-care problems worldwide. This project is supported by
the European Commission under the programme Quality of Life and
Management of the Living Resources of the 5th Framework Programme
and involves, among other countries, Italy. Since 2001, the National
Institute of Health of Italy is the repository of the National Twin
Registry, which is the world’s largest population twin registry, com-
prising approximately 650000 probable twin pairs born and resident in
Italy until December 31, 1995.
With the availability of this registry and the high prevalence of
migraine in the general population, an Italian study on twins affected
by migraine will better define the impact of genetic and environmental
factors on the etiology and pathophysiology of the disease. The large
size of the Italian population and its rich genetic heterogeneity could in
fact expand the present knowledge on migraine genetics. Moreover, the
diffusion of Headache Centres throughout Italy may allow the identifi-
cation of wide cohorts of migraine patients. The GenomEUtwin-
migraine project will consist of the following steps: (1) identification
of all probable twin pairs among migraine patients referred to the
National Institute of Health from selected Headache Centres by match-
ing the database of patients with the National Twin Registry; (2) direct
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interview of all twin pairs in whom at least 1 subject is affected by
migraine (affected twin pairs) by means of specific registry and med-
ical questionnaires; (3) neurological and physical examination and
blood collection from all affected twin pairs; (4) genetic analysis with
creation of a biological bank; and (5) statistical analysis.
FOOD AND HEADACHE: REAL FACT OR MYTH?
L. Savi, P. De Martino
Department of Neurosciences, Neurology III, Primary Headache
Centre, University of Turin, Molinette Hospital, Turin, Italy; e-mail:
lsavi@molinette.piemonte.it
A link between headache and food has been supposed since ancient
times. In the past, nausea and vomiting during a migraine attack were
often considered related to the previous consumption of certain foods.
Nowadays, many patients, and a great number of doctors too, think that
certain foods may trigger headache attacks, but the effective role of
dietary constituents as triggers is still a matter of an intensive debate.
Among primary headaches, migraine is certainly the subject of the
greatest number of studies regarding this aspect.
In 1972, Dalessio introduced the term “dietary migraine”, to clearly
distinguish those forms in which some particular kind of food is rec-
ognized as a trigger of the attacks.
Situations in which the headache attacks are triggered exclusively by
the consumption of a particular food are clearly distinguished from
others, in which, other triggers may be recognized besides food.
According to many studies, about 30% of migraine patients report that
there is a temporal relation between their headache attacks and the pre-
vious consumption of certain foods, especially cheese, chocolate, cit-
rus fruits, and alcoholic drinks.
Unfortunately, until now, double-blind challenge studies have not con-
firmed these observations.
The mechanism by which foods might trigger a headache attack is still
very far from being clear.
The incriminated foods are disparate and to date, a single common
chemical entity has not yet been found.
Hypotheses have been made, over the years (allergic mechanism, meta-
bolic alteration of some phenolic compound, vasoactive amine, altered
serotonin release from platelets, chemical entities acting on H1-
Histamine receptors, and as 5-HT2 serotonin receptor agonists). None
of these have been found to be true.
Tension-type headache (TTH) attacks have always been considered not
to be linked to food consumption, due to TTH’s completely different
pathogenetic mechanism.
Recent studies, however, showed that about 25% of TTH patients
report that certain kinds of foods may trigger their attacks.
Finally, in cluster headache, alcoholic drinks are the only recognized
dietary factor which may trigger the attacks during the cluster period.
Further studies are needed to answer these questions. These kind of stud-
ies, however, are difficult to perform, due to a series of variable factors.
If the role of food as a trigger of headache attacks could be more clear-
ly defined, the possibility of a more specific therapeutic approach
would arise, and this could lead to a better quality of life for patients.
MIGRAINE AND COELIAC DISEASE
1A. Gasbarrini, 1M. Gabrielli, 2G. Fiore, 1P. Pola, 3G. Di Trapani, 
2M. Giacovazzo, 1G. Gasbarrini
1Department of Internal Medicine, University of Rome “Cattolica del
Sacro Cuore”, Rome, Italy; 2Department of Internal Medicine,
University of Rome “La Sapienza”, Rome, Italy; 3Department of
Neurology, University of Rome “Cattolica del Sacro Cuore”, Rome,
Italy; e-mail: agasbarrini@rm.unicatt.it
Objectives Coeliac disease (CD) is a genetically-determined chron-
ic inflammatory intestinal disease induced by a gluten environmental
precipitant [1]. Subclinical CD has been associated with various neu-
rological disorders (i.e., neuropathy and cerebellar ataxia) [1].
Recent reports suggested a possible association between CD and
migraine [2]. The aim of our study was to assess CD prevalence in
migraine patients, regional cerebral blood flow in migraine patients
with and without CD, and effects of gluten-free diets on migraine
patients with CD.
Materials and methods Ninety migraine patients (63 F/27 M, 37±8
yr) were consecutively enrolled; 236 blood donors (147 F/89 M, 35±9
yr) without migraine history were the controls. Serum anti-transgluta-
minase and anti-endomysial antibodies were measured in all partici-
pants. In positive cases, diagnosis was confirmed endoscopically.
Patients with CD underwent gluten-free diets and were under observa-
tion for 6 months. A brain SPECT study was performed before and
after gluten-free diet.
Results Four of 90 (4.4%) migraine patients were positive for coeliac
disease compared to 0.4% of controls (p<0.05). One patient did not
have any migraine attacks during the entire follow-up period; an
improvement in migraine frequency/duration/intensity was observed in
the remaining 3. SPECT studies showed a regional baseline reduction
of brain tracer uptake in all 4 patients; it completely disappeared after
a successful gluten-free diet.
Discussion Possible mechanisms behind this association are: (1) autoim-
mune phenomena: serum antibodies from patients with CD strongly
react with human brain blood-vessel structures in vitro [3]; (2) a chronic
strong release of cytokines and molecules with vasoactive properties
from the gut of patients with active CD [4].
Conclusions This study suggests an association between migraine and
CD. If larger randomized controlled trials will confirm these prelimi-
nary findings, serological screening for CD could be proposed as part
of migraine management.
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OSMOPHOBIA IN MIGRAINE AND TENSION-TYPE
HEADACHE
1F. Dainese, 1F. Maggioni, 1F. Mainardi, 2M. Trucco, 1E. Mampreso,
1G. Zanchin
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The diagnosis of primary headache is based on the presence of codified
clinical features referred by the patient; nowadays, not a single pathog-
nomonic criterion has been identified. Clinical experience shows that
intolerance to smell is commonly mentioned by migraine patients. In
the II century B.C. Arethaeus the Cappadocian already asserted that the
sense of smell was altered during the course of an attack, and in the
XIX century Gowers, noticed that “a peculiar odour” could be a
headache trigger. Despite this, the relationship between osmophobia
and migraine has not been studied in depth. We recruited consecutive
patients from our Headache Centre with diagnosis of migraine with
aura (MA) and without aura (MO) and tension-type headache (TTH).
Patients with two or more forms of primary headaches were excluded.
Four hundred and ninety-six patients participated in the study (age 37.5
years ±11,8); of whom, 359 MO, 47 MA, and 90 TTH (69 episodic; 21
chronic). Among migraine patients, 42.9% with MO (154/359) and
40.4% with MA (19/47) reported osmophobia during the attacks; none
among the 90 TTH patients suffered this symptom. As an offending
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smell, food-related odour was mentioned by 51% of migraine patients
with osmophobia, perfumes by 64%, cigarette smoke by 58%, and
other types of smells by 6%. The olfactory stimulus triggered the attack
in 11%. Cigarette smoke and women’s perfumes were the smells more
frequently indicated. We conclude that osmophobia appears as a very
specific marker to discriminate adequately between migraine (MO and
MA), and tension-type headache.
VIDEO DISPLAY TERMINALS EXPOSURE AND HEADACHE
1E. Pucci, 1S. Buscone, 1G. Sances, 1S. Mazza, 1C. Tassorelli, 
1G. Sandrini, 1,2G. Nappi
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Introduction In the past two decades remarkable changes have
occurred in the workplace, above all as a consequence of the use of
video display terminals (VDT). More frequently, headache muscu-
loskeletal complaints, eye discomfort, palpitation and precordial pain,
depressed mood, irritability, sleep disorders, lack of appetite, sweating
and skin symptoms have been detected among users of VDTs.
Objective The aim of the present study was to evaluate workers’ expo-
sure to VDT as a risk factor for developing headache.
Methods The study was carried out on 86 healthy subjects, 43 VDT
users (33 females, 10 males; mean age 40.7 years ±9.04) and 43 non-
VDT users (34 females, 9 males; mean age 40.1 years ±9.1), employ-
ees from “IRCCS Mondino Foundation, Pavia”. For each patient we
collected: time of use, weekly VDT exposure, and clinical data.
Headache patients were evaluated by a headache diary based on IHS
classification.
Results In the VDT users group, 51.1% were affected by headache (13
MWOA, 7 ETTH, 1 MWA and CH), 84.4% referred visual distur-
bances and 60.5% visual disturbances with headache. In the non-VDT
users group, 40% referred headache (12 MWOA, 6 ETTH), 46.6%
referred visual disturbances and 66.6% referred visual disturbances
with headache.
Conclusions In our study no difference in developing a headache was
found between VDT users and non-VDT users. However, we found
evidence that in the group of VDT users with headache, 69% present-
ed headache “de novo” or worsened after 5 years of VDT use.
Therefore, we conclude that the prolonged exposure to VDT represents
a facilitating or aggravating factor in headache, that when present
results in visual and/or ocular disturbances.
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NEW INSIGHTS INTO TRIGEMINOVASCULAR ACTIVATION
IN MIGRAINE: A ROLE FOR SECRETONEURIN
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Background Numerous experimental evidence supports the role of the
33 amino acid neuropeptide secretoneurin in neurogenic inflammation
[1]. The involvement of this neuropeptide in trigeminovascular activa-
tion underlying migraine attacks has never been investigated.
Objective To determine the levels of secretoneurin in the internal jugu-
lar blood taken from migraine without aura (MwoA) patients assessed
during attacks and to verify the relation between these levels and those
of the end-products of nitric oxide, the nitrites, and those of endothelin
(ET)-1.
Patients and methods Ten MwoA patients were admitted to the
hospital during attacks. Internal jugular venous blood samples were
taken immediately after catheter insertion, at 1, 2, and 4 hours after
attack onset, and within 2 hours from its cessation. The levels of
secretoneurin and ET-1 were measured by sensitive radioim-
munoassays, those of nitrites by high-performance liquid chro-
matography.
Results A significant increase in secretoneurin levels was found in the
internal jugular venous blood of MwoA patients compared to the time
of catheter insertion (ANOVA: p<0.0001) with a peak at the first and
second hours (p<0.02 and p<0.01). A parallel increase in nitrite levels
was observed at the same time-points, which were correlated with the
levels of secretoneurin (R=0.51, p<0.01 and R=0.62, p<0.03). Higher
levels of ET-1 were found at each time of attack with respect to the
time of catheter insertion but no correlation was evident between ET-1
values and those of nitrites and secretoneurin.
Discussion The present study suggests the involvement of secre-
toneurin in the pathogenic events accompanying trigeminovascular
activation in migraine. This neuropeptide seems to play a role in stim-
ulating endothelial cells as suggested by the increased levels of nitrites.
This action on cerebral endothelium can also be exerted in concert with
calcitonin gene-related peptide [2]. The rise in ET-1 levels in the jugu-
lar blood seems to be a response to shear stress, instead of being a spe-
cific compensatory response to the effect of secretoneurin on cerebral
endothelium. 
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NEUROBIOLOGY OF CHRONIC MIGRAINE
I. Rainero
Neurology III, Headache Centre, Department of Neuroscience,
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Objective To present a systematic review of the present status of
knowledge about the neurobiological mechanisms underlying transfor-
mation of episodic migraine into chronic migraine.
Results Chronic migraine (CM), formerly known as transformed
migraine, is a headache disorder that affects 2–3% of the general pop-
ulation. It is particularly frequent in tertiary care structures and is an
important clinical problem for headache specialists. Analgesic overuse,
sleep disturbances, depression, and anxiety are often comorbid with
CM. The costs and burden of CM are significant. 
The pathophysiology of CM is still poorly understood. Within the
last 2 decades there has been an explosion of new information on the
mechanisms underlying chronic pain. Neurobiological studies have
provided new insights into the pathogenesis of chronic migraine.
Genetic factors play an important role in CM but the types and the
number of genes involved in the disease are, at present, unclear.
Certain features of chronic migraine, namely, increased headache
frequency, expansion of headache area, and cutaneous allodynia,
may imply sensitization of nociceptive neurons in the trigeminal
pathway. Neurophysiological studies have shown that repetitive acti-
vation of the trigeminal nerve can lead to a biological and function-
al change in trigeminal nucleus caudalis neurons, characterized by a
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HABITUATION IN SHORT-LATENCY EVOKED POTENTIALS
A. Ambrosini, F. Pierelli
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Evoked potentials were extensively studied in migraine during the last
decade. Almost every modality of stimulation has been used, but par-
ticularly visual and auditory stimuli. Compared to all other electro-
physiological measures performed in migraineurs, habituation of
evoked, i.e., amplitude reduction during sustained stimulation, was
most consistently found abnormal interictally. There is no habituation,
or even potentiation, of pattern-reversal visual evoked potentials (PR-
VEP) in the N1-P1 and P1-N2 components during sustained pattern-
reversal stimulation in migraineurs between attacks, compared to
healthy volunteers [1]. This lack of habituation normalizes during the
attack [2] and is present also when using other sensory modalities, such
as auditory [3] and somatosensory stimuli [4]. Besides habituation,
another interesting electrophysiological pattern interictally abnormal in
migraine is the intensity dependence of auditory evoked potentials
(IDAP). IDAP is indeed high in migraineurs resulting in a steep ampli-
tude-stimulus intensity function slope, but it is supposed to be as well
a mere consequence of lack of habituation of the auditory evoked cor-
tical potential [3].
Although habituation is a complex neurobiological phenomenon, it
might depend, for cortical evoked potentials, on the cortical pre-activa-
tion excitability level. According to the “ceiling theory”, a low pre-acti-
vation level of sensory cortices allows a wider range of suprathreshold
activation before reaching the “ceiling” and initiating a “reducing”
response, i.e., habituation. This theory, applied to evoked potential
findings in migraineurs, could explain both the low first block ampli-
tude for most evoked potentials and the lack of habituation on trial rep-
etition. The pre-activation level of cortical excitability depends on the
so-called “state-setting, chemically addressed connections” that origi-
nate in the brainstem and involve serotonin and noradrenaline as trans-
mitters. Low interictal activity of these systems, especially of the
raphe-cortical serotonergic pathway, could be responsible for the
observed lack of habituation of cortical responses in migraineurs.
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HABITUATION OF EVENT-RELATED POTENTIALS AND
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Introduction The majority of evoked and event-related potentials stud-
ies in migraine have shown two abnormalities: increased amplitudes of
averages of large numbers of trials and lack of habituation in succes-
sive trial blocks during the pain-free phase, with the ictal normalization
of evoked potential amplitudes and habituation. During the interictal
phase, a reduced habituation pattern of early and late LEPs’ component
in response to repetitive noxious stimuli was found in respect to con-
trol subjects. Furthermore, during migraine attack, patients showed a
decrease in nociceptive threshold and receptive field expansion.
Results from a number of experimental studies have indicated that
chronic analgesic exposure leads to changes in serotonin content and
density of 5-HT2A receptors in the central nervous system. This
plasticity of the serotonin-dependent pain control system may accel-
erate the process of sensitization, a biologic outcome that is
expressed clinically by the development of chronic migraine associ-
ated with analgesic overuse. Hypothalamic involvement may be a
key feature of chronic migraine. Neuroendocrine studies have shown
an abnormal pattern of hormonal secretion in the disease and sug-
gested a possible hyperdopaminergic state in patients with CM.
Finally, MRI studies have provided evidence that CM is associated
with a progressive impairment in iron homeostasis within the peri-
acqueductal gray, a centre of the descending antinociceptive neu-
ronal network.
Conclusions Despite no clear explanation of the mechanism under-
lying migraine transformation, experimental data suggest that the
process is related to a progressive sensitization of the cerebral
antinociceptive systems. Abnormal modulation of these systems may
explain the shift of the migraine phenotype from episodic to chronic
headache. The neuronal plastic changes in chronic migraine make
the antinociceptive systems an important target for several types of
interventions.
SALIVARY CORTISOL, DHEA-S AND TESTOSTERONE IN
CHRONIC MIGRAINE
1F.R. Patacchioli, 1P. Monnazzi, 1S. Simeoni, 2P. Santi, 2S. De Filippis,
2G. Coloprisco, 2A. Rodio, 2P. Martelletti
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Chronic migraine (CM) is the most disabling form of headache
among those in the ICDH-II. The failure in treating CM is often due
to a superimposed medication-overuse headache (MOH). As
described by the new classification of the International Headache
Society, it is caused by frequent use of antiheadache compounds for
more than 15 days/month in most patients, however, using the med-
ication daily. In this study we evaluated 20 CM sufferers, women
only, 14 of them affected by MOH, and six treated with botulinum
toxin type-A (BoNT-A) one month after withdrawal from MOH. The
control group consisted of 15 subjects, age- and BMI-matched with
other groups. None of the subjects had been under therapy with cor-
ticosteroids for at least 6 months before the study. The HPA axis
activity was specifically monitored by measuring salivary hormone
levels, which were found to be highly correlated with free plasma
levels, thus allowing the stressful event of venipuncture to be avoid-
ed. Samples of saliva were collected by the Salivette (Sarsted, Italy),
a sampling device which allows quick and hygienic saliva collection
through a polyester swab. In order to evaluate the circadian rhythm
of cortisol, DHEA-S, and testosterone, the participants were
instructed how to collect saliva samples at home, which was per-
formed twice a day (08:00 h and 20:00 h). In order to evaluate the
response to a mild physical stressor, the participants attended our
laboratory for exercise activity (which consisted of 2.5 minutes of
step-climbing exercise) from 10:00 AM to 12:00 AM. Immediately
before the start, at the end of the test and 10 minutes after comple-
tion of the test, saliva samples for hormone assays were taken and
blood pressure and heart rate were measured. MOH in CM is found
to be associated with an impairment of cortisol and DHEA-S circa-
dian variation. CM treated with BoNT-A, both in morning and
evening measurements, showed intermediate cortisol levels between
controls and abuser group. Furthermore, the ratio between testos-
terone and cortisol levels, which is an indicator of anabolic-catabol-
ic balance, appeared to be lower in CM patients, both MOH affect-
ed and BoNT-A treated.
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pattern of increased amplitude of LEPs and a decreased subjective pain
threshold. 
Objective The aim of the present study was to assess the habituation
of both LEPs and pain sensation during the ictal and interictal condi-
tion in migraine patients, in comparison with the habituation pattern of
healthy controls.
Materials and methods Eight migraine patients were selected and com-
pared with 10 healthy controls. Two consecutive series of 20 averaged
LEPs were recorded on FZ, CZ, and PZ derivations in patients and con-
trols, stimulating the right and left hands and supraorbital zones at an
intensity level set at a level 2.5 below the detection threshold; the subjec-
tive sensation was requested for each stimulus using a 0–10 point VAS.
Patients were evaluated during the attack and in attack-free conditions.
Results In normal subjects the N2a-P2 waves amplitude showed a ten-
dency toward habituation across the two repetitions, which correlated
with the habituation of the subjective rating of the stimulus. During the
interictal phase, patients showed a significant increment of the N2a-P2
amplitude in the second repetition when the face was stimulated, with an
increase of the pain rating, which was clear also for the stimulation of the
hands; in migraine patients there was a lack of correlation between the
LEPs amplitude and the subjective sensation. During the attack, both the
LEPs amplitude and the pain rating did not show any significant change
in respect to the interictal condition. The percent LEPs amplitude varia-
tion across the two repetitions correlated with the main indices of
migraine severity, mainly when the supraorbital zone was stimulated.
Discussion and conclusions The abnormal cortical excitability in
migraine, causing the altered habituation pattern of multi-modal evoked
responses, could condition an anomalous behaviour of the nociceptive
cortex during the interictal phase of migraine: it persists during the acute
phase, and correlates with the frequency and duration of migraine, as a
factor which may subtend the onset and chronicization of headache.
ELECTROPHYSIOLOGICAL EVIDENCE FOR SENSITISATION
PHENOMENA IN MIGRAINE
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Clinical studies showed that acute migraine attacks are accompanied
by increased cephalic/cranial skin sensitivity to touch, heat, and cold.
As established in animal models and pre-clinical studies, this hyper-
sensitivity probably reflects sensitisation of the primary nociceptors
and central trigeminovascular neurons. 
In humans, electrophysiological studies of trigeminal pathways are
useful to investigate peripheral and central mechanisms underlying this
disorder. Some authors found prolonged latency of the R2 component
of the blink reflex, which was interpreted as a marker of brainstem dys-
function; other studies did not confirm this finding. Recently, using a
novel “nociception specific” blink reflex permitting a more specific
stimulation of Aδ and C fibres, an increased R2 area was found in
migraineurs on the side of the headache, especially during the attack. 
Another useful tool for exploring the trigeminal system in humans is
the electrically elicited corneal reflex. A lower threshold for the corneal
reflex is found interictally in migraineurs compared with controls. This
reduction is bilateral even in migraineurs presenting strictly unilateral
headache. These findings provide additional evidence pointing to a
dysfunction of this system in migrainous patients. 
In order to clarify the pathophysiological mechanisms of migraine it
could be useful to explore the pain processing on the outside referred-
pain area (extracephalic). The nociceptive flexion reflex (NFR) is a
reliable and objective tool for exploring pain control systems in
humans. In a recent report we studied the function of the pain modu-
lating systems subserving diffuse noxious inhibitory controls (DNICs)
in primary headache, evaluating the RIII parameters during CPT. The
data obtained showed a significant facilitation during the cold-pressor
test in respect to the inhibition observed in controls. This study demon-
strated a dysfunction in systems subserving DNICs in both migraine
and CTTH. Impairment of endogenous supraspinal pain modulation
systems may contribute to the development and/or maintenance of cen-
tral sensitisation in primary headaches. Other preliminary data from
the population of chronic migraine patients showed a significant reduc-
tion of the RIII reflex and temporal summation threshold with
increased reflex area. These data suggest that in migraine sufferers, the
sensitisation of central nociceptors occurs not only in the trigeminal
district, but also widely involves the spinal cord.
Taken together, electrophysiological investigations of the trigeminal
networks in migraine are in favour of segmental hypersensitivity
and/or decreased control of descending inhibitory pathways, con-
firming that sensitisation of central trigeminal nociceptors occurs not
only during, but may even persist interictally, and the frequent bilat-
eral location of the abnormalities suggests a centrally located dys-
function.
TRANSCRANIAL MAGNETIC STIMULATION TO INVESTI-
GATE DYSFUNCTION OF CORTICAL ACTIVITY IN
MIGRAINE
F. Brighina, B. Fierro
Department of Neurology, University of Palermo, Palermo, Italy; e-
mail: fbrighina@neuro.unipa.it
Transcranial magnetic stimulation (TMS) can assess and modulate corti-
cal excitability. This last goal can be achieved by repetitive TMS (rTMS).
Excitability of the visual cortex has been studied in migraine through
phosphene threshold (PT), (i.e., the minimum intensity of magnetic
stimulation needed to evoke phosphenes).
Contradictory results have emerged, with some authors finding PT lev-
els reduced and others increased in migraineurs.
A few rTMS studies have been conducted in migraine. Bohotin et al. [1]
found that 10 Hz rTMS (a facilitatory frequency) favours recovery of
habituation of visual evoked potential (that is reduced in migraineurs),
while 1 Hz rTMS (an inhibitory frequency) was able to disrupt habitu-
ation in normal subjects. The authors speculated that migraineurs have
a reduced cortical activation that can be reverted by facilitatory rTMS;
moreover, 1 Hz rTMS reducing cortical activity can establish dysfunc-
tions similar to migraine in healthy subjects.
However, the effects of different rTMS frequencies can dramatically
change depending on the pre-existing cortical excitability. Zieman et
al. [2], showed that low-frequency rTMS determines paradoxical facil-
itation in motor cortex when delivered in a condition of cortical deaf-
ferentation that is known to reduce cortical inhibition.
We showed that low-frequency rTMS has paradoxical facilitatory
effects on the striate and extrastriate cortex in migraine [3, 4]. We inter-
preted it as a result of reduced efficiency of cortical inhibitory circuits
unable to be up-regulated by rTMS. In support of this hypothesis, we
recently also found a dysfunction of cortical activity in the motor cor-
tex of migraineurs. Through the technique of paired pulse stimulation
we showed that migraineurs present reduced intracortical inhibition at
baseline. After 1 Hz stimulation, a paradoxical potentiation of intra-
cortical facilitation (ICF) occurs, opposite to the suppression of ICF
induced by the same trains in healthy controls. 
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LASER EVOKED POTENTIALS FOR ASSESSING FACIAL
PAIN
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Trigeminal nociceptive pathways play a crucial role in chronic facial pain.
Currently, laser evoked potentials (LEPs) are the most widely agreed-
upon method for studying trigeminal nociceptive pathways. Laser-gen-
erated radiant heat pulses selectively excite free nerve endings in the
superficial skin layers and can activate Aδ and C nociceptors or warm
receptors. Low-intensity pulses directed to the skin of the face evoke
pinprick sensations and brain potentials (Aδ-LEPs), both induced by
the activation of type II AMH mechanothermal nociceptors. The affer-
ent volley is conducted along small-myelinated (Aδ) primary sensory
neurones, and relayed to the spinal trigeminal nucleus and brain.
Aδ-LEPs consist of a widespread negative-positive complex (N2-P2)
with a maximum amplitude at the vertex. This signal is generated by
deep midline structures, probably the anterior cingulate gyrus, and
bilateral opercular-insular regions. The main current aim of clinical
Aδ-LEP studies in facial pain syndromes is to provide information on
Aδ-fibre function and pathophysiology of neuropathic pain.
Patients with symptomatic trigeminal neuralgia (TN) and about 50% of
those with idiopathic TN have abnormal Aδ-LEPs. Hence, Aδ-LEPs
may indicate trigeminal dysfunction also in patients with normal
trigeminal reflexes and no evidence of structural lesion of the trigemi-
nal system. Possibly Aδ-LEPs, because they are mediated by a small
number of afferents, are diagnostically more sensitive than trigeminal
reflex testing. Naturally, the finding of normal Aδ-LEPs by no means
excludes the diagnosis of idiopathic TN. This diagnosis only relies on
the clinical description of paroxysmal pain.
In patients with supraorbital postherpetic neuralgia (PHN) Aδ-LEPs are
constantly abnormal. However, Aδ-LEPs abnormalities do not correlate
with severity and characteristics of the pain, thus suggesting that the pain
in PHN does not chiefly arise from a dysfunction of Aδ fibres. In our
experience patients with burning-mouth syndrome and atypical facial
pain have always normal Aδ-LEPs. In patients with temporomandibular
disorders (TMD), Aδ-LEPs have a normal latency, but the mean ampli-
tude is slightly reduced with respect to control values. Although this data
demonstrates that TMD patients have a trigeminal nociceptive pathways
dysfunction, this dysfunction may be a consequence of chronic pain
rather than having a pathophysiological role in TMD.
In conclusion, Aδ-LEPs provide a sensitive and reliable tool for evalu-
ating the trigeminal nociceptive Aδ pathways in facial pain syndromes.
Currently, the main limitation to their use is the relatively scarce avail-
ability of laser stimulators.
HEMODYNAMIC EVALUATION OF CEREBRAL VASOMOTOR
REACTIVITY IN JUVENILE MIGRAINE PATIENTS: A TRAN-
SCRANIAL DOPPLER STUDY
1P.A. Battistella, 1G. Santarello, 2P. Rampazzo, 2M. Ermani, 
2G. Meneghetti
1Departments of Paediatric and 2Neurological Sciences, University of
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Transcranial Doppler Sonography (TCD) is a non-invasive technique
that can measure local blood flow velocity in large intracranial arter-
ies. TCD can provide an index of relative flow changes in response to
physiological stimuli (e.g., hypocapnia and hypercapnia), which tests
vasomotor reactivity (VMR) of the distal cerebral arteriolar bed. TCD
vasomotor reactivity testing can detect impairment of cerebral hemo-
dynamics in patients with different cerebrovascular disorders includ-
ing migraine. In this study we aimed to investigate cerebrovascular
reactivity in the anterior and posterior parts of the circle of Willis in
children with migraine by means of TCD. Thirty-five young patients,
(22 males, 13 females; aged 8 to 17 yrs) affected by migraine: 19 with
aura (MwA) and 16 without aura (MwoA), were included as outpa-
tients. Diagnosis of migraine was made according to the International
Headache Society criteria (1988). All patients were studied in an
attack-free period and had discontinued prophylactic therapy at least
two months before the study. Duration of the disorder was at least 6
months. Exclusion criteria included cardiac or systemic disease.
Patients were free of symptoms 48 hrs before the study. Twenty
headache-free, age and sex-matched subjects were selected as a con-
trol group. Duplex sonography excluded stenotic lesions of the
extracranial vessels. Basal blood flow velocities and the Pulsatility
Index (PI) of the middle cerebral arteries (MCAs) were bilaterally
recorded through the transtemporal window at a depth of 52 mm while
the blood flow velocity and the PI of the basilar artery (BA) were
recorded through the transforaminal window at a depth of 76 mm.
VMR was studied by recording both the increase and decrease of the
blood flow velocities in the MCAs and in the BA after hypercapnia,
reached by maximal apnea test, and after hypocapnia, reached by
hyperventilation. Basal mean values of the blood flow velocities and
the PI of the MCAs and of the BA did not differ significantly in both
groups of patients (MwA and MwoA). No significant differences in
VMR in the anterior and posterior sections of the circle of Willis were
detected in patients with MwA or MwoA (as a whole or as single enti-
ties, respectively) compared with controls. Functional assessment of
the cerebral microcirculation by a non-invasive technique seems to be
a useful tool in identifying patients with migraine at higher risk of
major cerebrovascular events.
DIAGNOSING MIGRAINE ACCORDING TO THE ICHD-II
GUIDELINES
M.G. Buzzi
IRCCS Foundation Santa Lucia, Rome, Italy; e-mail:
mg.buzzi@hsantalucia.it
The revised diagnostic criteria provide a fairly new tool for making the
diagnosis of migraine (Chapter 1), given the new entities that have been
included in the present classification, such as chronic migraine or spo-
radic hemiplegic migraine. There are also subtypes that have been
excluded, such as opthalmoplegic migraine, now included in Chapter
13. The probability of diagnosing a migrainous attack is proposed in
code 1.6, suggesting that the longitudinal observation of attacks for a
given period of time may provide a definite diagnosis for which the cri-
teria are not satisfactory upon first observation. This possibility has a
procedural implication, i.e., the need for patient follow-up, although
guidelines strictly serve to diagnose the attacks. The same applies to
those migraine subtypes which have been, at least in part, associated
with genetic defects, such as familial or sporadic hemiplegic migraines.
The motor disturbance only fits these diagnoses and the very fine dif-
ferential diagnosis with basilar-type migraine is founded on this spe-
cific symptom. Again, longitudinal observation of the latter subtype
may lead to changing the diagnosis if the motor disturbance appears
during an attack of expected basilar-type migraine [1]. Genetics are
also extending the similarities between these two subtypes [2]. The
relevance of premonitory symptoms during an attack has been sorted
out, and though there is not enough evidence for making them manda-
tory as diagnostic criteria [3], they provide useful information in clini-
cal practice, whereas some accompanying symptoms, namely osmo-
phobia, are supported as possibly useful in the appendix section of the
guidelines.
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The criteria per se do not represent the main change in the ICHD-II
guidelines, given that they are proposed on the basis of valid and reli-
able evidence. The main body of the guidelines is better represented by
the notes, the comments, and the appendix, because those parts are
open to discussion. The hope is that in the next revision there will be
more “pathogenesis”-based” criteria to better delineate the boundaries
or to break down the apparent discontinuity between different migraine
subtypes. 
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CHAPTER 4 OF ICHD-II: OLD CONCEPTS AND NEW VIEWS
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In the recently published International Classification of Headache
Disorders 2nd edition (ICHD-II) – chapter IV, previously entitled
“Primary Miscellaneous Headaches” (IHS 1988), emerges as one of
the chapters that underwent the most profound revisions, as indicated
by its title, which has now been changed to Other Primary Headaches.
It has become increasingly clear, over recent years, that many of the
forms included in this chapter raise major problems with regard to their
differential diagnosis from other conditions, since some of them may
mimic, especially at their onset, serious forms of symptomatic
headache due to organic disease of underlying structures. Therefore,
the ICHD-II Subcommittee has made a considerable effort to group
under this chapter all the possible forms of primary headache that do
not fit within the first three chapters of ICHD-II and to provide detailed
diagnostic criteria for each one of them. Therefore, chapter IV of
ICHD-II has been enriched by the addition of newly identified entities,
whose clinical features have been adequately documented in the litera-
ture. These new entities are: primary thunderclap headache, hypnic
headache, hemicrania continua and new daily-persistent headache,
and they have been added to the previous: primary stabbing headache,
primary cough headache, primary exertional headache and primary
headache associated with sexual activity. 
Conversely, other forms originally included in the “Primary
Miscellaneous Headaches” chapter of the first IHS classification, such
as the “external compression headache” or the “cold-stimulus
headache”, have been moved, in view of their specific pathogenetic
mechanism, to chapter XIII of the ICHD-II (Cranial neuralgias and
central causes of facial pain).
Headaches listed in chapter IV of ICHD-II are probably more common
than previously thought. Most of these forms are first observed in
Emergency Departments because of the suddenness of their onset and
their pharmacological treatment is almost exclusively based on anec-
dotal reports. A positive response to indomethacin has been reported in
some of them and has been elevated to the role of diagnostic criterion
in the case of hemicrania continua.
In the years to come, a strong effort will be required by the scientific
headache community in order to field-test the proposed criteria for the
various forms of “Other primary headaches”, to conduct ad hoc stud-
ies for the clarification of their pathogenetic mechanisms – about
which little is currently known – and to perform controlled studies for
evaluating the effectiveness of options suggested in isolated reports.
MEDICATION-OVERUSE HEADACHE: CLINICAL AND THER-
APEUTIC PROBLEMS
1A. Ferrari, 1S. Leone, 1C.P.R. Coccia, 1G. Pasciullo, 2G. Sances, 
1A. Bertolini, 1E. Sternieri
1Headache Centre, Toxicology and Clinical Pharmacology Section,
University of Modena and Reggio Emilia, Modena, Italy; 2Headache
Centre, IRCCS “C. Mondino” Foundation, UCADH, Pavia, Italy; e-
mail: annaf@unimo.it
The interactions between chronic headache and medication overuse are
complex and not yet fully clarified. In particular, the mechanisms by
which medication overuse takes part in the chronicization process are
still object of hypotheses. Certainly, medication overuse complicates
the therapeutic approaches to chronic headache. Medication overuse
hampers the effect of prophylactic therapies, and only the interruption
of the overuse, over a variable period of time, leads to the disappear-
ance, or at least the reduction in the frequency of headache. Only at that
point it is possible to start the prophylactic treatment with a well-
founded probability of success. Unfortunately, interrupting medication
overuse is not an easy task, due to both the severity of the pain symp-
tomatology and to rebound headache which can compel the patient to
resume medication.
Objectives The aim of our research was to analyze patients with med-
ication-overuse headache, with respect to the characteristics of drug
medication behaviour and its consequences for headache treatment.
Patients and methods We studied a consecutive series of 50 patients,
newly admitted to the in-patient service of the Headache Centre of the
University of Modena and Reggio Emilia. Data were collected by
means of a questionnaire, specifically prepared for this study, recorded
into a specific database and analysed by SPSS 6.1.2 program, version
for Windows 98.
Results The combination of indomethacin plus caffeine plus prochlor-
perazine, and triptans were the medications most frequently overused
by our patients; only a few patients overused ergot preparations. The
majority of patients used the same type of drug daily. All patients
referred they increased the frequency of self-medication because the
headaches were getting worse. For most patients medication overuse
made the headache more endurable, thus allowing them to work or
function more or less normally in daily life. Only a minority experi-
enced withdrawal symptoms after discontinuation of the medication
overuse. After detoxification, antidepressants were the class of drugs
most used for prophylaxis.
Discussion During chronic use of a medication indicated for acute
treatment of headache, the therapeutic results do not derive solely from
the drug but also from the organism’s adaptation to the repeated use.
This time-process of compensatory adjustments might partly explain
both the chronicization of headache and the withdrawal symptoms
when medication overuse is interrupted.
Conclusion Medication-overuse headache should be prevented because
its management is very difficult. It is necessary to address, at the same
time, both the chronic pain condition and the medication overuse.
APPLICABILITY OF ICHD-II CRITERIA FOR PRIMARY
HEADACHES: VERIFICATION WITH THE AID OF A COM-
PUTERIZED DEVICE
1A. Alberti, 2M. Pedini, 1G. Capocchi, 1P. Sarchielli
1Neurologic Clinic, Department of Neurosciences, 2Computer Science
Educational Laboratory, University of Perugia, Perugia, Italy; e-mail:
headache@unipg.it
Background Diagnostic requirements for primary headaches in the
new classification system ICHD-II appear to be improved and certain-
ly represent an evolution of the previous criteria included in the first
IHS classification edition [1, 2]. Some modifications were made to the
old criteria concerning all primary headaches and a new entity, chron-
ic migraine, was introduced among the complications of migraine.
S13
Objective With the aim to verify the applicability of classification cri-
teria for primary headaches of the new classification system, we devel-
oped a computerized, structured medical record based exclusively on
the proposed new classification system for primary headaches. This
computerized system examines all the diagnoses of primary headaches
on the basis of the variables needed to fulfil their mandatory criteria.
Methods The program, developed with the help of an expert, is called
“IHS Diagnostic Criteria for Primary Headaches” version 2.0 ITA, and
is strictly based on the ICHD-II operational diagnostic criteria for pri-
mary headaches.
The clinical sheets relative to 200 consecutive patients attending our
headache Centre in 2004 were examined and included all items need-
ed to make a diagnosis of one of the primary headache disorders
according to the new ICHD classification.
Results The software was able to furnish a single diagnosis in 82% of
the cases, while in 15% of these, the output diagnoses were multiple (up
to 4), and in many cases were of “probable forms”. In the remaining 3%
of the cases, the diagnosis was 14.1 Headache not elsewhere classified,
because they did not fit into any of the existing chapters of primary
headaches and the headache was not attributable to another disorder.
Discussion The introduction of “probable subtypes” for the episodic
and chronic forms necessitates a careful re-examination of these defin-
itions and will lead to suggestions for overcoming possible drawbacks
in the diagnosis that, however, is ultimately entrusted to the clinician.
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PSYCOBIOLOGICAL ASPECTS IN CHRONIC TENSION-TYPE
HEADACHE
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Knowledge of the possible pathophysiological mechanisms of tension-
type headache (TTH) is mandatory to postulate the “sites” of action of
psychological factors.
Both peripheral and central phenomena of sensitization seem to be
involved in the chronic form of TTH (CTTH). The former one consists
of a decrease in the pain threshold of pericranial myofascial nocisen-
sors as a result of repeated stimulation by neurotransmitter release fol-
lowing microtraumatisms of muscle fibres and/or tender insertions due
to a spontaneous activity in myofascial trigger points. The latter repre-
sents the most important mechanism in CTTH and mainly consists of
a segmental sensitization of second order neurons in the spinal dorsal
horn/trigeminal nucleus secondary to prolonged nociceptive input from
pericranial myofascial tissues. Moreover, the findings of decreased
mechanical, thermal, and electrical pain thresholds, both in cephalic
and extracephalic structures in patients with CTTH, also suggest
changes in supraspinal pain modulation.
Psychological factors might play an important role in both peripheral and
central mechanisms of sensitization. The Italian Collaborative Group for
the Study of Psychopathological Factors in Primary Headaches assessed
that about 85% of patients with TTH had at least one, and almost 50% of
patients had two psychiatric disorders or psychosocial stressors; affective
disorders were more frequent in the chronic than in the episodic form. A
subsequent study, when comparing, by correspondence, the same TTH
patients versus migraine patients from headache centres in Italy, showed
that CTTH with pericranial muscle disorder correlated with anxiety and
depression, whereas CTTH without pericranial muscle disorder correlat-
ed with somatoform disorder. The influence between psychological prob-
lems and CTTH may be bidirectional with each other increasing the risk
for the other. For example, depression might be a consequence of chron-
ic headache but it might also make the progression of an episodic into a
chronic headache easier. Repeated or sustained conditions of mental
stress may induce an activation of myofascial trigger points resulting in
peripheral sensitization. Moreover, it is well known that the raphe mag-
nus nucleus and the locus coeruleus exert a descending inhibitory modu-
lation of pain at the level of spinal dorsal horn/trigeminal neurons by
means of serotonergic and noradrenergic pathways, respectively; there-
fore, an impairment of these neurotransmitters may contribute to central
sensitization. In contrast, several psychological disorders are associated
with changes of some neurotransmitters such as noradrenaline and sero-
tonin. Altogether these data suggest a common neurobiological dysfunc-
tion for psychiatric disorders and CTTH, consisting of an involvement of
serotonergic and noradrenergic systems.
QUALITY OF LIFE MARKERS IN MIGRAINE
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It is well known that migraine induces disability and an impaired qual-
ity of life, work, social activities, and family life, even between attacks.
The impact of migraine on quality of life has been traditionally evalu-
ated by the health-related quality of life (HRQoL) instruments that can
detect changes over time in response to at least major changes in
migraine therapy. The SF-36, a general HRQoL measure, and several
migraine-specific HRQoL instruments, have proved useful endpoints
for migraine clinical trials. Their role in clinical practice is, however,
yet to be established (Becker, 2002); besides, it is not clear which clin-
ical features have the greatest impact on a migraineur’s quality of life
and if specific concomitant aspects, such as possible compromised
quality of sleep, excessive daytime sleepiness, or chronic fatigue,
might contribute to quality of life impairment in migraine.
The aim of this study was the assessment of sleep quality and daytime
functioning parameters, such as sleepiness and fatigue, and the verifi-
cation of their possible relationship with traditionally assessed quality
of life dimensions. One hundred consecutive patients (84 F, 16 M;
mean age±S.D. 39.9±11.4 years), fulfilling the diagnostic criteria for
migraine without aura (IHS 1988, 2004) were enrolled and 24 normal
subjects (20F, 4M; mean age±S.D. 36.6±14.1 years) represented the
control group. The Pittsburgh Sleep Quality Index, Epworth Sleepiness
Scale, and Fatigue Severity Scale were employed. The impairment in
subjectively estimated quality of sleep and complaint of chronic fatigue
was significantly more represented in migraine without aura patients
than in controls. According to our data, both altered sleep quality and
fatigue occurred in episodic migraine in the absence of any psychiatric
disorders; thus, it might be hypothesized that they depend on the patho-
genetic mechanisms of migraine themselves. Finally, both poor sleep
and fatigue were related to quality of life as assessed by the means of
SF-36, so it might be suggested that these parameters contribute to the
estimated quality of life in episodic migraine patients.
MUSCLE TENDERNESS IN DIFFERENT HEADACHE TYPES
AND ITS RELATION TO ANXIETY AND DEPRESSION
1F. Mongini, 2G. Ciccone, 1A. Deregibus, 1L. Ferrero, 1T. Mongini
1Section of Headache-Facial Pain, Department Clinical
Pathophysiology, University of Turin, Turin, Italy; 2Unit of Cancer
Epidemiology, ASO S. Giovanni Battista, Turin and CPO Piemonte,
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To assess the extent to which muscle tenderness may relate to anxiety,
and depression in patients with migraine and tension-type headache,
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both episodic and chronic. Four hundred and fifty-nine patients with
episodic migraine (EM, 125), chronic migraine (CM, 97), episodic
tension-type headache (ETTH, 82), chronic tension-type headache
(CTTH, 83), and EM + ETTH (72) were enrolled. For each patient a
psychological assessment on the Axis 1 of the DSM-IV and muscle
palpation of pericranial and cervical muscles were carried out. A
Pericranial Muscle Tenderness Score (PTS) and a Cervical Muscle
Tenderness Score (CTS) were calculated (range 0–3). Logistic and lin-
ear regression analyses were employed to assess relations between
muscle tenderness, demographic variables, and psychiatric disorders
in the different patient groups. Odds ratio for “male gender” was high-
er in groups with tension-type headache. Only EM patients showed a
positive association with increasing age. Anxiety and depression were
significantly associated with CM. A significant negative correlation of
PTS and CTS was observed in EM patients. In relation to male gen-
der, the PTS was significantly lower in EM, ETTH, and CTTH; CTS
was significantly lower in EM, CM, and CTTH. Anxiety and, even
more so, anxiety and depression combined were positively associated
with higher PTS and CTS in EM patients. Anxiety and depression
were also positively associated to higher CTS in patients with
EM+ETTH. In CTTH patients, only PTS was positively associated
with anxiety and depression.
We conclude that in patients with EM the presence of anxiety or anxi-
ety and depression combined considerably increases the level of mus-
cle tenderness in the head and, even more, in the neck, and might facil-
itate the evolution into CM.
HEADACHE, INSOMNIA AND PSYCHIATRIC DISORDERS:
FROM PAIN TO MENTAL SUFFERING
C. Gentili, L. Palagini, E.L. Balsamo, M. Guazzelli
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The study of pain, as an experience elicited by nociceptive afferences,
has been well investigated by recent psychological research, while the
relationship between pain and mental suffering has been quite forgot-
ten by psychopathological speculation. Correlations between somatic
pain and mental suffering, now included in the psychiatric concept of
comorbidity, on the other hand, received strong interest until the mid-
dle of the past century. This issue has been raised again with the growth
of neurosciences, as demonstrated by studies on the relationship
between headache, insomnia, and psychiatric vulnerability. Studies
about facilitating effects of insomnia on headache were preceded by
those on protective effects in sleep. Clinical observations were later
confirmed by evidence on the relationship between sleep deprivation
and headache, and by the hypothesis of a self-enhancing loop between
insomnia and headache. Therefore, relationships between headache
and anxiety as well as between headache and depression are no longer
questionable. The pervasive association between depression or anxiety,
chronic insomnia and primary headache could be viewed within the
context of the psychopathology of somatization and conversion, both
milestones of the psychoanalytical concept. In this context, certain
painful manifestations are results of neurotic defences, which uncon-
sciously refuse mental suffering leading to a headache or insomnia.
Similarly, in hypochondria the transformation of anguish into somatic
diseases occurs at the expense of losing reality judgment which weak-
ens to a delusional state. Modern psychiatry simplifies this issue. It rel-
egates insomnia associated with mental disorders to comorbidities and
disregards headaches sine materia by considering them part of the clin-
ical phenomenon of anxiety and mood disorders, or the core symptom
of Somatoform Pain Disorder. Primary headache, chronic insomnia
and psychiatric disorders can be viewed also as mutual facilitating
processes. The failure of one single aspect, i.e. somatic pain expressed
as headache, autonomic phenomena as insomnia, or mental suffering as
a psychiatric disorder, gradually leads to an overall imbalance. The
development of functional brain imaging methodologies is now defin-
ing neurobiological bases of the differences and similarities between
pain and mental suffering. Available data that neuronal networks
underlying nociception and mental suffering are widely overlapping,
suggests different aspects of the same dimension, where life events,
mental experiences and neurometabolic processes are partial aspects of
the same psycho-neuro-biochemical loop as body and mind of the psy-
chophysical unity of each person.
TIME COURSE OF HEALTH-RELATED QUALITY OF LIFE,
BODILY PAIN, ANXIETY, AND DEPRESSION IN PRIMARY
HEADACHES
A. Gallanti, S. Zago, A. Cremona, R. Ferrucci, M. Mari, N. Bresolin
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In this preliminary study, the time course of quality of life (QoL), bod-
ily pain, anxiety, and depression were documented in outpatients at the
basal visit, and at 3 and 6 months follow-up in sixteen headache out-
patients (3 men and 13 women with a mean age of 29.31 years, range
21–62). During the study, patients received only symptomatic treat-
ment (simple or combination analgesics and triptans). No psychologi-
cal therapies were introduced. QoL was assessed using the medical
outcomes study Short Form Health Survey (SF-36), a generic, self-
administered instrument, which has been widely used in several chron-
ic disorders [1]. The McGill-Melzack Pain Assessment Questionnaire
was used to assess the quality and intensity of the bodily pain [2]. The
Beck Depression Inventory (BDI) was applied for assessment of
depression [3]. Finally, the State-Trait Anxiety Inventory –form Y [4]
was used to assess anxiety traits.
In 7 of the 16 patients (43.75%), QoL was globally restored to the basal
visit level three months after recruitment. Nearly identical prevalences
were observed in the 3-month follow-up and the 6-month follow-up.
The patients’ perception of the bodily pain showed only marginal
changes or remained stable at the two follow-up time points.
Depression was a common finding at the basal visit (75% had a BDI
score indicating a mild to moderate depression or a moderate to severe
depression). At the six month follow-up in 6 of the 16 patients (37.5%)
a degree of reduction of the depressive disorder was observed. The per-
centage of patients with anxiety traits (81.2%) also showed a declining
trend in 12 of the 16 patients (75%).
The results of this preliminary report highlight the importance of health
status evaluation as an essential step in the longitudinal assessment of
patients with headache attending a headache centre.
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COMORBIDITY OF MIGRAINE AND EPILEPSY
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In clinical practice, the finding of headache and epilepsy in the same
patient and, moreover, in the presence of ictal and interictal epilepti-
form EEG patterns in patients with headache, is well known. These
associations have stimulated research in the clinical and pathogenic
relationships between headache and epilepsy.
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Studies of the incidence of this association in epileptics and headache
sufferers and an analysis of the link between the two different types of
attacks have led several authors to support a non-casual clinical asso-
ciation between epilepsy and headache. So far, the pathophysiology of
this condition remains unknown [1].
In adult patients, several studies demonstrated, according to IHS crite-
ria, that the most common types of headache associated with epilepsy
were migraine and tension-type. However, the rate of unclassified
headaches has been remarkably high [2].
Probably, the most common relationship between seizures and
migraine is when migraine-like headaches occur after seizures.
Postictal headaches are often indistinguishable from migraine and are
equally common in patients with or without a family history of
migraine.
Epileptiform abnormalities have been revealed in 9–13% of patients
with migraine; this rate is significantly higher than expected from the
normal population. Simple and complex partial seizures, primary and
secondary generalized seizures, and tonic-clonic seizures have been
reported associated with headache.
It can be difficult to differentiate seizure disorders from migraine phe-
nomena (and vice versa) in some patients. It is particularly a problem
in children with atypical clinical presentations with or without abnor-
mal EEGs [3].
In the absence of EEG recorded seizures, it is not uncommon to
introduce an anticonvulsant if the history suggests a severe problem
compatible with a diagnosis of epilepsy. Remission of the suspect-
ed events under anticonvulsant medication may indicate that the ini-
tial diagnosis of epilepsy was correct. However, there is evidence
that in some patients, migraine phenomena also respond to these
drugs. Valproate, gabapentin, topiramate, and tiagabine have been
demonstrated to be efficacious. Furthermore, epileptic patients with
a history suggesting migraine require a combination of both
antiepileptic and antimigraine drugs in order to achieve full control
of epilepsy.
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THE COMORBIDITY OF MIGRAINE AND VASCULAR DIS-
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The relationship between migraine and vascular disorders has been
repeatedly investigated without convincing evidence concerning the
mechanisms that could be implicated in their comorbidity. In a previ-
ous study, with the aim of identifying vascular disorders in the relatives
of children and adolescents with migraine (143 subjects) and of con-
trols (164 subjects), we found evidence of a common pathogenetic
mechanism underlying migraine and vascular disorders. Indeed, the
results revealed an increased risk of vascular diseases in the families of
migraine patients, which may reflect an age-related phenotype of com-
mon genetic origin.
Objective In order to verify the results of our previous research, we
extended our study to include a broader population.
Materials and methods We investigated the family history of new
cases: 20 migraine with aura patients (MA), 69 migraine without aura
patients (MO), and 162 controls. We also studied additional risk factors
(atrial fibrillation), other confounding variables (smoking, oral contra-
ceptives) and the presence of headache in the families of the new cases
recruited. We also enrolled another control group, consisting of 81 ten-
sion-type headache sufferers (TTH), in order to verify whether the
association with vascular disorders is specific to migraine, or if it is
also present in other headache varieties.
Results The results of our previous study were confirmed in the wider
sample of 639 subjects (54 MA, 177 MO, 81 TTH, and 327 controls):
we found a significantly higher prevalence of at least one vascular dis-
ease in the parents and grandparents of migraine patients (MO+MA)
compared with controls and TTH patients (p=0.043). However, the
analysis of the data collected from the new samples enrolled (332 sub-
jects: 20 MA, 69 MO, 81 TTH, and 162 controls), allowing us to
account for other confounding variables (i.e., smoking and oral contra-
ceptives), did not show a significant difference in the prevalence of vas-
cular disease between cases and controls.
Conclusions The vascular risk in the families of migraine patients is
not higher than that expected in the general population, thus excluding
a common pathogenetic mechanism underlying migraine and vascular
disorders.
COMORBIDITY BETWEEN HEADACHES AND PSYCHIATRIC
DISORDERS
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In general, pain is an alarm symptom responsible for individual respons-
es aimed at avoiding potentially harmful events essential to promoting
longevity. However, aberrant pain, including that of visceral origin, can
lead to severe, debilitating conditions that pervade all aspects of life.
The experience of pain most commonly begins with a noxious stimulus
that is transmitted along nociceptive pathways to the brain. Specifically,
signals arising from viscera, e.g., the gastrointestinal tract, are conveyed
along sensory pathways (by Aδ and C-fibres) to the sensory ganglia
(either spinal or nodose), transmitted to the dorsal horn of the spinal
cord (laminae I and II) and finally, after this complex processing are sent
to the central nervous system where they are integrated with cognitive
and emotional information to produce an appropriate response. Chronic
pain represents a key symptom in a variety of functional gastrointesti-
nal disorders (FGIDs), particularly irritable bowel syndrome (IBS).
Although the pathogenetic mechanisms leading to chronic pain in
FGIDs are still far from being fully elucidated, clinical and experimen-
tal evidence clarified the major aspects involved in pain neuropatho-
physiology. An increased perception of visceral stimuli, generally
referred to as hypersensitivity, which can often be observed in patients
with FGIDs, may occur at three primary levels (i.e., the enteric nervous
system, the spinal cord, and the brain). Specifically, visceral hypersen-
sitivity may arise as a result of: (1) Mucosal inflammation triggers
hypersensitivity through the close interaction between enteric nerves
and an increased number of inflammatory cells (e.g., mast cells, T lym-
phocytes, macrophages), which have been detected in the intestinal
mucosa of patients with IBS. These inflammatory cells release a variety
of mediators, including cytokines, nitric oxide, histamine, and proteas-
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es influencing sensory nerve function. Neuro-immune interactions
evoke increased visceral sensory perception and this may contribute to
abdominal discomfort and pain; (2) Persistent up-regulation of noxious
sensory input results in neuroplastic changes occurring in the dorsal
horn of the spinal cord. These changes include either an abnormal
increase of nerve terminals containing sensory neurotransmitters (e.g.,
substance P and/or calcitonin gene-related peptide) or transmitter-recep-
tor up-regulation; (3) Psychosocial stressors, including abuse, may trig-
ger functional bowel disorders. In particular, acute stress can affect
digestive motor function and visceral perception contributing to symp-
tom generation. Recent studies show that stress induces the release of
corticotropin-releasing factor (CRF) that may be responsible for mast
cell activation and mediator release.
MIGRAINE AND TENSION-TYPE HEADACHE IN CHILDREN
UNDER SIX YEARS OF AGE: ANALYSIS OF COMORBIDITY
FACTORS
1U. Balottin, 1F. Nicoli, 1C. Termine, 1M. Quadrelli, 1G. Pitillo, 
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Objective To assess the evolution of idiopathic headache with early
onset and to investigate the influence of early somatic complaints, life-
events and psychological factors at onset and during the course of
headache. We also investigated the validity of the ICHD-II criteria for
idiopathic headache in pre-school children.
Methods Prospective evaluation of 25 consecutive headache patients
referred before the age of six to our Departments of Child and
Adolescent Neuropsychiatry. Headache diagnosis was based on both
ICHD-II criteria and “intuitive” clinical criteria. All patients were
assessed by a structured interview to detect early developmental disor-
ders, interictal somatic complaints, and life-events (DSM-IV). All
patients underwent clinical observations and assessment of psycholog-
ical factors by means of interviews and CBCL (ICD-10). All these
evaluations were performed at recruitment (TO) and follow-up (T1).
Chi-square test was performed.
Results Twenty-five children (12 M; 13 F) were monitored through a
clinical follow-up (mean duration, 4.2 years; range: 2.2–6.6 years).
Headache evolution at T1: 16/25 (64%) remission (HR); 9/25 (36%)
persistence (HP). An ICHD-II diagnosis of migraine without aura
(MO) or tension-type headache (TTH) was possible in only 9/25 cases
(36%) at onset (T0): 5/9 MO and 4/9 TTH. At follow-up (T1), an
ICHD-II diagnosis was possible in 100% of the children with HP: 1/9
MO and 8/9 TTH.
Early developmental disorders were present in 11/25 children with a
significantly higher prevalence in HP compared to HR patients (78%
vs 25%). No significant differences were found between HP and HR
patients with reference to interictal somatic disorders at T1.
We detected a life event associated with the headache onset in 40% of
our patients, and associated with headache evolution in 24% of them.
Psychological disorders were detected in 16/25 (64%) cases at T0 but
no significant differences were found in their prevalence between HP
and HR patients at T1.
Conclusions Our results suggest that ICHD-II criteria are too restric-
tive for the classification of MO and TTH in pre-school children.
Nevertheless, a diagnosis based on the same criteria was possible after
a few years follow-up.
We found a significant association between early somatic disorders and
headache persistence: early somatic disorders could have not only a pre-
dictive role on the headache onset, but also a negative prognostic value.
The high rate of psychiatric disorders detected at recruitment was not
related to headache persistence at follow-up. On the contrary, life-events
play an important role both at onset and during the course of the symptom.
CLINICAL AND PROGNOSTIC VALUE IN MEASURING
HEADACHE DISABILITY
1T. Catarci, 2G. Sandrini
1University Centre for Headache and Adaptive Disorders, Rome, Italy;
2IRCCS “C. Mondino” Foundation, Pavia, Italy; e-mail: teresa.catarci@
fastwebnet.it
In 1980 disability was defined by the WHO as “any restriction or lack
of ability to perform an activity in the manner or within the range con-
sidered normal for a human being”. In 2001 “The International
Classification of Functioning, Disability and Health” was published by
the WHO and the disability language was changed into “residual func-
tion” rather than “handicap”. This makes it easier to understand that
also headaches can cause disability not only during the acute pain but
also in the interictal phase.
It can be clinically relevant to measure headache disability, not only for
legal purposes, but also at patient follow-up and to improve communi-
cation with the treating physician. Headache disability can be mea-
sured by disability scales such as HDI, MIDAS, HIT or by quality of
life scales (SF-36, MSQ, MqoLQ, MSQOL, etc). Nevertheless, none of
these are ideal and there is no expert consensus on the gold standard to
be used. MIDAS is the best studied and validated scale in Italy, but can
only be used in evaluating the impact of prophylactic headache treat-
ment, it does not consider interictal disability and is not sensitive in dif-
ferentiating moderate to severe disability in chronic headache. At pre-
sent, there is no scale to be used as a diagnostic tool, but both MIDAS
and HIT can be used at follow-up to evaluate the efficacy of a preven-
tive treatment. A QoL scale can be added to evaluate interictal disabil-
ity and balance treatment efficacy vs tolerability.
In conclusion, there is a definite need of more complete, flexible, and
reliable methods to evaluate headache disability.
CHRONIC DAILY HEADACHE IN ADOLESCENCE: A FOL-
LOW-UP STUDY
V. Guidetti
Department of Neurological and Psychiatric Sciences, University of
Rome “La Sapienza”, Rome, Italy; e-mail: v.guidetti@iol.it
PATENT FORAMEN OVALE AND MIGRAINE: COMORBIDITY
OR RISK FACTOR?
P. Milia, A. Alberti, F. Galletti, G. Cardaioli, P. Sarchielli
Department of Neurosciences, University of Perugia, Perugia, Italy; 
e-mail: pmilia@hotmail.com
The first description of paradoxical embolism appeared in the literature
in 1877, hypothesizing a clot passing through the patent foramen ovale
(PFO).
The prevalence of PFO in the healthy population is approximately
20–25%. During the past 20 years an association of PFO with stroke,
migraine headache and decompression sickness has been suggested.
A case control study was performed to assess the association between
PFO and patients with migraine. It concluded that the prevalence of
right-to-left shunt (RLS) in patients with migraine with aura was sig-
nificantly higher (48%) than in healthy controls and was similar to the
prevalence of RLS in young patients with stroke. Later, a consecutive
unselected cohort of migraine patients was studied. It was found that
PFO was associated with migraine with aura but not with migraine
without aura. 
We could speculate that an aspect of migraine, such as aura, is
explained by paradoxical embolism, which shunts brain platelet aggre-
gates or neuromediators, normally inactivated by pulmonary filter, thus
initiating the attack. In contract, migraine with aura has long been sus-
pected as a risk factor for stroke in young adults on evidence of focal
alterations in cerebral blood flow sharing aura; stroke may occur dur-
ing migraine attack and headache is present in about 25% of strokes.
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Focusing on these results it seems clear that the risk of stroke in
patients having both conditions is higher. But these observations might
also be subject to bias: firstly, because cardiac imaging is performed
most frequently in young persons and this may justify the high inci-
dence of PFO in this group; secondly because migraine has a preva-
lence in persons between 25 and 55 years of age as well.
At this time, following the conclusions of Wilmshurst, we should per-
form a PFO closure in selected patients with migraine, so as to achieve
a dual effect: reduce the risk of stroke and abolish the symptoms of
migraine. But other evidence describes the transformation of migraine
with aura in a daily pattern after disclosure of RLS. Questions persist
and much of the current evidence is circumstantial or anecdoctal.
VASCULAR RISK FACTORS IN MIGRAINE: RIGHT-TO-LEFT
SHUNT – PATENT FORAMEN OVALE
G. Malferrari, G. Ferrarini
Neurology Department and Unit of Migraine, Reggio Emilia Hospital,
Reggio Emilia, Italy; e-mail: giovannimalf@libero.it
Patent foramen ovale (PFO), with or without coexistent atrial septal
aneurysm, is generally considered to be associated with brain disorders,
including first-ever ischemic stroke in young patients, cryptogenic
stroke, migraine, and cerebral decompression sickness in scuba divers.
Some authors do not confirm the association between isolated PFO and
increased risk of ischemic stroke or recurrent stroke. The size of PFO
and the degree of right-to-left cardiac shunt (RLS) in these disorders are
debated. The presence of large PFO and high-degree RLS was demon-
strated to increase the risk of cryptogenic stroke, recurrent stroke, the
number of silent ischemic brain lesions in divers, migraine with aura,
and cerebral decompression sickness. Other studies showed that either
percutaneous or surgical closure of PFO decreases the number of recur-
rent ischemic strokes, improves migraine symptoms, decreases the
number of decompression cerebral ischemic events, and supports the
positive relation between high degree RLS and the aforementioned
pathologies. Contrast transcranial Doppler ultrasonography (c-TCD) is
a complementary method to contrast-enhanced transesophageal
echocardiography (c-TEE) for RLS diagnosis. Its sensitivity approach-
es 90% and specificity approaches 92% compared with c-TEE. c-TCD
does not require sedation of the patient, thus ensuring better collabora-
tion during the Valsalva maneuver (VM). It does not provide any infor-
mation concerning either the morphology of the interatrial septum or
the size of PFO. The degree of RLS with c-TCD is expressed in num-
bers of microbubbles passing through the middle cerebral arteries. The
application of VM was standardized for c-TCD RLS diagnosis at an
international consensus meeting and more recently by Droste et al.
HEADACHE IN THE ELDERLY
1C. Lisotto, 2F. Mainardi, 2F. Maggioni, 2G. Zanchin
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Objective Although the prevalence of headache in the elderly is rele-
vant, until now few studies have been conducted in patients over the
age of 65 years. We report the prevalence of headache in a population
of subjects aged 65 years and over seen at our Headache Centre.
Materials and methods We retrospectively analysed the clinical
charts of 5036 consecutive patients >18 years of age referred to our
Centre from 1995 to 2003, with specific attention to the subgroup of
patients over 65 years of age.
Results We could identify 319 patients aged 65 years and over (6.3%
of the total population). Primary headaches were diagnosed in 80.9%
of the patients, secondary headaches were found in 10.6% of the sub-
jects, while cranial neuralgias, central and primary facial pain and
other headaches accounted for 8.5% of the cases. Among the primary
headaches, the prevalence was almost identical for migraine without
aura (26.3%), chronic tension-type headache (26.3%), and chronic
migraine (25.2%). Patients suffering from both migraine without aura
and tension-type headache accounted for 12.0% of the cases. Less fre-
quent were migraine with aura (4.7%), episodic cluster headache
(2.7%), hypnic headache (1.6%), episodic tension-type headache
(0.8%), and chronic cluster headache (0.4%). There was a great pre-
ponderance of females, who represented 79.1% of the cases. The most
frequent secondary headache was cervicogenic headache (73.6% of
cases); we diagnosed giant cell arteritis in 11.8% and chronic post-trau-
matic headache in 5.9% of the patients with secondary headaches,
respectively. In the group of cranial neuralgias and other headaches we
diagnosed patients with trigeminal neuralgia (48.1%), post-herpetic
neuralgia (7.4%), and headache not elsewhere classified (44.5%).
Discussion The onset of headache occurred before the age of 45 years
in most cases of primary headaches, in particular in chronic migraine
(90.8%), migraine without aura (66.2%), and chronic tension-type
headache (64.7%), while hypnic headache typically started after the
age of 65 years (75.0% of subjects). In 2 patients the onset of migraine
with aura occurred over the age of 65 years and in 3 patients episodic
cluster headache appeared for the first time after the age of 65 years. In
geriatric patients with cluster headache we did not find any male pre-
ponderance (50.0% of the cases).
Conclusions Overall, the prevalence of headache in the elderly seems
to be remarkable and noteworthy. Further clinical studies should be
carried out, also with the aim of defining possible therapeutic guide-
lines for geriatric patients.
ASSESSMENT OF THE EFFICACY AND TOLERABILITY OF
TRIPTANS IN CLINICAL PRACTICE
E. Sternieri, A. Ferrari, S. Leone, C.P.R. Coccia, A. Bertolini
Headache Centre, Toxicology and Clinical Pharmacology Section,
University of Modena and Reggio Emilia, UCADH, Modena, Italy; e-
mail: sternieri.emilio@unimo.it
In most cases a triptan is prescribed to a patient suffering from
migraine who has been taking OTCAs for years, alone or combined
with caffeine, antiemetics, barbiturates, etc.
A proper use of triptans is therefore indispensable to correctly assess
whether they are efficacious and/or toxic in a completely different set-
ting from the one in which controlled clinical trials are conducted.
Patient’s judgments on the treatment are therefore fundamental to
assess if it is ineffective and/or causes toxic effects.
The physician knows that the efficacy and toxicity among triptans are
similar in clinical practice and that the response is individual and close-
ly connected to the patient’s compliance and expectations. Most side
effects of triptans appear the first time they are taken and their efficacy
is rarely the same each time they are taken. It is therefore advisable to
agree with the patient upon the use of the triptans: triptans are indis-
pensable drugs to treat migraine, but they are not miraculous. To pre-
vent the patient from stopping treatment or from trying different trip-
tans and then returning to self-medication, the patient must agree to fill
out a form on the efficacy and toxicity of the drug being taken.
Naturally, before preparing this form, the physician has to decide
whether to use the same parameters of efficacy and tolerability in clin-
ical practice and controlled clinical trials.
Whatever instruments are used to assess the drug, there are some key
elements to consider: time when the migraine attack started; time when
the drug was taken; presence of autonomic symptoms or aura; intensi-
ty of the pain when it started and at the moment when the drug was
taken; duration of attack; should there be any relapse, at what time it
appeared; should there be any side effects, their intensity and duration.
The information gathered must then be discussed with the patient to
decide whether to continue or modify the treatment. Data on the effi-
cacy and tolerability of triptans, also if combined with other drugs,
could help to identify sub-groups of patients suffering from migraine
who are non-responders to triptans and/or prone to toxic effects.
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A NEW QUESTIONNAIRE FOR ASSESSMENT OF ADVERSE
EVENTS ASSOCIATED WITH TRIPTANS – METHODS OF
ASSESSMENT INFLUENCE THE RESULTS
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Triptans are the treatment of choice for migraine sufferers with dis-
abling attacks. The proportion of patients reporting side effects after
any acute treatment may vary in regard to the method of assessment.
We prospectively surveyed adult headache sufferers, who had been
using the same triptan for at least 3 months (from March 2001 to
December 2003). Participants were asked about their headache and
treatment history. Subjects then completed a standardized question-
naire, assessing adverse events in two different ways. First, subjects
were asked if they had any adverse events when using the triptan. If
they answered yes, they were asked to list them and grade their sever-
ity as mild, moderate, or severe. After returning the first part of the
questionnaire, subjects received a second form, where 49 possible
adverse events were listed. We contrasted and correlated both sets of
answers. We surveyed 148 subjects (87.8% female, mean of 39.5
years). Most patients (65.6%) reported no side effects in the unprompt-
ed questionnaire. However, most of them (56.8%) reported at least one
side effect in the prompted questionnaire. Most patients who reported
side effects in the unprompted questionnaire said they had just one
adverse event (X%), while most reported 2 or more side effects in the
prompted questionnaire (Y%). Both in the unprompted (X%) and in the
prompted (Y%) questionnaires, most side effects were rated as mild or
moderate. Seven (4.7%) subjects graded their adverse events as severe
in the prompted questionnaire, but had not self-reported them. We con-
clude that when assessing triptan adverse events, the method of data
collection may dramatically influence the results.
THE PROBLEM OF NON-RESPONDERS TO TRIPTANS
1F. Maggioni, 2P. Sarchielli, 1G. Zanchin
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TOLERABILITY OF ANTIMIGRAINE DRUGS IN CHILDREN
AND ADOLESCENTS
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Department of Neurosciences, University of Perugia, Perugia, Italy; e-
mail: beatrice73@tin.ti
Migraine is a common complaint during childhood and adolescence.
Although epidemiologic studies performed in paediatric age groups
show that 3–5% of school-aged children experience periodic attacks of
migraine and that this proportion increases to 20% through adoles-
cence, there are few controlled clinical trials regarding symptomatic
and prophylactic drug treatment. 
Analgesics and NSAIDs are the most frequently used drugs in child-
hood and adolescence for the symptomatic treatment of migraine
attacks of slight or moderate intensity. The first-choice drug under age
12 is acetaminophen. This drug is well tolerated and side effects are
infrequent and of slight intensity. Ibuprofen is also well tolerated and
few mild side effects have been recorded in the two control studies car-
ried out for the assessment of its effectiveness for the treatment of acute
juvenile migraine. Acetylsalicylic acid is not recommended under age
14 because of the potential occurrence, although rare, of Reye’s syn-
drome. Ergot derivatives in the past played an important role in the
treatment of spontaneous migraine attacks, particularly in adults, but
their role was strongly confined to a small number of patients by the
triptan revolution. The principal adverse events of ergot derivatives are
like those found in adults: nausea and vomiting, abdominal pain, diar-
rhea, and muscular cramps. They have not been reported in the limited
experience with ergot derivatives in children and adolescents com-
plaining of migraine.
Although they are considered first-choice drugs for moderate and
severe migraine attacks in adults, triptans are still under study in
migraine patients under age 18. The Italian Health Ministry rules do
not approve their use in patients under age 18. They can only be legal-
ly given if the therapeutic plan for their use has been previously
approved by the Ethics Committee and after informed consent of the
patient/parents. Promising results have been obtained, particularly for
sumatriptan in nasal spray formulation, and zolmitriptan and rizatrip-
tan, with a high tolerability and safety profile. Unlike the adult studies,
the oral triptans tested in children have not been effective when com-
pared to placebo.
Triptans used in juvenile migraineurs demonstrated to be well tolerat-
ed. The percentage of side effects such as somnolence, asthenia, and
dizziness are lower than those recorded in adults. Chest tightness, con-
striction, or pain have never been reported. For sumatriptan nasal spray,
taste disturbance was the most commonly reported adverse event. No
drug-related severe adverse events or clinically relevant changes in lab-
oratory parameters, electrocardiogram, or vital signs were reported in
all studies concerning triptan use in children.
TRIPTANS AND MORE
L.A. Pini, A. Bertolini, M.M. Cainazzo
Headache Study Centre, University of Modena and Reggio Emilia,
Modena, Italy; e-mail: pinila@unimore.it
The introduction and the development of the 5-HT1 B-D agonists, the
triptans, have generated an impressive rush of studies on migraine and
headaches, giving the researcher a tool for exploring the pathophysiol-
ogy of migraine attack.
Pharmacological studies have developed various new molecules with dif-
ferent chemical structures from sumatriptan, the first triptan structurally
derived from serotonin, but with the same pharmacological activity.
The most important differences among the triptans are in pharmacoki-
netics, mainly bioavailability, which, for example, after oral adminis-
tration varies from 13% for sumatriptan to 70% for naratriptan. A
greater lipophilicity that increases passage through the blood-brain bar-
rier is not essential for the activity of triptans: in fact sumatriptan seems
to be able to bind pontine structures at therapeutic concentrations to the
same extent of zolmitriptan (Dobson, 2004).
Serotonin-1F receptor (5-HT1F) agonists may relieve acute migraine
without causing vasoconstriction. Selective 5-HT1F receptor agonists
(LY334370; LY344864) are effective in preclinical migraine models
and are non-vasoconstrictors. LY334370 is effective in acute migraine,
and does not cause any symptoms/signs of coronary vasoconstriction.
Preclinical experiments and clinical observations infer a role for selec-
tive 5-HT1F agonists in migraine (Ramadan, 2003).
Calcitonin gene-related peptide (CGRP) may have a causative role in
migraine. In an international, multicentre, double-blind randomized
clinical trial, 126 patients with migraine received intravenously, BIBN
4096 BS, a highly specific and potent non-peptide CGRP-receptor
antagonist, at doses of 0.25, 0.5, 1, 2.5, 5, or 10 mg vs placebo over a
period of 10 minutes. The 2.5 mg dose was selected for its response
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rate of 66% as compared with 27% for placebo (p=0.001). The overall
rate of adverse events was 25% after i.v. administration of BIBN 4096
BS at the dose of 2.5 mg and 20% for the BIBN 4096 BS group as a
whole, as compared with 12% for placebo. The most frequent side
effect was paresthesia. There were no serious adverse events so that the
authors concluded that BIBN 4096 BS was effective and safe in treat-
ing acute attacks of migraine (Olesen, 2004).
ANGIOTENSIN INHIBITION: A NEW STRATEGY FOR
MIGRAINE PREVENTION?
F. Granella, P. Immovilli, C. Sagone
Institute of Neurology, Department of Neurosciences, University of
Parma, Parma, Italy; e-mail: franco.granella@unipr.it
Most of the recommended drugs for migraine prophylaxis cause
adverse events that preclude long-term treatment and have limited effi-
cacy. Thus, there is a need for new preventive drugs that have greater
efficacy and are better tolerated.
A promising new approach is the use of molecules able to reduce the
level of angiotensin II, either by inhibiting the angiotensin converting
enzyme (ACE) or by blocking the angiotensin II type 1 (AT1) receptor.
After some exploratory small-scale studies, two recent randomised,
double-blind, placebo controlled studies have proven the efficacy of the
ACE inhibitor lisinopril and the AT1 blocker candesartan, respectively. 
The efficacy of lisinopril in migraine prophylaxis was discovered by
serendipity, observing an impressive improvement of migraine in a
patient treated with this drug for hypertension. In a subsequent ran-
domised, controlled crossover study, 60 patients affected by migraine
with or without aura were treated for 3 months with lisinopril 20 mg
once daily and for another 3 months with placebo. In the 47 partici-
pants with complete data, days with migraine were significantly
reduced by 21% (CI 9–34%). Responders (subjects in whom days with
migraine were reduced by at least 50%) were 14 (29.8%) for active
treatment vs placebo and 17 (36.2%) for active treatment vs run-in.
In another randomised, controlled crossover trial, 60 patients received
for 3 months candesartan cilexetil 16 mg daily and for another 3
months placebo. In a period of 12 weeks, the mean number of days
with headache (primary endpoint) was 18.5 with placebo vs 13.6 with
candesartan (p=0.001) in the intention-to-treat analysis. The number of
responders was 23 (40.4%) out of 57 for days with migraine.
Other indirect clues pointing to the efficacy of reducing angiotensin
levels to prevent migraine come from a meta-analysis involving 12000
patients who were treated with AT1 blockers for other conditions, but
in whom headache was reduced by one third compared to those taking
placebo, and from a recent Italian study showing that among 1537
hypertensive patients treated with nitrates, the use of ACE inhibitors
reduced headache caused by nitrates by 50%. 
The mechanism of action of ACE inhibitors and AT1 blockers in
migraine prevention is unknown. Whatever the mechanism of action,
however, the efficacy and the excellent profile of tolerability of ACE
inhibitors and, even more, of AT1 blockers potentially indicate these
substances as first-line drugs for migraine prophylaxis.
ANTIEPILEPTIC DRUGS IN CHRONIC HEADACHE
1M.P. Prudenzano, 1M. Massimo, 1M. Gesualdi, 2D. Mei, 2G. Di Trapani,
1M. Savarese, 1P. Lamberti, 1P. Livrea
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Neurology, University of Rome “Cattolica del Sacro Cuore”, Rome,
Italy; e-mail: m.p.prudenzano@neurol.uniba.it
Objective About 40% of headache sufferers referring to tertiary
headache centres complain of chronic headache [1]. The management
of chronic headache is often difficult not only because of the high fre-
quency of attacks but also because of its possible association with psy-
chopathological symptoms, psychiatric disorders, and analgesic
overuse [2]. No therapeutical guidelines are available for chronic
headache. In the past years antiepileptic drugs (AEDs) have begun to
be used both in headache and mood disorders treatment. The aim of
this study was to compare the efficacy and tolerability of valproate,
lamotrigine, gabapentin, and topiramate on both headache and psy-
chopathological comorbidity of chronic headache patients.
Materials and methods A sample of adult patients, who were consec-
utively referred to the Headache Disorder Centre, Department of
Neurological and Psychiatric Sciences, University of Bari, and affect-
ed by chronic headache, was enrolled. All patients underwent a
detailed clinical interview to gather information about headache sub-
type. The Symptom Check List 90R was administered to all of them to
identify the possible association with psychopathological disorders.
Patients were randomly assigned to valproate, lamotrigine, gabapentin,
or topiramate treatment. A headache diary was delivered to collect data
concerning headache course during therapy. Drug efficacy was evalu-
ated after a three-month therapy period. Drug tolerability was assessed
by investigator observation, patient self-reporting and clinical labora-
tory data, when necessary.
Results Results show a high percentage of headache response in all
chronic headache subtypes and in all treatment groups. All drugs were
well tolerated. An improvement was found in patients with anxiety and
depressive symptoms.
Discussion These results suggest that AEDs can be an effective and
well-tolerated therapeutic option in chronic headache management.
These drugs might act on the nociceptive system and prevent both
peripheral and central sensitization which are considered the basic
mechanisms of chronic pain [3]. AEDs acting through potentiation of
GABAergic pathways might furthermore have “sedating” effects,
whereas AEDs acting through the reduction of glutamate release may
have “activating” effects on mood [4].
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A STUDY ON PHARMACOEPIDEMIOLOGIC DATA IN
HEADACHE TREATMENT IN THE POPULATION OF CATAN-
ZARO
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Introduction Headaches and migraines occur in a large proportion of
the population. The prevalence of headache increases with age and is
as high as 5% in the adult population.
Our aim was to study and compare pharmacoepidemiology of
headache treatment in two different settings: inside and outside a spe-
cialized Centre.
Method We asked 32 physicians of Catanzaro to directly administer a
detailed questionnaire to their headache patients. The questionnaire
sought information concerning demographic characteristics, occur-
rence, and frequency of headache, possible risk factors for onset of
headache and the usage patterns of specific headache medications.
Results We analysed the differences in headache treatment between
612 subjects at the first visit (‘naive’) (F/M: 2.41; mean age =
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37.31±14.09 years) and 620 subjects at follow-up (F/M: 3.18; mean
age=44.30±15.37 years) at the Headache Centre of Catanzaro. Most
patients suffered from migraine. At the first visit, 49.4% of them were
taking drugs prescribed by a doctor; 41.5% were taking over-the-
counter analgesics (OTCAs); 9.1% were not taking any drug. At fol-
low-up, 81.3% of patients were taking prescription drugs; 15.8%
OTCAs; 2.9% were not taking drugs (overall chi-square=139.229,
p<0.001). Non-selective analgesics were the most-used drugs. Triptans
were used by 9.1% of ‘naive’ patients and by 31.8% of patients at fol-
low-up (Fisher’s Z=7.655, p<0.001). Nimesulide was the most-used
drug. A prophylactic treatment was given to 16.8% of ‘naive’ patients,
and to 58.2% of patients at follow-up (Fisher’s Z=12.135, p<0.001).
Antidepressants were the class of drugs most used for prophylaxis.
Amitriptyline was the drug for prophylaxis most frequently used by
patients at the control visit, while flunarizine was the most frequently
used by ‘naive’ patients. Before being examined in a specialized cen-
tre, few patients took prescription drugs, triptans, or prophylactic
drugs; specialized care increased the proportion of patients taking pro-
phylactic drugs, and changed the type of acute treatment used to spe-
cific medication for headache.
Conclusions The present results suggest that antiinflammatory drugs
were the most-used drugs in the management of headache symptoms.
These drugs could explain the high frequency of chronic headache
episodes and drug-drug and drug-food interactions.
ECONOMIC EVALUATION OF CHRONIC TENSION
HEADACHES
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Objective To measure the cost of botulinum toxin type A (BTX-A)
treatment of chronic tension-type headache.
Design A retrospective chart analysis and prospective pharmaceutical
economics analysis was completed.
Setting Day Hospital of the Regional Referral Headache Centre at
Sant’Andrea Hospital in Rome.
Patients In phase I clinical charts were randomly selected for 100
patients treated from February 2002 to January 2003. In phase II chron-
ic tension-type headache patients were treated from February 2002 to
January 2003.
Intervention Patients were treated with 100 U of BTX- A every three
months for one year.
Measurements and results Treatment outcomes ranged from com-
plete resolution of headache symptoms to a worsening of symptoms
resulting in discontinuation. Headache medication use before and after
treatment was analyzed. After BTX-A treatment, 85% of patients expe-
rienced at least some degree of pain relief and reduced their use of
analgesics. 
The cost of treatment was based on drug acquisition costs, supplies,
and professional time needed to administer treatment. The average cost
of conventional headache medications before BTX-A treatment was €
853.43, and after treatment was € 450.47. The cost of BTX-A treatment
was € 642.00. Adding the cost of adjunctive conventional medications
brought the total cost of BTX-A treatment to € 1,092.47.
Conclusions The reduced percentage of patients using a variety of
headache medications after BTX-A treatment likely results from a
reduction in their headache symptoms. 
BTX-A treatment reduced use of conventional headache medications
and expenditures although the net cost of treatment increased with
BTX-A use.
LITERATURE REVIEW OF TRIGEMINAL AUTONOMIC
CEPHALALGIAS AND HEMICRANIA CONTINUA IN ASSOCI-
ATION WITH ORGANIC PATHOLOGIES: ONE-YEAR AFTER
THE NEW ICHD-II CLASSIFICATION
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Objective The aim of the study was to identify all relevant papers in
the literature reporting cases of chronic paroxysmal hemicrania (CPH),
SUNCT syndrome and hemicrania continua (HC) in association with
organic pathologies.
Materials and methods On the basis of our previous review, we
extended a systematic search of case reports from 1975 to 2003 and
critically reviewed the diagnoses and possible pathogenetic link
between the lesion and the headache according to new IHS criteria
(ICHD-II, 2004).
Results We detected 22 cases which presented as CPH-like (17
females (77.3%) and 5 males (22.7%); mean age at onset of symptoms:
41.04±17.88 years). Twelve cases were presented as SUNCT-like syn-
drome (6 males (50%) and 6 females (50%); mean age at onset:
38.75±15.93 years). We also found eleven “symptomatic” cases of HC
(8 females (72.7%) and 3 males (27.3%); mean age at onset:
36.00±12.96 years).
Discussion The mean age in “secondary” cases approximately repro-
duces the ratio seen in idiopathic cases, except for SUNCT-like syn-
drome, where the age in idiopathic cases is generally higher. CPH-like
and HC-like are more common in females, as in primary cases; in “sec-
ondary” SUNCT syndrome, the gender ratio is 1:1, while in primary
cases a male preponderance was generally observed.
In CPH-like cases, the most commonly associated pathology is the neo-
plastic one, followed by inflammatory/infectious diseases. In HC-like
cases, post-traumatic cases are predominant. SUNCT-like cases are fre-
quently associated with vascular and bone malformations in the poste-
rior fossa. Most recent observations showed cases of SUNCT syndrome
also associated with neoplastic lesions within the cavernous sinus and
pituitary adenomas. These results are somewhat different from those
seen in cluster-like cases, where the most frequently observed patholo-
gy in association with the headache was vascular in nature.
Conclusions We present new data about some trigeminal autonomic
cephalalgias and HC associated with organic pathologies. We stress the
importance of a complete neuroradiological investigation in these
headache syndromes, especially in the presence of atypical symptoms. 
HEADACHE ATTRIBUTED TO HEAD AND/OR NECK TRAU-
MA: A COMMENT ON ICHD-II CHAPTER 5 BASED ON
CLINICAL DATA
1G. Bono, 1M. Mauri, 2G. Sances, 2F. Antonaci, 2E. Guaschino
1UCADH, Sections of Varese, Hospital of Circolo and Pavia, Italy;
2IRCCS “C. Mondino Foundation”, Pavia, Italy; e-mail: neuro-
va@tin.it
General comment The main changes to Chapter 5 in the new classifi-
cation include separate sections for head injury and whiplash, more
accurate and objective criteria for qualifying and grading the type and
severity of traumatic events, and new diagnostic subgroups (5.5, 5.6,
5.7). However, the evidence of causation remains based on a very strict
time-interval (7 days) for both the acute and the chronic forms, with the
consequence of having many patients not-classified.
Clinical data The lack of case-control prospective studies and the dif-
ferent criteria and methods adopted even in recent years by different
authors have largely contributed to the generation of controversial data
on many issues regarding post-traumatic headaches.
From the analysis of the literature and the revision of our case series,
some aspects seem to be in contrast with certain statements and opinions
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that are at the basis of the new classification of Chapter 5. Namely, the
most severe traumas are less frequently associated with headache symp-
toms, whose development is significantly delayed from the event (over
1–3 months) and frequently related to a nearly full recovery of cognitive
function. Furthermore, the post-acute phases seem to be generally char-
acterized by a well defined complex of symptoms (indicating
brain/cervical dysfunction), but by a rather variable and poorly defined
headache picture (particularly, after mild head trauma). Only later
(weeks after injury), sometimes with a free-interval, chronic forms of
headache develop with clinical characteristics reproducing primary
headache forms or other headache pains attributable to definite disorders.
Thus, the transition from an acute to a chronic condition is not simply a
matter of time, but probably involves different mechanisms also induc-
ing substantial differences in the clinical expression of symptoms. De
novo migraine headaches following mild head injury, in particular, seem
to be largely independent from the expression of an acute post-traumat-
ic headache, postulating a role of injury in the modulation of migraine
threshold in predisposed individuals. However, the role of trauma-relat-
ed cervical abnormalities should also be considered as a pathogenetic
factor in the production of late-onset syndromes resembling cervicogenic
headache in the chronic and long-lasting post-whiplash headaches.
Conclusions Post-traumatic headaches offer a in vivo model for patho-
genetic considerations regarding different types of primary and sec-
ondary headaches, with relevant therapeutic implications.
HEADACHE ATTRIBUTED TO CRANIAL AND CERVICAL
VASCULAR DISORDER
A. Carolei, S. Sacco
Department of Neurology, University of L’Aquila, L’Aquila, Italy; e-
mail: a_carolei@yahoo.com
Headache attributed to cranial or cervical vascular disorder is report-
ed in Chapter 6 of the International Headache Society Classification,
second edition. The chapter includes headache attributed to ischemic
stroke or transient ischemic attack, to non-traumatic intracranial haem-
orrhage (intracerebral haemorrhage and subarachnoid haemorrhage), to
unruptured vascular malformation (saccular aneurysm, arteriovenous
malformation, dural arteriovenous fistula, cavernous angioma, and
encephalotrigeminal or leptomeningeal angiomatosis), to arteritis (giant
cell arteritis, central nervous system angiitis, and secondary central ner-
vous system angiitis), to carotid or vertebral artery pain (arterial dissec-
tion, post-endarterectomy headache, carotid angioplasty headache,
intracranial endovascular procedures, and angiography), to cerebral
venous thrombosis, and to other intracranial vascular disorder
(CADASIL, MELAS, benign angiopathy of the central nervous system,
pituitary apoplexy). In many of these conditions headache is overshad-
owed by focal signs and/or disorders of consciousness. In others, such
as subarachnoid haemorrhage, headache is usually the prominent symp-
tom. In a number of other conditions that can induce both headache and
stroke, such as dissections, cerebral venous thrombosis, giant cell arteri-
tis and central nervous system angiitis, headache is often an initial warn-
ing symptom. The classification of secondary headaches is based on the
same criteria: Criterion A specifies the headache characteristics;
Criterion B requires the presence of the causative vascular disorder;
Criterion C defines the causal association (commonly simply a close
temporal association); and Criterion D stipulates that the headache
greatly improves or disappears after the cure or remission of the
causative disorder. A limit in the possible application of these criteria is
that for most of the headaches attributed to cranial and vascular disor-
ders the characteristics as specified in Criterion A are not well defined.
Moreover, Criterion D is not always applicable because some forms do
not resolve nor greatly improve within the specified time. When this is
not the case, or before the specified time has elapsed, a diagnosis of
Headache probably attributed to vascular disorder is usually applied.
The alternative, when headache does not resolve or greatly improve
after 3 months, is a diagnosis of A6.8 Chronic post-vascular-disorder
headache. The new edition of the International Headache Society
Classification better defines Headache attributed to cranial or cervical
vascular disorder, reporting also emerging diseases. Furthermore, its
framework allows a better characterization of each headache and will
hopefully stimulate more nosological research into headache attributed
to cranial or cervical vascular disorder.
HEADACHE ATTRIBUTED TO DISORDER OF 
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“Headache attributed to disorder of homoeostasis”, Chapter 10 of the
new IHS classification, is difficult to interpret because of the complex-
ity of the clinical description. The new classification, in fact, has made
numerous modifications to this group of headaches no longer classify-
ing them as “Headache associated with metabolic or systemic disease”
but as “Headache attributed to disorder of homoeostasis”, focusing,
therefore, the attention on the etiology of these disorders.
Those headaches that appear to be in close temporal relation with the
metabolic alterations, that involve a marked worsening of a pre-exist-
ing headache, that introduce clear evidence that the disorder of
homoeostasis could aggravate the primary headache and, finally, that
show improvement or resolution of the headache after relief from the
disorder of homoeostasis, are classified under this category.
The new classification has also introduced “Headache probably attrib-
uted to disorder of homoeostasis” when the disorder cannot be effec-
tively treated, or when there is no spontaneous resolution of the disor-
der, and “Chronic post-homoeostasis disorder headache” when the dis-
order of homoeostasis remits, but the headache does not resolve or
improve after three months.
The new criteria have revised headache attributed to dialysis, headache
attributed to fasting, and headache attributed to hypoxia and/or hyper-
capnia, and have conferred a nosografic value to “Diving headache” in
this latter subgroup. Also in this subgroup, headache in subjects with
sleep apnoea headache has been better characterized and several stud-
ies have given importance, regarding the genesis of the disorder, to the
mechanism of hypercapnia.
“Headache attributed to arterial hypertension”, which includes sever-
al forms, and “Cardiac cephalalgia”, which appears during acute
myocardical ischaemia, have been moved into Group 10; while
“Headache attributed to hypothyroidism”, which in the previous clas-
sification was considered together with other metabolic pathologies, as
syndromes not sufficiently validated, was added.
In conclusion, the classification of these headache forms, under
Chapter 10 of the new IHS classification, will be confirmed or modi-
fied based on future studies.
HEADACHE AND AIDS
M. De Marinis, E. Coalizzo, L. Natale
Department of Neurological Sciences, University of Rome “La
Sapienza”, Rome, Italy; e-mail: m.de.marinis@mclink.it
The recent Classification of the “International Headache Society” con-
siders headaches secondary to HIV and AIDS as specific entities, that
are coded at point 9 “Headache attributed to infection”. With regard to
this, it should be said that, presently, there are few data in the literature
that can support the identification of the subgroup 9.3 “Headache
attributed to HIV/AIDS”, as coded by the present classification.
In the acute phase of HIV infection, some authors have reported that
headache frequently occurs as part of the infectious disease syndrome,
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that also includes fever, chills, malaise, myalgia, arthralgia, and asthe-
nia. This headache has no specific features.
Headache may also be a symptom of aseptic meningitis that is a fre-
quent complication of HIV infection. In this case headache has to be
coded at point 9.1 “Headache attributed to intracranial infection”. In
this same group a variety of headaches that may occur in patients with
AIDS have to be included. Headache, in fact, may be associated with
other diseases, such as meningitis and/or encephalitis due to cerebral
cryptococcal infection or toxoplasmosis. When headache is due to
Kaposi’s sarcoma, endocranial hypertension is involved.
Tuberculous meningitis may also occur in immunosuppressed patients.
In this condition, obstructive hydrocephalus is a frequent complication.
Headache, in this case, may have some specific features due to intracra-
nial hypertension.
Some authors have investigated the changes of idiopathic headaches
(migraine and tension-type headache) in patients with AIDS. It has
been found that migraine tended to decrease during the course of this
disease, whereas tension-type headache tended to increase.
In HIV/AIDS, headache may also be caused by some treatments.
The study of headache in patients with HIV/AIDS is not easy because
of the wide variability of individual conditions and the interference of
different factors and complications. 
Prospective studies on headache associated with HIV/AIDS infec-
tions are warranted in order to lend support to the existence of this
entity that the International Headache Society Classification has just
coded at point 9.3.
GUIDELINES FOR MIGRAINE: UPDATE ON SYMPTOMATIC
DRUGS
G. Zanchin
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The subcommittee for the Symptomatic Treatment of Migraine col-
lected and evaluated the available literature, from the end of 2001 to the
present, concerning drugs for acute migraine treatment. All articles
reported on Medline and Pubmed were examined, whereas abstracts
were excluded.
The levels of evidence, the scientific strength of evidence and the clin-
ical judgment were redefined for each symptomatic drug, integrating
information available in the first edition of the guidelines (2001) with
that found in the past 2 years. The levels of recommendation (I-IV)
were reformulated for approval by the subcommittee.
As in the previous version, recommendation class I includes all triptans
and among NSAIDs: acetylsalicylic acid, lysine salicylates, ibuprofen,
and naproxen sodium, as well as dihydroergotamine in all formulations.
Among triptans, frovatriptan has recently been approved for the Italian
market, while sumatriptan nasal spray for the treatment of migraine
attacks in adolescents is under examination by the Ministry of Health.
Under recommendation class II, ergotamine s.c. and i.m., diclofenac
oral route, ketoprofen, ketorolac, naproxen, paracetamol with and with-
out codeine, and some antiemetics to be administered i.v. (prochlor-
perazine, chlorpromazine and, metoclopramide) have been placed
under recommendation class II.
New drugs are under observation for inclusion in this class, i.e., calci-
tonin gene-related peptide receptor antagonist BIBN 4096 BS i.v. and
the novel AMPA/GluR5 antagonist, LY293558 i.v., which have recent-
ly been demonstrated to be efficacious and well tolerated in acute
migraine.
Other drugs to be discussed for inclusion in recommendation class II
are dipyrone i.v. and droperidol i.m., as well as sodium valproate i.v.
for acute migraine treatment in the Emergency Department, on the
basis of the results of recent randomized, double-blind, placebo con-
trolled studies.
Based on recent evidence in the literature, indomethacin, prochlorper-
azine, and caffeine could shift from recommendation class III to rec-
ommendation class II. Rofecoxib 25 and 50 mg oral route, on the basis
of evidence of effectiveness and good tolerability for the acute treat-
ment of migraine, can also be considered for inclusion in this class.
Recommendation class III includes association drugs with butalbital,
for which the risk of abuse is emphasized, oral ergotamine with and
without caffeine, and rapid dissolution piroxicam. Drugs with scarce or
limited evidence are reported in recommendation class IV, such as
nimesulide, desamethasone and i.v. hydrocortisone, granisetron and
oral metoclopramide, the latter two to be considered as adjuvants for
nausea and vomiting.
PROPHYLACTIC TREATMENT OF MIGRAINE
L.A. Pini, D. Brovia, A. Bertolini
Headache Study Centre, University of Modena and Reggio Emilia,
Modena, Italy; e-mail: pinila@unimore.it
Recent studies on migraine pathogenesis suggested some newer targets
for preventive drug therapy, such as cortical GABA-dependent hyper-
ecitability and excitatory amino acids.
The mechanism of action of antiepileptic drugs is not completely
understood, but they all share a common role in enhancing gamma-
aminobutyric acid-mediated inhibition.
Sodium valproate is the most used anticonvulsant in migraine preven-
tive treatment. Also, lamotrigine has been used in antimigraine treat-
ment, mainly to prevent high frequency migraine with aura. 
Topiramate is effective for migraine prevention and its cognitive side
effects are of less concern with the lower doses needed for migraine.
Topiramate seems to be a good therapeutic option for about half of the
patients with refractory migraine. In these patients, response is usually
excellent. Intolerance due to adverse events appears only in one-fifth of
the cases and at low doses (Pascual, 2003).
Botulinum toxin type A shows promise as a safe, tolerable, and effec-
tive drug for migraine prevention, with the unique advantages of almost
no systemic adverse events and a long interval between treatments,
while the high cost could reduce wide use. The angiotensin converting
enzyme receptor blocker candesartan, and the ACE inhibitor, lisinopril,
appear to be effective and well tolerated in the prevention of migraine
in patients without hypertension. Tizanidine, an α2 central agonist,
seems to be effective in controlled clinical trials, as hydroxocobalamin,
but it is necessary to compare these results with those of other preven-
tive treatments. The phytoestrogens have been tested as preventive in
menstrual migraine with promising results. Tiagabine, levetiracetam,
zonisamide and montelukast require more controlled trials.
Resource utilization is an important aspect in evaluating the economic
impact of migraine prophylaxis. Adding a preventive medication to
migraine management reduces the use of other migraine medications,
as well as visits to physician offices and Emergency Departments. In
addition, both acute and preventive drugs are associated with lower uti-
lization of computed tomography and magnetic resonance imaging
scans. Therefore, migraine preventive drug treatment is effective in
reducing resource consumption when added to therapy consisting only
of an acute medication (Silberstein, 2003).
THERAPEUTIC GUIDELINES FOR CLUSTER HEADACHE:
AN UPDATE 
1M. Fanciullacci, 2M. Alessandri
1Headache Centre, Department of Internal Medicine, University of
Florence, Florence, Italy; 2Headache Centre, Unit of Internal
Medicine, Misericordia Hospital, Grosseto, Italy; e-mail: fanciullac.
marcello@tiscali.it
The search was conducted on PubMed from the date of publication of
the SISC guidelines to April 2004.
Pharmacological acute treatment In an open label trial, 5 mg olan-
zapine alleviated pain quickly and had a consistent response across
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multiple treated attacks in both episodic and chronic forms. In a dou-
ble-blind placebo-controlled randomized trial, patients with episodic
or chronic cluster headache, whose attacks lasted at least 45 minutes
were effectively treated with 20 mg sumatriptan nasal spray.
Pharmacological prophylactic treatment In an open trial,
gabapentin, at the daily dosage of 300 mg t.i.d., was administered for
60 days in episodic cluster headache and for 6 months in the chronic
form. The drug induced remarkable effects on both forms. In a pilot
study, baclofen, which was given 15 to 30 mg daily for the cluster peri-
od and 2 weeks afterward, was effective and retained its efficacy on
repeated clusters. The preventive use of naratriptan, 2.5 mg once or
twice daily, mostly as an add-on to high-dose verapamil treatment
(480–960 mg/day) in patients with cluster headache improved the
headaches. Intravenous boluses of 250 mg methylprednisolone on 3
consecutive days, followed by prednisone (90 mg/day) as a prophylac-
tic treatment for episodic cluster headache, made the attacks signifi-
cantly less frequent in the active phases.
Non-pharmacological treatment Fourteen cluster headache patients
were treated with greater occipital nerve block as transitional therapy
(treatment initiated at the same time as preventive therapy). Headache
intensity, frequency and duration were significantly decreased com-
paring the week before with the week after the nerve block.
Seventeen patients underwent trigeminal nerve root section for
intractable chronic cluster headache. A follow-up period ranged from
3 months to 19 years and showed that trigeminal nerve section was
an effective treatment with acceptable morbidity. A case of a patient
suffering from episodic cluster headache who responded to radiofre-
quency ablation of the cervical zygapophyseal joints was reported.
After the ablative procedure there were no noticeable side effects.
Five patients with intractable chronic cluster headache were treated
with long-term, high-frequency, electrical stimulation of the posteri-
or hypothalamus. Since the treatment, all patients continued to be
pain-free after 2 to 22 months of follow-up monitoring and no
adverse events were observed.
SYMPTOMATIC AND PROPHYLACTIC THERAPY OF TEN-
SION-TYPE HEADACHE
1M. Guazzelli, 2M.P. Prudenzano
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Tension-type headache is the most common type of primary headache.
Its lifetime prevalence in the general population ranges from 30–78%
[1]. The division into episodic and chronic forms has shown to be very
useful both in clinical practice and in research. Either the episodic or
chronic forms can be further subdivided into a subtype associated with
pericranial tenderness and a subtype without pericranial muscle ten-
derness. Therapy should be chosen according to headache frequency,
attack duration, and intensity. Possible comorbidity with other disor-
ders is also to be considered in the management of tension-type
headache patients. Simple analgesics and NonSteroidal Anti-
Inflammatory Drugs (NSAIDs) are first-choice drugs in the treatment
of episodic tension-type headache. Among them, acetylsalicylic acid,
ketoprofen, ibuprofen, naproxen, and acetaminophen are the best sup-
ported by scientific literature. Combination preparations of NSAIDs
with caffeine or codeine are more effective than simple molecules, but
they should not be taken frequently in order to avoid symptomatic
abuse and headache chronicity. Amitriptyline is the best documented
and most widely used prophylactic drug for tension-type headache. Its
effect might be due not only to 5-HT reuptake inhibition but also to
other mechanisms, such as norepinephrine reuptake inhibition,
NMDA receptor antagonism, and blockade of muscarinic receptors
[2]. Several open-label studies and a double-blind, placebo-controlled
study have suggested that tizanidine, which is an alpha-2 adrenergic
agonist that inhibits the release of norepinephrine in both the spinal
cord and brain, can be effective in tension-type headache therapy [3].
Recent clinical results have suggested that botulinum toxin type A
may be a promising treatment option for patients with chronic tension-
type headache [4].
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NON-PHARMACOLOGICAL THERAPIES
L. Savi, P. De Martino
Department of Neurosciences, Neurology III, Primary Headache
Centre, University of Turin, Molinette Hospital, Turin, Italy; e-mail:
lsavi@molinette.piemonte.it
Non-pharmacological therapy (NPT) of primary headaches considers
two main aspects: advice to patients and therapy (symptomatic and/or
prophylactic).
Bearing in mind that many differences exist among the various forms
of headache, patients are first invited to adopt and to keep what are gen-
erally called “healthy daily life habits”: stop smoking; cut alcoholic
drinks consumption; maintain the sleep-waking cycle; eat at given
hours and practice some sport. Of course, when some particular trigger
of the headache attacks is identified, it should be avoided, if and when
it is possible.
Patients’ characteristic behaviours, related to the pain onset, represent
the so-called non-pharmacological symptomatic therapy (sleep or rest
in a silent or quiet place; hot or cold local applications on the pain site,
etc.). There are no scientific data that these methods are of some effec-
tive value.
NPTs have been used over the years as a prophylaxis: acupuncture;
behavioural therapy; hyperbaric oxygen therapy; hypnotherapy; ortho-
dontics or gnathologic techniques; physical therapy; and various surgi-
cal therapies. 
Relaxation, biofeedback and cognitive-behaviouristic therapy are the
main forms of the so-called behavioural therapy. This kind of therapy,
and sometimes psychotherapy, may be useful in treatments for anxiety
and depression, frequent co-morbid manifestations of various headache
forms.
Finally, many different treatments are included under the name “phys-
ical treatment”: hot and cold applications on the aching site; massages;
ultrasounds; TENS; stretching exercises to improve one’s posture;
physical exercises; and traction exercises.
At present, the effectiveness of the various NPTs in the treatment of
primary headaches has been proved for some techniques (biofeed-
back), but it is still controversial for others.
NPTs represent, in any case, a possible treatment for headache in all
those situations when it is better to completely avoid the use of drugs
(pregnancy, breast feeding, serious concomitant illnesses, etc.) and
they may be useful in association with pharmacological therapy, when
this is not too problematic for the patient. This therapy may also be use-
ful in some special situations, such as: ineffective or inadequate
response to drug therapies; absence of patient’s compliance; patient’s
refusal to use drugs; psychiatric comorbidity; environmental trigger
factors, which show a temporal relation with the onset of the crises; and
less than four days per month of headache.
S24
TREATMENT OF CHRONIC MIGRAINE AND MEDICATION-
OVERUSE
E. Sternieri, C.P.R. Coccia, S. Leone, G. Pasciullo, A. Bertolini, 
A. Ferrari
Headache Centre, Toxicology and Clinical Pharmacology Section,
University of Modena and Reggio Emilia, UCADH Section Modena II,
Modena, Italy; e-mail: sternieri.emilio@unimo.it
According to the 2nd edition of “International Classification of
Headache Disorders”, migraine is classified as “chronic” when occur-
ring on 15 or more days per month for more than 3 months”. Most
cases of chronic migraine start as migraine without aura, and chronic-
ity may be regarded as a complication of episodic migraine. Usually, if
migraine attacks occur on 15 or more days per month, medication
overuse is present. But a sample of patients presents both migraine
attacks and tension-type headache, so it is difficult for patients to esti-
mate how many attacks fulfil one or another set of criteria. In all cases,
the first step of treatment is to stop the intake of drugs used for many
years and to start an intravenous therapy and a preventive treatment
program. Another preliminary step is the identification of comorbid
psychiatric conditions and exacerbating factors. If large amounts of
butalbital-containing analgesic combinations are used, phenobarbital
should be administered in order to prevent withdrawal symptoms.
Similarly, benzodiazepines and opiates must be gradually reduced. In
some cases in-patient treatment is required.
PET THERAPY: A NEW THERAPEUTIC STRATEGY FOR
CHILDHOOD HEADACHE
D. Moscato, M.I. Peracchi, F. Bochicchio, A. Falasconi, M. Pesti
Childhood Headache Centre, Saint Charles Hospital IDI, Rome, Italy;
e-mail: dmoscat@tin.it
Pet therapy is behavioural therapy that has been implemented for the
past few years for the treatment of psychic discomfort and other psy-
chosocial disturbances [1, 2].
We implemented a preliminary experimental stage for 6 months where
15 children and adolescents suffering from headache and psychosocial
disturbances (anxiety, family, or school discomfort, etc.) attended 1
weekly session for 8 to10 weeks.
In the evaluation of headache, a >50% improvement was obtained, also
for the associated symptoms, and in the parent-child compliance.
We then proposed Pet therapy to headache suffering subjects, for whom
the pathology was mainly linked to an environmental uneasiness.
A treatment cycle of 12 sessions per week of 1–2 hours each was estab-
lished with psychotherapists and pets. An evaluation test and headache
assessment with a chart were carried out before and after therapy (pro-
jective and psychometric tests: drawing of the family, the tree; the CDI
and FAB-C tests).
Pet therapy in our group is conducted by 3 psychotherapists who
attended Delta Society courses.
The pets permanently available for Pet therapy are 3 dogs, 2 Persian cats,
and about 50 canaries in an aviary. The dogs, the cats, and the ferrets are
brought by their owners, whereas the aviary belongs to our hospital. 
Pet therapy is conducted in a garden of about 800 m2, with some trees,
a playground, and a small wooden house for winter activities, on the
hospital premises devoted exclusively to these activities.
Our study included 34 patients (pt): 15 females; 19 males, aged 4 to 16
years (MwoA 16 pt, MwA 2 pt, ETTH 8 pt, CTTH 8 pt,), ranging from
4 to 16 years divided into 2 groups, pre/post-puberty.
Evaluating the headache graph at the beginning and end (after 6
months) of treatment, a significant reduction in the frequency (6.1±1.7;
3.6±1.3 p<0.002) and duration (7.3±1.9h; 4.9±1.4h; p<0.05) of the cri-
sis was observed.
The psychological characteristics evaluated through the various tests
indicated, especially for CDI (15.5–8.5) and FAB-C (13.5–10.3), a
considerable improvement also in this aspect.
These are preliminary data and the patients are few, but if further stud-
ies confirm them, Pet therapy could be an important therapeutic
approach also for headache in childhood.
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CEREBROVASCULAR DISEASE AND MIGRAINE: PATHO-
GENETIC IMPLICATIONS AND THERAPEUTIC OPPORTUNI-
TIES
S. Gori, N. Morelli, S. Fanucchi, G. Orlandi, L. Murri
Institute of Neurology, Department of Neurosciences, University of
Pisa, Pisa, Italy; s.gori@med.unipi.it
The association between migraine and cerebrovascular disease has been
described in several studies. An increased risk of stroke in migraneurs
has been reported: data from the literature showed that this association
becomes significant in women less than 45 years old who are smokers,
hypertensive, taking oral contraceptives, and confirmed that migraine,
especially with aura, represents a risk factor for ischaemic stroke in
women of childbearing age. Recent investigations documented that the
prevalence of right-to-left shunt (RLS) in patients with migraine with
aura (MA) is significantly higher than in healthy controls and similar to
the prevalence of RLS in young patients with cryptogenic stroke. These
findings suggested the possible role of RLS in both the increased risk of
stroke in migraineurs and the pathophysiology of aura. Despite several
studies that documented an increased occurrence of patent foramen
ovale (PFO) in MA and emphasized its role in the pathophysiology of
aura, no data have been available until now concerning the possible cor-
relation between the entity of RLS and the clinical picture in MA
patients. We studied a sample of 42 consecutive patients affected by
migraine with aura according to IHS diagnostic criteria (1988) with
RLS documented by means of Transcranial Doppler ultrasound.
According to these data RLS does not affect either clinical presentation
or entity of RLS, at least as estimated by Transcranial Doppler testing,
and fails to correlate with several parameters that are clinical markers of
severity in migraine with aura (i.e., mean duration of aura, frequency of
attacks, days/month with migraine, MIDAS score). Percutaneous clo-
sure of PFO in cryptogenic stroke for selected patient is advisable and
this treatment has been documented to modify the course of migraine
with aura in patients with such comorbidity. Nevertheless, conflicting
data on the possible benefit of PFO closure in MA have been docu-
mented. The therapeutic implications of cerebrovascular disorders and
RLS comorbidity in migraine patients are still being discussed.
THE ROLE OF PHARMACOTHERAPY IN THE PREVENTION
OF CHRONIC MIGRAINE
1M. Fanciullacci, 1F. De Cesaris, 2M. Alessandri, 1U. Pietrini, 
1E. Del Bene
1Headache Centre, Department of Internal Medicine, University of
Florence, Florence, Italy; 2Headache Centre, Department of Internal
Medicine, Misericordia Hospital, Grosseto, Italy; e-mail: fanciullac.
marcello@tiscalinet.it
Episodic migraine should be considered a chronic progressive disorder
with marked deterioration of quality of life. Up to 2.4% of the general
population experiences chronic migraine (CM); the principal factors
that predict its onset and persistence are female gender and high
headache frequency. In addition, migraine patients are at risk for sub-
clinical cerebellar infarcts, that rises with increasing attack frequency. It
is reasonable to assume that attack frequency and severity are directly
correlated with the development of structural damage and disability and
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to use them as surrogate markers of disease progression. Therefore, the
group of migraine patients with high frequency of marked disabling and
prolonged attacks deserve clinical vigilance to prevent the progression
of the disease – we should begin thinking of abortive and prophylactic
pharmacotherapy as a disease-modifying agent. Central sensitization
plays an important role in the pathophysiology of CM: two thirds of
migraine patients develop central sensitization, arguably a form of pro-
gression of the attack. The development and maintenance of cutaneous
allodynia later in the attack is propelled by sensitization of the central
trigeminovascular neuron that receives converging sensory input from
the meninges as well as from scalp and facial skin. Probably the cumu-
lative effects of repeated migraine attack generating central sensitivity
over the years will provoke an age-related progression of the disease
and the clinical onset of chronic headache. Taking triptan as soon as
possible prevents allodynia and therefore might be an important strate-
gy to prevent permanent instauration of central sensitization and onset
of CM. In contrast, the overuse of abortive medication might accelerate
disease progression. Migraine patients, in fact, are particularly predis-
posed to develop chronic headache in association with medication
overuse (30–50%). Overuse prevention is a paramount goal of CM pre-
vention. Prophylactic drugs might contribute to arrest the process of
migraine chronicization, but their long-term effects on the natural histo-
ry of migraine have not yet been well studied. However, it is reasonable
to recommend lengthy prophylaxis for patients with factors indicating
migraine progression, to greatly decrease attack frequency. In contract,
there is evidence that patients with high headache frequency but not
daily headache show greater improvement with prophylaxis than
patients with daily headache. The first migraine attacks in patients with
high risk of chronicization may soon be viewed as a signal to begin
aggressive protective pharmacotherapy, most likely, with new proce-
dures and drugs, with the aim of preventing CM.
PHARMACODYNAMIC AND PHARMACOKINETIC INSIGHTS
IN HEADACHE PATIENTS WITH DRUG OVERUSE
1A. Bianchi, 1A. Capasso, 2,3S. Salomone
1Department of Pharmaceutical Sciences, Division of Clinical
Pharmacology, University of Salerno, Salerno, Italy; 2Department of
Experimental and Clinical Pharmacology, University of Catania,
Catania, Italy; 3Stroke and Neurovascular Regulation Laboratory,
Massachusetts General Hospital, Harvard Medical School,
Charlestown, USA; e-mail: abianchi@unisa.it
A substantial proportion of headache patients overuse acute medica-
tions. Overuse has been considered to be responsible, in many cases,
for the development or maintenance of chronic daily headache (CDH).
Our aim is to evaluate recent experimental and clinical data on the
pathophysiology of this syndrome. The biochemical basis of CDH is
not known, but the 5-HT system seems to be involved. Indeed, chron-
ic overuse of acetaminophen induces alterations of this system both at
the level of CNS and platelets, in some animal models. Similarly, some
abnormalities in 5-HT levels and in 5-HT receptors have been found in
patients with CDH. 
Since triptans are the most effective anti-migraine drugs used and show
agonist action mainly at 5-HT(1B/1D/1F) receptors; their effect after
chronic use and/or after overuse deserves particular attention. In a
recent study [1], the effects of protracted triptan treatment have been
evaluated in rats on 5-HT1 receptor mRNA expression and function in
tissues related to migraine pathophysiology. Despite a reduction in 5-
HT(1B/1D/1F) receptor mRNA, no significant effect was detected in
two functional assays. Therefore, the significance of 5-HT receptor
expression in migraine pathophysiology as well as pharmacokinetic
implications need further analysis. In another recent study [2], the out-
comes of analgesic overuse have been evaluated by comparing a group
of patients who discontinued medication overuse to a group who con-
tinued the overuse. After one-year of follow-up there was a decrease in
the frequency of headache in 73.7% of group 1 (successfully detoxi-
fied) and in only 17.2% of group 2. Similarly, the duration of head pain
was reduced by 61.2% in group 1 and 14.8% in group 2. Rigorous pre-
scribing guidelines as well as successful detoxification are therefore
needed when treating patients with drug overuse.
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REHABILITATION PROCEDURES FOR MEDICATION-
OVERUSE HEADACHE (MOH)
S. De Filippis, E. Salvatori, I. Cuomo, P. Martelletti
Regional Referral Headache Centre, Department of Medicine, II
School of Medicine, University of Rome “La Sapienza”, Sant’Andrea
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Chronic headaches represent a disorder with high social impact pro-
ducing direct and indirect costs. Daily intake of analgesic drugs is the
clinical evolution of this disorder. MOH is a new form of secondary
headache with various clinical manifestations appearing after the sud-
den suspension of analgesics, ergot-derivatives, barbiturates, and trip-
tans, taken alone or in association, according to the quantitative profiles
defined by IHS (ICDH-II, 2004).
The MOH detoxification procedure has to be intended as part of a
wider therapeutic project, which comprehends the detoxification and
the rebound phase, the treatment of the complications, and, in particu-
lar, the phase of relapse prevention.
A multidisciplinary approach to MOH can be held in Day Hospital
(weaning phase) and subsequently in the outpatients department (ther-
apeutic re-programming).
The principal endpoints supporting the rehabilitative treatment of
MOH are:
- Removal of the psychophysical pain with daily i.v. therapy;
- Efficacy of the doctor-patient relationship to assure treatment conti-
nuity also after drug abuse;
- Specific therapies for each patient;
- Involvement of the patient in his therapeutic project.
The therapy is divided in light and heavy analgesic intake: an outpa-
tient treatment will be sufficient in the first case, and a day hospital
treatment in the second.
The rebound syndrome following MOH is based on the alteration of
one or more of the following neuronal systems: noradrenergic hyper-
activity, modification of the NMDA receptors, alteration of the GABA-
Benzodiazepine receptor, and hyperactivity of the HPA axis.
The psychological aspect that combines the pain with analgesics use is
important in the comprehension of this headache type and the con-
comitant abuse. Many patients feel forced to take analgesics to calm
the pain. Therefore, our task will be to suggest adequate drugs pre-
venting the return of headache chronicity and/or natural crises coming
back after hangover MOH removal.
CHRONIC HEADACHE AND MEDICATION-OVERUSE: LONG-
TERM FOLLOW-UP AFTER DETOXIFICATION
G. Relja, A. Granato, L. Locatelli, R.M. Antonello, M. Zorzon
Neurological Department, Headache Centre, University of Trieste,
Trieste, Italy; e-mail: m.chert@fmc.units.it
The recent revision (2004) of the International Headache Society (IHS)
“The International Classification of Headache Disorders” defined the
clinical characteristics, the type and dosage of drugs, and the duration
of the medication-overuse headache.
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All experts agree on the necessity in interrupting the overused medica-
tion to stop the chronic headache and to obtain positive results with the
subsequent prophylactic therapy.
Head-to-head controlled trials on different therapeutic approaches are
lacking and consequently guidelines for the treatment of medication-
overuse headache are currently not available.
Long-term follow-up studies after detoxification are few and report a
relapse in 39–66% of patients.
Fifty (46 F, 4 M) daily abusers of analgesics with chronic headache
were re-evaluated four years after detoxification. All patients were
admitted to the Trieste Headache Unit and treated with abrupt stoppage
of overused medication, intravenous hydrating therapy and intravenous
therapy with benzodiazepines (i.e., delorazepam) and S-adenosylme-
thionine. Symptomatic and antiemetic drugs were used only in case of
severe rebound headaches.
A questionnaire on demographic characteristics, working and recre-
ational activities, incidental comorbidities, features of the headache
and use of medications was administered to patients. They underwent
neurologic and general examination.
Thirty-two percent of patients had one or more relapses of medication-
overuse headache, whereas the remaining 68% had less than 15
headache attacks per month and no longer experienced analgesics abuse.
Predictive factors for relapse were urban domicile, small family, ciga-
rette smoking, lack of hobbies, comorbidity with depression and arter-
ial hypertension, and inadequate prophylactic therapy. An extension of
the analyses to other variables is under way.
The positive results confirm that these patients should be treated early
with detoxification and subsequent prophylactic therapy.
Comparison studies evaluating different therapeutic strategies are war-
ranted.
ORAL PRESENTATIONS
EPISODIC AND CHRONIC MIGRAINE:
PATHOGENETIC ASPECTS
FACILITATORY EFFECTS OF 1 HZ RTMS IN MOTOR COR-
TEX OF PATIENTS AFFECTED BY MIGRAINE WITH AURA
F. Brighina, A. Palermo, G. Giglia, C. Pecoraro, S. Scalia, 
M. Francolini, B. Fierro
Department of Neurology, University of Palermo, Palermo, Italy; e-
mail: fbrighina@neuro.unipa.it
Objective We previously showed paradoxical facilitatory effects of
low-frequency rTMS on the striate and extrastriate cortex of patients
suffering from migraine with aura [1, 2].
In this study we evaluated the effects of 1 Hz rTMS on excitability of
inhibitory and facilitatory circuits of the motor cortex to explore if the
abnormal pattern of excitability extends beyond the sensory cortex also
involving motor areas in migraine with aura.
Materials and methods Nine patients affected by migraine with aura
and 8 healthy controls were included in the study. The hot-spot for acti-
vation of the right abductor pollicis brevis (ABP) muscle was checked
by means of a figure-of-eight coil and the motor threshold (MT) was
recorded on this point. A train of 600 magnetic pulses at 1 Hz fre-
quency and 90% MT intensity were delivered to the hot-spot. Before
and after rTMS, the excitability of intracortical inhibitory and facilita-
tory circuits were assessed by means of a paired pulse paradigm (con-
ditioning stimulus: 80% MT, and test stimulus: 120% MT) with two
different interstimulus intervals: 2 msec (inhibitory) and 10 msec
(facilitatory). Amplitude of the responses was expressed as the per-
centage of motor evoked potential (MEP) to the test stimulus alone.
Results At baseline conditions, migraineurs showed significantly
reduced levels of intracortical inhibition (ICI), as compared to controls.
Intracortical facilitation (ICF) in controls was significantly decreased
by 1 Hz rTMS, whereas it was increased in migrainers. ICI levels were
not significantly affected by low frequency stimulation. 
Discussion Our results showed that the motor as well as sensory cor-
tex of migraine patients present an abnormal modulation of cortical
excitability, where a relevant role is likely played by the inefficiency of
inhibitory circuits.
Conclusions This study further contributes to the hypothesis of
reduced cortical inhibition in migraine with aura.
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EVALUATION OF CORTICAL BLOW FLOOD USING fMRI IN
A SUBJECT AFFECTED BY MIGRAINE WITH AURA DURING
AND AFTER THE ATTACK
R. Grugno, A. Vitetta, P. Di Bella, P. Bramanti
Neurologic Injury Centre, University of Messina, Messina, Italy; e-
mail: rgrugno@virgilio.it
Objective Recent studies have emphasized an altered BOLD signal
(Blood Oxygenation Level-Dependent) in subjects affected by migraine
with aura. Several authors have therefore studied these types of subjects
using functional magnetic resonance imaging (fMRI) during migraine
attack or during the period between two attacks, thus highlighting an
abnormal response of regional cortical blood flow (rCBF) in the occipital
areas by administering a visual stimulation task. However, it is very diffi-
cult to plan a study on subjects during the migraine attack, because one
can not predict when a spontaneous attack may occur. In fact, many stud-
ies succeeded in observing the BOLD signal during an attack, because the
visual stimulation task, at times, triggers it. Thus, we assessed a subject
with fMRI in two different moments: during the migraine attack, and after
a fortnight in order to observe the differences in rCBF.
Materials and methods In order to enroll a patient during migraine
attack, we told all our outpatients affected by migraine with visual aura
to contact us as soon as the attack began. Thus, it was possible for us
to carry out a fMRI on a 27-year-old male using a visual stimulation
task. After a fortnight, the task was repeated and we also carried out an
EEG, TMS, VEP, and a blood test.
Results The fMRI data showed a markedly reduced activation in the
occipital areas during the migraine attack, while the data obtained from
the subsequent fMRI also showed a reduced activation, almost like the
first. The EEG was altered for the presence of epileptiform activity.
Discussion Our results showed a different pattern of activation of the
occipital areas correlated with migraine symptoms. Furthermore, the
electrophysiological data obtained demonstrated altered activity due to
the patient’s disorder in agreement with the literature. We thus support
the concept of cortical spreading depression which is, according to
recent literature, a fundamental pathophysiologic mechanism that trig-
gers migraine with aura attacks.
Conclusions Our results, however, need to be verified on a larger sam-
ple, even if we realize that it is difficult to coordinate this series of
examinations during a migraine attack.
NEPRILYSIN LEVELS IN MIGRAINE ATTACKS
1P. Sarchielli, 1F. Coppola, 1A. Alberti, 2Ar. Floridi, 1Al. Floridi, 
1G. Capocchi
1Neurologic Clinic, Department of Neurosciences, University of
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Background Neprilysin (neutral endopeptidase, EC 3:4:24:11, CD10)
(NEP) is a Zn metallopeptidase which has been demonstrated to inter-
vene in limiting neurogenic inflammation through the degradation of
sensory neuropeptides [1]. The involvement of this endopeptidase in
antagonizing neurogenic inflammation consequent to trigeminovascu-
lar activation during migraine attacks is not known.
Objective The aim of this study was to investigate the circulating and
cellular expression of NEP in the internal jugular blood of migraine
without aura patients (MwoA) assessed during an attack.
Patients and methods Ten MwoA patients were admitted to the hos-
pital during the attacks. Internal jugular venous blood samples were
taken immediately after catheter insertion, at 1, 2, and 4 hours after
attack onset, and within 2 hours from its cessation. NEP levels in plas-
ma from the internal jugular blood were assessed using a fluorimetric
technique. Neprilysin, expressed as the antigen CD10, was determined
in jugular blood cells as mean fluorescence intensity (MFI) and as per-
centage of positive cells by two-colour immunofluorescence.
Results Plasma levels of NEP tended to be significantly increased from
the second hour after catheter insertion (p<0.01) and remained elevat-
ed for the entire attack. They then returned to values lower than those
measured at the onset of attacks.
A similar trend was observed for the percentage of CD10-positive cells
in jugular venous blood and MFI, which peaked at 2 and 4 hours after
attack onset. 
Discussion Trigeminovascular activation during migraine attacks caus-
es the release of sensory neuropeptides, such as CGRP and neurokinin
A. Based on the results of the present study, it can be hypothesized that
NEP intervenes in limiting neurogenic inflammation by cleaving and
inactivating a proportion of these peptides released during migraine
attacks [2].
J Headache Pain (2004) 5:S27–S46
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HIGH PLASMA LEVELS OF PROLACTIN IN CHRONIC
MIGRAINE
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1Department of Neurology, 2Endocrinological Service, 3Department
of Internal Medicine, “S. Lazzaro Hospital, Alba, Italy; e-mail:
cicaves@tin.it
It is not always clear why a migraine transforms from an episodic into
a chronic form.
Considering the close correlation in women between hormones and
migraine, we tested for thyroid hormones and plasma prolactin levels in
all new patients who came to our Centre because their migraine wors-
ened in the last year. All of the patients underwent a general physical
and neurological examination, MRI, and angio MRI, Rx of the cervical
spine, and extensive blood screening, also including sexual hormones,
TSH, FT3, fT4, prolactin levels, ACTH, cortisol, and subsequently also
an endocrinologic evaluation. In some case, they also underwent other
examinations because of the presence of other pathologies (e.g., hyper-
tension). We screened 15 patients with chronic headache who had a nor-
mal neurological exam and a negative neuro-radiological evaluation,
having migraine and/or tension-type headache during the last year. They
were 14 females and 1 male. Ten of them had a pure chronic form of
migraine, 2 a chronic tension-type headache, and 3 patients had both
types. Among the pure chronic migraine type, 6 patients had high plas-
ma levels of prolactin, ranging from 1200 to 3200 pm/l. They were all
female, aged from 22 to 57 years, none except one had menstrual alter-
ations, nor any other symptom of hormonal disorders; the most peculiar
aspect was that the characteristics of their headache did not change, and
they responded completely to the international criterion for defining
migraine. In the other 4 patients with chronic migraine, the male patient
had an important chronic sinusitis of the maxillary and ethmoidal sinus-
es, another patient had an important intolerance to some type of flours,
and after having eliminated that ingredient from her diet, she was almost
completely headache free, another had an important cervical spine dis-
order, and the fourth had a history of antiinflammatory drug abuse. All
patients with high levels of prolactin promptly responded to the reduc-
tion in prolactin alone, obtaining an important decrease in the intensity
and number of attacks. We can conclude that thorough screening of the
hormonal profile, in our case prolactin, is often useful, and it is possible
to identify a symptomatic cause of migraine chronicity, also in the
absence of any signs or symptoms of hormonal disorders.
NOCICEPTIN IN THE CEREBROSPINAL FLUID OF CHRON-
IC MIGRAINE AND FIBROMYALGIA PATIENTS
1P. Sarchielli, 1L. Pierguidi, 1A. Alberti, 2Ar. Floridi, 1Al. Floridi, 
1G. Capocchi
1Neurologic Clinic, Department of Neurosciences, University of
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Backgroud Nociceptin is the endogenous ligand of the G-coupled,
naloxon insensitive ORL-1 receptor. An increased expression of both
nociceptin and the ORL-1 receptor has been demonstrated in the dor-
sal horn of the rat spinal cord in experimental pain models, thus indi-
cating the involvement of the nociceptin/ORL-1 system in the mecha-
nisms of pathological pain. No studies have been carried out until now
on the levels of nociceptin in chronic migraine and fibromyalgia.
Objective The aim of the present study was to verify the CSF levels of
nociceptin in 20 chronic migraine (CM) patients, 20 patients with an
antecedent history of migraine without aura diagnosed as having prob-
able chronic migraine (PCM) and probable analgesic-abuse headache
(PAAH), as well as in 20 patients affected by primary fibromyalgia
syndrome (PFMS). The CSF levels of prostaglandin PGE2 were also
determined in all patient groups. Control values for nociceptin and
PGE2 were obtained from the CSF of 20 control subjects, for whom the
CSF examination and other instrumental investigations excluded dis-
eases of the central and peripheral nervous system.
Methods CSF levels of nociceptin and PGE2 were determined by sen-
sitive immunoassays.
Results Levels of nociceptin and PGE2 were significantly higher in the
CSF of both patients with CM and PCM+PAAH compared with con-
trol subjects (nociceptin=p<0.01 and p<0.02, PGE2=p<0.03 and
p<0.02), without significant differences between the two groups.
Patients with PFMS also had significantly higher levels of both noci-
ceptin and PGE2 (p<0.02 and p< 0.01, respectively), which did not dif-
fer from those in CM and PCM+PAAH patients. In PFMS patients no
significant differences emerged between nociceptin and PGE2 levels in
patients with and without analgesic abuse.
CSF values of nociceptin were positively correlated with PGE2 values
in both patients with CM (R=0.62, p<0.01) and PCM+PAAH (R=0.60,
p<0.02). A statistically significant correlation was also found between
nociceptin and PGE2 levels in the CSF of PFMS patients (R=0.48,
p<0.01).
Discussion Experimental findings suggest an anti-analgesic action of
nociceptin originating in the brain, which is coupled to a descending
neuronal pathway mediated by spinal PGE2 [1]. This pro-nociceptive
action of nociceptin can be hypothesized in both chronic migraine and
fibromyalgia, where it seems to be related to PGE2 secretion and does
not appear to be influenced by analgesic abuse. 
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PRIMARY HEADACHES: CLINICAL ASPECTS
ATTACHMENT STYLE AS A PREDICTOR OF DISABILITY IN
A CLINICAL POPULATION OF PATIENTS WITH EPISODIC
MIGRAINE
1G. Di Lorenzo, 2P. Rossi, 1M.G. Malpezzi, 2C. Di Lorenzo, 2J. Faroni,
2F. Cesarino, 1A. Siracusano, 1A. Troisi
1Psychiatry Unit, Department of Neuroscience, University of Rome
“Tor Vergata”, Rome, Italy; 2Headache Clinic, INI Grottaferrata,
Rome, Italy; e-mail: di.lorenzo@med.uniroma2.it
Objective To assess the relative role of socio-demographic variables,
migraine characteristics, and psychological factors in influencing
migraine-related disability.
Methods The sample included 197 outpatients with episodic migraine.
Measures included: disability (MIDAS), adult attachment style (ASQ),
depressive symptoms (BDI), trait anxiety and anger (STAI – T and
STAS – T). Statistical analysis was based on a stepwise regression
model using total MIDAS score as dependent variable and age, gender,
number of migraine days per month, duration of attack, pain severity,
BDI, STAI – T, STAS – T and ASQ scales as predictors.
Results The model was highly significant (F=14.11, p<0.001) and
accounted for 25.1% of the total variance in disability. Number of
migraine days per month (beta=0.32, p<0.001), duration of attack
(beta=0.17, p=0.008), pain severity (beta=0.16, p=0.012), gender
(beta=0.16, p=0.015) and an insecure style of adult attachment
(Confidence scale of the ASQ; beta=-1.71, p=0.007) emerged as sig-
nificant predictors of migraine-related disability.
S29
Conclusions These findings show that attachment style is a significant
predictor of disability in patients with episodic migraine even after
controlling for the confounding effect of severity.
COGNITIVE DYSFUNCTIONS IN MIGRAINE: NEUROPSY-
CHOLOGICAL INVESTIGATION TOOLS AND VARIABILITY
OF RESULTS
F. Lanaia, R. Morana, A. Librante, M.L. Lo Bartolo, R. Tarantello, 
F. Le Pira
Department of Neuroscience, University of Catania, Catania, Italy; e-
mail: lepira@unict.it
Cognitive dysfunctions in migraine patients have been reported by
several authors. These findings, however, are controversial. While
some studies claimed the presence of deficits, others did not con-
firm these results. This variability may depend on clinical variables
(type of migraine, duration of disorder, side of pain, attack fre-
quency, therapy) but may also be influenced by the neuropsycho-
logical tests chosen to study the patients. In previous studies, we
found significant differences in attention and memory perfor-
mances related to the type of migraine and the side of pain. The
aim of the present study was to investigate the possible effect of
neuropsychological tests on the detection of cognitive dysfunc-
tions. In this preliminary paper our investigation was limited to
attention, verbal, and visual memory. Fourteen patients suffering
from migraine were studied. Informed consent was obtained.
According to the International Headache Society criteria, 8
patients were diagnosed with migraine with aura, and 6 were diag-
nosed with migraine without aura. The mean age and education
were, respectively, 35.14±9.6 years and 13.07±3.2 years.
Exclusion criteria included other types of headache, a history of
central or peripheral nervous system diseases, trauma, systemic
diseases, and major psychiatric disorders. We used the following
tests: Symbol Digit Modalities test, Rey’s 15-words Immediate and
Delayed Recall and Visual Reproduction test. Comparing our
results with normative data, we found the presence of attention
defects in 35% of subjects and short and long-term verbal memory
and visual memory defects in 14% of the subjects.
Our data suggest that using the neuropsychological tests chosen in
the present study and comparing the results with normative data we
were able to detect cognitive dysfunctions only in a small number of
migraineurs. In conclusion, together with other reported clinical vari-
ables, the choice of different neuropsychological tests may also influ-
ence the detection of cognitive defects in migraine. 
SUBCLINICAL TEMPOROMANDIBULAR AND CERVICAL
SPINE DYSFUNCTIONS IN MIGRAINE PATIENTS: PRELIM-
INARY RESULTS
1G. Bruti, 2A. Rivaroli, 2V. Rondelli, 1V. Villani, 1C. Mostardini, 
1F. Di Stani, 2A. Brunelli, 2P. Cascone, 2G. Iannetti, 1R. Cerbo
1Headache Unit and 2Oromaxillo-Facial Pain Unit of the Pain Center
“Enzo Borzomati”, Policlinico Umberto I, Department of Neurological
Sciences; 2Department of Maxillo-Facial Surgery, University of Rome
“La Sapienza”, Rome, Italy; e-mail: gianluca.bruti@uniroma1.it
Background Epidemiological and clinical studies have disclosed an
association between temporomandibular dysfunction and headache,
even if the relationship between migraine and disorder of the masti-
catory system is not completely understood. Nevertheless, aetiologi-
cal connections between diseases of the temporomandibular system
and of the cervical spine as well as between the cervical spine and
headache have often been discussed in the past. It has recently been
suggested that the trigeminocervical complex plays a crucial role in
the pathophysiology of the neck discomfort which accompanies the
migraine attack.
Objective Aim of the study was: (1) to investigate the function of the
temporomandibular system and of the cervical spine in a population of
migraine patients; (2) to verify the presence of a correlation between
the clinical features of pain and the subclinical temporomandibular
joint and cervical spine dysfunctions.
Materials and methods Twenty migraine patients were consecutively
recruited according to IHS criteria (2004). All study subjects were sub-
jected to the following clinical and instrumental procedures: (1) a clin-
ical investigation of the temporomandibular system according to the
“Craniomandibular Index” of Friction and Schiffman (1986); (2) elec-
trognathography and electromyography of the temporomandibular
joint; (3) physical examination of the cervical spine included items that
belong to the diagnostic criteria for cervicogenic headache.
Results We enrolled 20 migraine patients (mean age 35±10 years) and
10 healthy controls (mean age 32±12 years). Migraineurs showed a
significantly higher score in the clinical evaluation of both the tem-
poromandibular joint and cervical spine than healthy controls (p<0.05).
Electrognathography and electromyography data of the temporo-
mandibular joint showed significant differences between patients and
healthy controls (p<0.05). 
In particular, when we considered separately the two groups of
migraineurs, we found that patients with “back pain” showed higher
levels of clinical and electrophysiological dysfunctions than both
patients with “anterior pain” and controls. Duration of illness and fre-
quency of attack were positively correlated with these clinical and elec-
trophysiological data (p<0.05).
Conclusion Our data suggest the presence of subclinical temporo-
mandibular and cervical spine disorders in all migraineurs and in
particular in those with “back pain”. These dysfunctions are corre-
lated with the severity of migraine and may depend on a dysregula-
tion of the trigeminocervical complex. It may be important to identi-
fy these clinical features in migraine patients not only for the thera-
peutic implications but also for understanding the pathophysiological
link between the mandibular system, cervical spine, and migraine
attack.
A SELF-ADMINISTERED QUESTIONNAIRE FOR SCREEN-
ING OF MIGRAINE IN PRIMARY CARE: A PROTOCOL FOR
VALIDATION OF THE ITALIAN VERSION OF THE ID
MIGRAINETM
1F. Brighina, 1G. Salemi, 1B. Fierro, 2V. Raieli, 3G. Santangelo, 
4V. Saporito, 5M. Gasparro, 6F. Lanaia, 6R. Morana, 7G.B. La Pegna,
7E. Cumbo, 8G. Randisi, 8L. Giglia, 9G. Calagna
1Department of Neurology, University of Palermo, Palermo, Italy;
2Child Neuropsychiatry Department, “G.F. Ingrassia” Hospital, AUSL 6,
Palermo, Italy; 3Child Neuropsychiatry Department, “Civico ARNAS”
Hospital, AUSL 6, Palermo, Italy; 4Headache Outpatient Service,
AUSL 6, Bagheria, Palermo, Italy; 5Neurology Unit, Hospital “Villa
Sofia”, Palermo, Italy; 6Department of Neurology, University of
Catania, Catania, Italy; 7Neuroscience Department, A.S.S. 2,
Caltanissetta, Italy; 8Neurology Unit, Hospital “S. Elia”,
Caltanissetta, Italy; 9Psychiatry Unit, Civic Hospital, Partitico,
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Objective Epidemiological studies show that despite the disability
and burden of migraine less than one-half of migraineurs received a
diagnosis of migraine and only one-third of them are treated with pre-
scription drugs [1]. Recently, Lipton et al. [2], while evaluating
screening tools for the diagnosis of migraine in primary care, vali-
dated a three-question based self-administered questionnaire (ID
MigraineTM), which was able to identify migraineurs in primary care
setting with high sensitivity (0.81), specificity (0.75) and positive
predictive value (0.93).
The objective of this study was to validate an Italian version of ID
MigraineTM in primary care setting; evaluating also the potential appli-
cation of this tool for epidemiological studies of migraine.
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Materials and methods The study will be conducted at 5 headache
outpatient services in Sicily. Seventy healthy subjects and 160 consec-
utive patients affected by migraine and other headaches will be divid-
ed into groups (equally balanced) according to age (6–14, 15–54, ≤55
years) and diagnostic criteria (migraine, other primary headaches,
symptomatic headaches, and healthy controls); men and women will be
selected in about the same percentage. The headache subtypes will be
classified by headache specialists according to the criteria of the last
IHS classification.
Patients and controls will then receive an Italian version of the ID
MigraineTM, a self-administered questionnaire composed of three
questions. The results obtained with the questionnaire will be com-
pared with the diagnosis made by the headache specialist to assess sen-
sitivity, specificity and predictive positive and negative values of the
questionnaire.
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SHIFT WORK: RISK FACTOR FOR HEADACHE
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Introduction Shift work is intended as any kind of work planning which
is different from the ordinary daily schedule [1]. In Europe, shift work
involves 33% of the employed population, and several studies have indi-
cated that it may represent a stressful condition significantly affecting
physical health and favouring the development of heart and gastroenteric
diseases, sleep disorders, and changes in biological rhythms and repro-
ductive function [2]. In this study, we have evaluated whether shift work
may be associated with headache in a population of hospital workers.
Material and methods According to the medical surveillance protocol
of D.Lgs 626/94, a group of 228 subjects working at our Institute were
enrolled. We administered a dedicated headache questionnaire based
on IHS criteria only to subjects reporting headache.
Results Of the 228 subjects, 157 underwent a clinical examination.
Forty-two of them (26.7%) complained of headache, which was diag-
nosed as follows: migraine without aura (n. 21), tension-type headache
(n. 18), episodic cluster headache (n. 2), and migraine with typical aura
(n. 1). In 50% of the cases, shift work (14.00h through 22.00h, 7.00h
through 14.00h, and 22.00h through 7.00h) was found to be the major
risk factor for the development of headache. Prolonged PC use, excess
responsibility or rather reduced visibility in one’s own acts among the
work group, and social and familial problems were the risk factors in
the remaining cases. Within the shift workers complaining of headache
(n. 21, 18 females and 3 males), 12 subjects had an episodic tension-
type headache (57.1%), 8 a migraine without aura (38.1%), and 1 an
episodic cluster headache (4.8%).
Conclusions Thus, shift workers often suffer from headache, mainly of
the tension type. In this case, in the face of particularly intense and/or
prolonged precipitating factors (such as lack of adequate night sleep,
altered biological rhythms, and psycho-physical stress), the increased
nociceptive afferents may negatively affect the pain control processes
and result in headache. In the case of migraine, hormone fluctuations,
changes in sleep-wake cycle, stress, anxiety and depression may act on
a state of latent dysexcitability triggering the process of cortical spread-
ing depression, the activation of the trigeminovascular system, and thus
attack onset [3].
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CENTROTEMPORAL SPIKES IN CHILDREN WITH MIGRAINE,
POSSIBLE COMMON PATHOGENETIC BACKGROUND: 
PRELIMINARY DATA AND METHODOLOGICAL ISSUES
D. Puma, V. Raieli, D. Ragusa, G. La Franca, M. La Vecchia, 
E. Pandolfi, M. Eliseo
Division of Child Neuropsychiatry, “G.F. Ingrassia” Hospital,
Palermo, Italy; e-mail: domenicopuma@inwind.it
Objective The aim of the study was to investigate the relation between
rolandic centrotemporal spikes (CTS) and headache in children.
Material and methods We conducted a study on patients consecutive-
ly referred because of headache to the Department of Child
Neuropsychiatry “G.F. Ingrassia” Hospital, A.U.S.L. n. 6, Palermo
(Italy) in 2003. The sample consisted of the first 100 consecutively
referred children and adolescents with headache. The mean age was
10.8 years; 114 (48%) were males. A control group was formed with
the first 100 children admitted to this department without diagnosis of
headache, epilepsy and encephalopathies.
The headache was categorized according to the classification of the
International Headache Society (IHS).
Results The sample was subdivided into 57 migraine, 17 episodic ten-
sion-type headache, 13 chronic daily headache, 3 idiopathic stabbing
headache, 8 post traumatic headache, and 2 other secondary headches.
Only 4 children, who suffered from migraine (about 7%), presented
CTS on the electroencephalogram (EEG). The EEG showed character-
istic high-voltage sharp waves in the centrotemporal regions, which are
activated with drowsiness and sleep. CTS may represent a neurobio-
logical marker for the increased risk of developing benign childhood
epilepsy with centrotemporal spikes (BECTS).
On the contrary, this association was never observed in other groups of
headache and in the control group.
Conclusions This study confirms that CTS are not pathognomonic of
centrotemporal epilepsy and that CTS and headache in children are sta-
tistically related. These findings might reflect a common pathogenetic
background. 
Focal spikes and sharp waves with predominantly centrotemporal local-
ization are the electroencephalographic hallmark of Rolandic epilepsy
(or BECTS). This EEG trait, but not BECTS itself, has been reported to
follow an autosomal dominant mode of inheritance with incomplete
penetrance and age dependency. Several linkage studies exploring can-
didate loci have given negative results. The first positive evidence for
linkage in families with centrotemporal spikes was found on chromo-
some 15q14. These markers are localized in direct vicinity to the alpha
7 subunit gene of the AChR (neuronal nicotinic acetylcholine receptor).
HEADACHE AND EPILEPSY: TWO CHRONIC DISORDERS
WITH CLINICAL COMORBIDITY
R. Nardello, C. Muratore, A. Barbagallo, S. Mangano, A. Vecchio
Mother-Child Department, Division of Child Neuropsychiatry,
University of Palermo, Palermo, Italy; e-mail: r.nardello@virgilio.it
Introduction Headache and epilepsy are both frequent disorders in
childhood. Although comorbidity has been recognized for some time,
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headache in epileptic patients is frequently underestimated by the
physician because epilepsy is considered a more serious problem of
childhood than the former. Both disorders are characterized by recur-
rent attacks, they share the same age at onset, and often some symp-
toms, too. In addition, several migraine attacks can be mistaken for
epileptic seizures, mainly, when their temporal relationship is close and
they are sensitive to antiepileptic drugs.
Objective The aim of this investigation was to study the relationship
between epilepsy and migraine among a select sample of patients
referred to our Department for both disorders.
Patients On the basis of clinical symptoms, electroencephalography
and neuroimaging findings, we recruited 8 epilepsy-referred patients (3
males and 5 females) with headache who fulfilled ILAE and IHS diag-
nostic criteria for epilepsy and migraine, respectively. We included
only idiopathic or cryptogenic epilepsy. Of the 8 comorbid cases, 4
patients had temporal lobe epilepsy (TLE), 3 patients had occipital lobe
epilepsy (OLE) and 1 had generalized epilepsy. The mean age of onset
of epilepsy and migraine was 7.9 years (range 4–13) and 6.7 years
(range 4–12), respectively. Moreover, we found that the migraine
attack preceded the epileptic seizures in 3 patients and followed them
in 3 patients, too, whereas two children had an interictal attack. Our
patients showed an incidence of family history of migraine (4/8) high-
er than the incidence of family history of epilepsy (2/8). In most
patients the antiepileptic drugs, valproate and carbamazepine, were
effective in the treatment of epilepsy and migraine.
Discussion It has been reported that the risk of headache is increased in
both idiopathic/cryptogenic and symptomatic epileptic patients. Most of
the children in our study had partial-onset epilepsy (7/8); nevertheless,
previous studies revealed that the headache may be present in both gen-
eralized and partial-onset seizures but the latter showed a mild associat-
ed increased risk for headache. These findings suggest that the specific
location of the epileptic focus may play a significant role in the patho-
genic mechanisms of migraine because the occipital lobe is considered
the brain structure mainly involved. Several investigations pointed out
an increased incidence of epilepsy among migrainous patients as well as
a higher ratio of headache among epileptic patients.
It is likely that the association between these disorders is related to a
state of brain hyperexcitability due to a threshold decrease resulting
from environmental and genetic factors.
A PROSPECTIVE STUDY OF HEADACHE IN MULTIPLE
SCLEROSIS PATIENTS
P. Sarchielli, L. Greco, A. Candeliere, L. Pierguidi, A. Alberti, 
G. Capocchi
Neurologic Clinic, Department of Neurosciences, University of
Perugia, Perugia, Italy; e-mail: headache@unipg.it
Background It has not been clearly established and is still controver-
sial whether multiple sclerosis (MS) can cause headaches. Headache,
however, has been described in MS patients and classified as either
migraine or tension-type, but no distinctive “MS headache” has been
defined until now [1]. Some MS patients referred headaches at the
onset of their first symptoms and in some cases headaches recurred
with subsequent relapses.
Results With the aim to clarify the association between MS and
headaches, and in particular migraine, a prospective study was con-
ducted on 110 relapsing-remitting MS patients. Fifty MS patients
(45%) reported headaches, compared with 8 of 60 (13%) patients ini-
tially suspected to have MS but subsequently proven to have other dis-
orders, and 19 of 100 (19%) age-matched patients with other neuro-
logical disorders.
Among patients with MS complaining of headaches, 28 (56%) suffered
from migraine (26 without aura), the remaining from tension-type
headache, mainly in the frequent form. Eighteen MS patients with
migraine and 20 MS patients with tension-type headache suffered from
their respective headaches before MS onset. 
Ten MS patients with migraine reported that their initial attack or sub-
sequent exacerbations were heralded by a migraine-like headache.
Four of these patients had urgently referred to hospital due to the onset
of acute headache. Three patients with migraine occurring for the first
time during exacerbation of symptoms showed demyelinating lesions
on MRI.
Discussion The present study suggests that headache is a frequent
complaint of MS patients (54%), which is represented in 25% of cases
by migraine. Migraine has been recently identified as a risk factor for
susceptibility to MS [2]. Migraine could also be an expression of the
pathogenic mechanisms underlying relapses via activation of the
trigeminovascular system by autoreactive cells and mononuclear cells
through their proinflammatory products. In some rare cases, migraine
in MS patients could result from the strategic location of demyelinat-
ing lesions in CNS areas believed to be involved in triggering or main-
taining migraine attacks, such as putative “migraine generators”.
References 
1. Evans RW, Rolak LA (2001) Migraine versus multiple sclerosis.
Headache 41:97–98
2. Zorzon M, Zivadinov R, Nasuelli D et al (2003) Risk factors of
multiple sclerosis: a case-control study. Neurol Sci 24:242–247
SPONTANEOUS CSF LEAK SYNDROME
1E. Ferrante, 2R. Wetzl, 1A. Citterio, 2A. Savino
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Objective To investigate clinical, MRI, radioisotope findings, and ther-
apeutic outcome of spontaneous cerebrospinal fluid leak (SCSFL).
Background Spontaneous CSF leakage from dural tear or spinal
meningeal diverticula has been suggested as the pathogenic mechanism
of SCSFL.
Methods We describe 18 patients (pts) (12 females, 6 males, mean
age 35 years) with SCSFL, of whom 1 was affected by Marfan’s syn-
drome (MS) and 1 by type 1 Arnold-Chiari malformation (ACM),
seen from 1992 to 2003. The pts underwent brain CT and MRI, spinal
MRI and MRI myelography (7 pts), measurement of CSF pressure (14
pts), radioisotope cisternography (RCS) (7 pts), and meningeal biop-
sy (1 pt).
Results Seventeen pts (94%) had orthostatic headache and 1 non-pos-
tural headache. Additional symptoms included nausea, vomiting, dizzi-
ness, vertigo, diplopia, rachialgia, and poor anterograde memory. CSF
pressure was low in 12 pts and normal in 2 pts, in 4 pts it was not pos-
sible to measure because of the presence of bilateral chronic subdural
hematomas (BCSH), with mass effect (3 pts) and anticoagulant thera-
py (1 pt), 8 pts had increased CSF albumin, and 5 pts had pleocytosis.
Diffuse pachymeningeal gadolinium enhancement (DPGE) on brain
MRI was found in 16 pts (88%) and it was absent in 2 pts (11%).
BCSH was found in 4 pts (22%), hygroma in 3 pts (16%), and brain
descent in 5 pts (27%), of whom 1 pt showed ACM. Spinal MRI and
MRI myelography (performed in 7 pts) showed cervical pachy-
meningeal enhancement in 5 pts, dorsal syringomyelia in 1 pt with
ACM and sacral radicular cysts in 1 pt and sacral bilateral diverticula
in the patient with MS. RCS showed CSF leakage sites in 2 pts (28%),
limited ascent of the tracer to the cerebral convexity in 2 pts (28%), and
early appearance of radioisotope in the bladder in 3 pts (42%).
Meningeal biopsy was normal. Lumbar epidural blood patch (EBP)
was performed in 2 pts (11%), with headache recovery, the patient with
ACM underwent occipital decompression. BCSH with mass effect was
drained in 3 pts (16%). SCSFL was misdiagnosed at the time of BCSH
draining in 2 pts. In 14 pts (77%) treatment consisted of bed rest with
recovery after a period of 3–4 weeks. No relapses were reported during
the follow-up, which ranged from 9 months to 6 years.
Conclusions Patients with SCSFL syndrome have distinct MRI and
RCS abnormalities and generally respond favourably to bed rest and
hydration. Sometimes EBP or surgical treatment is necessary.
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SPONTANEOUS INTRACRANIAL HYPOTENSION: AN
UNKNOWN CAUSE OF NON TRAUMATIC BILATERAL
CHRONIC SUBDURAL HEMATOMA
1E. Ferrante, 1A. La Camera, 2A. Savino, 3F. Spanò, 1M. Collice
1Department of Neuroscience, 2Emergency and 3Cardiologic Admission,
Niguarda Hospital, Milan, Italy; e-mail: enricoferrante@libero.it
Objective To demonstrate that spontaneous intracranial hypotension
(SIH) could be an unknown cause of non traumatic bilateral chronic
subdural hematoma (BCSH).
Materials and methods From April 2001 to March 2004, 28 non trau-
matic cases of BCSH were surgically treated in Niguarda Hospital.
Twenty-six cases were etiologically diagnosed (cardiac diseases in anti-
coagulant therapy, hypertension, coagulation deficits, hepatic diseases,
etc). Only 2 cases were of unknown causes. We describe these cases.
Results The first case concerns a 58-year-old man with orthostatic
frontal headache, vomiting and dizziness. Because the headache wors-
ened, after 23 days, the patient was admitted to our hospital. CT scan
revealed a BCSH. He was operated on but the headache did not resolve
and CT scan after ten days showed reaccumulation of a right subdural
mass. The patient was again treated and the headache improved 2 days
after the second operation. MRI with gadolinium 6 months after the
onset of symptoms showed a diffuse pachymeningeal enhancement, a
sign of SIH. The patient is asymptomatic at 2-year follow-up. The sec-
ond case involves a 58-year-old man, affected by diabetes mellitus,
with acute orthostatic headache and subsequent hearing loss. After 45
days he presented diplopia and mental confusion. Brain CT and MRI
without contrast revealed BCSH. The patient underwent craniectomy
for BCSH evacuation on the 66th day after headache onset. Despite
transient improvement of the headache, CT scans showed recurrence of
a subdural mass and the patient was operated on after 12 days on the
left side and after 17 days on the right side with headache recovery. A
MRI after 3 months showed caudal dislocation of the brain and dis-
placement of the pons against the clivus, signs of SIH. The diplopia
disappeared after 4 months.
Discussion SIH due to CSF leakage is an important cause of headache but
is not a well recognized entity. The misdiagnosis of SIH can have serious
consequences: BCSH, caused by the loss of buoyancy and downward dis-
placement of the brain, can result in the tearing of bridging veins.
Conclusions Misdiagnosed symptomatic subdural masses may require
surgical evacuation, but it is quite likely the recurrence rates are
increased in these cases. Cerebral and spinal MRI with gadolinium are
necessary before surgical treatment in the presence of BCSH of
unknown etiology.
JUVENILE HEADACHE I
IMPACT OF HEADACHE AMONG ADOLESCENTS AT A
JUNIOR HIGH SCHOOL
T. Russo, R. Della Cagna, F. Bologna, F. Pistoia, S. Sacco, C. Marini,
A. Carolei
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Objective The prevalence of headache may be underestimated among
children. We evaluated the prevalence of different headache types in
adolescents aged 14 to 15 years at a junior high school and its impact
on school performance and quality of life.
Methods The population study was selected by a multistage question-
naire between May and June 2004, in 4 primary schools of L’Aquila.
Data were collected by screening questionnaires, consisting of 31 items,
administered to all students; a clinical interview, based on 33 questions;
and the Migraine Disability Assessment Scale (MIDAS), administered
to all headache sufferers. The MIDAS questionnaire is a 7-item ques-
tionnaire (with 5 scored items). The MIDAS score was categorized into
four grades of increasing disability severity (minimal or absent, mild,
moderate, and severe). Headache was diagnosed according to the diag-
nostic criteria of the International Headache Society, 2nd edition. 
Results Among a total of 151 students examined, 48 (31.8%; 95% CI
24.4–39.2) reported recurrent headache episodes (4 men and 44
women, mean age 15±0.6 years). Migraine without aura was diagnosed
in 25 subjects, migraine with aura in 3, chronic migraine in 1, proba-
ble migraine with aura in 4, tension-type headache in 13, and unspeci-
fied headache in 2 subjects. Disability on the MIDAS score was absent
or minimal in 17 (35.4%), mild in 12 (25.0%), moderate in 7 (14.6%),
and severe in 12 (25.0%) students. In particular, the missed school days
in the last 3 months were 2.54±3.25 and the days at school with per-
formance reduced by half or more in the last 3 months were 4.19±5.01.
Headache was mostly worsened by stress (21%), study (29%), and
sinusitis (33%). A positive familial history of headache was found in
71% of the headache sufferers. Self-medication with analgesics was
reported by 31 subjects (65%) with headache. No subject was taking
antimigraine drugs or preventive medications. 
Conclusions Headache is a common disorder among adolescents in
L’Aquila, having a relevant impact on school activity, and requires
more appropriate medical treatment.
ASSESSMENT OF TEMPERAMENT IN CHILDREN AFFECT-
ED BY DIFFERENT TYPES OF HEADACHE
L. Mazzone, D. Mugno, V. Genitori D’Arrigo, D. Mazzone
Division of Child Neurology and Psychiatry, Department of
Paediatrics, University of Catania, Catania, Italy; e-mail: mazzone@
unict.it
Introduction Temperament is generally defined as a set of inherited
personality traits that appear early in life, are relatively stable, cross-sit-
uationally consistent, and evident throughout the age span and diverse
cultures. Temperamental extremes and specific temperament dimen-
sions constitute risk factors of psychopathological vulnerability and
early precursors of impaired adjustment. The aim of our study was to
assess temperament in children affected by different types of headache. 
Patients and methods Two-hundred children (M/F: 1.1), aged 6 to 15
years (mean age 10.66±3.79), were divided into 4 groups: (A) n=50,
affected by tension-type headache; (B) n=52, affected by migraine without
aura; (C) n=45, affected by migraine with aura; (D) n=53, control group.
Diagnosis of headache was made according to International Headache
Society (IHS) criteria. The EAS Temperament Survey was applied; in chil-
dren it measures the dimensions activity, emotionality, sociability, and shy-
ness. Statistical analysis was performed by Anova and Bonferroni test. A
P value of <0.05 was used as the cutoff point of significance.
Results Groups A and B shared statistically significant higher levels of
emotionality compared to group D, with no statistical difference between
the two groups. Group A also showed higher levels of shyness and lower
levels of sociability and activity compared to groups B, C, and D.
Conclusions Tension-type headache could be an expression of psy-
chopathological vulnerability, as demonstrated by the presence of
many temperamental extremes in these children, compared to children
affected by different types of headache as well as the control subjects.
JUVENILE HEADACHE: WHAT IS THE PHYSICIAN’S OPINION
ABOUT THE CHILD’S AND MOTHER’S EXPECTATIONS?
1V. Raieli, 2G.B. La Pegna, 3V. Saporito, 1G. La Franca, 
1M. La Vecchia, 1E. Pandolfi, 1D. Puma, 1D. Ragusa, 1M. Eliseo
1“L. Biondo” NPI Division, “G.F. Ingrassia” Hospital, AUSL 6,
Palermo, Italy; 2Department of Neuroscience, Caltanissetta, Italy;
3Bagheria District, AUSL 6, Palermo, Palermo, Italy; e-mail:
vinzi.raielk@inwind.it
Objectives The aim of this study focused on the paediatrician’s opin-
ions about the child’s and mother’s expectations with regard to the
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diagnostic and therapeutic approaches made by the paediatrician and
neuropsychiatrist.
Methods A questionnaire was given to paediatricians during scientific
conferences. The questionnaire was composed of questions about their
opinion as to the child’s and mother’s fears, the reasons for medical
visits, and their expectations. We also asked their opinions about the
use of symptomatic and prophylactic therapy.
Results We interviewed 50 paediatricians. The duration of the first
visit was about 20–30 minutes for 66% of the paediatricians and was
estimated sufficient by 78% of them. Fifty-eight percent of doctors
believed that the principal reasons for the visit were because pain was
more frequent, the attacks were severe and there was fear that they
could be caused by a brain tumor (respectively 58%, 26% and 24%).
According to the opinion of the doctors, the mothers’ more important
expectations were the reassurance of their fears and the prescription of
medical diagnostic tests (respectively 60% and 50%), while 68% of
doctors thought that the mothers were rather satisfied with their action.
Whereas, they believed that the child wanted to be mainly reassured, to
be cured and to have explanations about the reasons of his/her
headache (respectively 62%, 48% and 44%). About 90% of paediatri-
cians believed that the use of symptomatic drugs was necessary when
the child’s pain was severe, while the use of preventive pharmacologi-
cal therapies was estimated useful and necessary by 74% of the doctors
if the headaches were severe and frequent.
Discussion These data suggest that our population of paediatricians eval-
uated their action as sufficient with regard to treating headache in children,
with a good percentage of mothers showing satisfaction. The paediatri-
cians found prescribing medical diagnostic tests useful in reassuring the
mother about her fears. The doctors also considered useful the use of
drugs in symptomatic and preventive therapy, but in clinical practice most
children admitted for the first time to a paediatric headache center had
never undergone a preventive therapy, even when suggested by the guide-
lines.
HEADACHE IN CHILDREN AND QUALITY OF LIFE:
RESULTS OF 2 ITALIAN MULTICENTRE STUDIES (2001 –
2003)
1P.A. Battistella, 1S. Polvara, 1C. Favaro, 1M. Vidi, 1E. Nodari, 
1M. Trapanotto, 2L.N. Rossi, 3G. Lanzi, 3S. D’Arrigo, 4L. De Carlo, 
5S. Soriani, 6G. Mazzotta, 6P. Sarchielli, 6V. Gallai†, 7V. Guidetti, 
7D. Moscato, 7P. Curatolo, 7M. Verdecchia, 8E. Tozzi, 9P. Tamburro, 
9G. Di Meo, 10A. Pascotto, 10F.M. Ruju, 11V. Raieli, 11G. Santangelo, 
11A. Vecchio
Paediatric Headache Centres of 1Padua, 2Milan, 3Pavia, 4Rovigo,
5Ferrara, 6Perugia, 7Rome, 8L’Aquila, 9Chieti, 10Naples, 11Palermo,
Italy; e-mail: battist@pediatria.unipd.it
Studies carried out on the quality of life (QoL) in young headache
patients are currently the object of increasing interest (Nodari, 2002).
In our first multicentre study (2001) (7 Centres), we analyzed 356 pri-
mary headache sufferers (171 M, 185 F, aged 10 to 18 years), 207
migraineurs (M) and 149 with tension-type headache (TTH), according
to IHS 1988. The Langeveld’s instrument (1996) was adapted, validat-
ed in the young Italian population (Nodari, 2002) and simplified (46
items). The 4 areas explored were: 1) Functional status, 2)
Psychological functioning, 3) Physical functioning, and 4) Social func-
tioning. Moreover, there were two VAS, related to satisfaction with life
in general (VAS1) and satisfaction with health (VAS2).
The analysis of variance showed significant differences between
patients and controls unaffected by headache (n=356) in all the sub-
scales of the questionnaire as well as in the 2 VAS. 
In a more recent (2002–2003) multicentre study (13 Centres), we ana-
lyzed 3 subgroups: (A) 351 pts (157 M and 194 F, 10 to 18 yrs), 233
with M (208 without aura (MwoA), 25 with aura (MwA)), 118 with
TTH (84 ETTH, 34 CTTH); (B) 351 controls, selected using less rigid
criteria with respect to those used in the previous study: we included
healthy subjects, and subjects with occasional headaches, who had
never gone to a headache specialist; (C) 50 headache sufferers selected
from public school (23 MwoA; 27 TTH). 
The comparison between groups A and B revealed significantly worse
scores in 3 subscales (“impact of headache”, “somatic symptoms”, and
“sleep”) for group A. No differences were found in QoL subscales in
the 2 samples of headache sufferers (A vs C).
In group A worse scores resulted in some subscales with respect to: (1)
type of headache, i.e., M vs TTH, and respectively, CTTH vs ETTH;
(2) pattern of headache, i.e., worse scores in patients suffering from
high frequency and medium-strong intensity of attacks; (3) previous
hospitalisations for headache, more school absences, and poorer acad-
emic performance.
Conclusion This study confirms the strong impact of headache on the
QoL of young patients, with worse scores in children with migraine.
Moreover, it shows an inverse correlation between the QoL and the
seriousness of the headache pattern, in agreement with other authors
(Langeveld, 1997; Hunfeld, 2001). Finally, in the chronic headaches a
worse QoL is evident, in agreement with recent findings in this field of
study (Hershey, 2001; D’Amico, 2003; Powers, 2003).
QUALITY OF LIFE IN PAEDIATRIC PRIMARY HEADACHE:
ASSESSMENT USING THE PEDSQL 4.0
M. Trapanotto, B. Ludovico, M. Gugliotta, J. Varni, F. Benini, 
L. Bianchin, E. Bertossi, P. Battista, P.A. Battistella
Department of Paediatrics, University of Padua, Padua, Italy; e-mail:
manuela.trapanotto@unipd.it
Health-related quality of life (HRQoL) is an emerging field of clinical
research in the paediatric setting. Only in recent years have some ques-
tionnaires to measure HRQoL been developed in the paediatric setting,
showing a significant impairment of QoL in juvenile headache patients.
In particular, the Pediatric Quality of Life Inventory, version 4.0
(PedsQL 4.0) is a modular instrument for measuring HRQoL in children
and adolescents ages 2 to 18. The PedsQL 4.0 Generic Core Scales are
multidimensional child self-report and parent proxy-report scales that
encompass 23 items subdivided in four areas of functioning: (1) physi-
cal functioning, (2) emotional functioning, (3) social functioning, and
(4) school functioning. It represents a valid, developmentally appropri-
ate measure of QoL for children from age 2 to 18 years. The aim of this
study was to compare the Italian version of the PedsQL 4.0 in a clinical
sample of primary headache outpatients and in healthy controls.
The PedsQL 4.0 instrument was administered to 2 groups (age 5–18
years): (A) fifty-six headache patients (27 M, 29 F) (age 5–7, n=7; age
8–12, n=37; age 13–18, n=12) and their parents were evaluated. The
children were diagnosed according to the current criteria of the
International Headache Society (MwA=28, MwoA=3, ETTH=18,
CTTH=1); mixed headache were 6; (B) one hundred forty-two healthy
controls age and parent-matched (n=142; 72 M, 70 F) without
headache were evaluated in school.
Internal consistency reliability for the total scale score was determined
by calculating Cronbach’s coefficient α, demonstrating a good reliabil-
ity (> 0.70). Self-report and proxy-report demonstrated significant cor-
relation across all scales, with a good interrater-reliability between
children and parents (p< 0.05). The analyses yielded meaningful dif-
ferences between groups A and B:
a. age 5–7 years: the parents of children with headache obtained lower
scores than the parents of controls on the Physical Scale and Total
Scale; 
b. age 8–12 years: the parents of children with headache obtained
lower scores than the parents of controls on the Emotional Scale;
c. age 13–18 years: adolescents with headache obtained lower scores
than controls across all scales.
Moreover, MwA, MwoA, and CTTH patients had lower scores than
ETTH patients. QoL scores were lower in patients with higher
headache frequency, intensity, and with a longer chronicity.
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Internal consistency and interrater-reliability scales were good, demon-
strating satisfactory psychometric properties. Some differences
emerged between patients and controls in different scales, underlining
the weight of particular dimensions in different age groups. Finally,
diagnosis, frequency, intensity, and chronicity negatively influenced
the QoL of headache patients.
WHEN THE SUFFERING IS NO LONGER TOLERABLE:
HEADACHE OR MADNESS?
D. Ragusa, V. Raieli, G. La Franca, M. La Vecchia, E. Pandolfi, 
D. Puma, M. Eliseo
Department of Child and Adolescent Neurology and Psychiatry, “G.F.
Ingrassia” Hospital, ASL 6, Palermo, Italy; e-mail: donatellaragusa@
inwind.it
Introduction This study was based on the comorbidity data of mental
and psychiatric disorders present in young patients referred to our
headache centre and that found in the literature.
Methods We conducted a retrospective study, from 2000 to 2002, on
patients ranging in age from 6 to 17 years and suffering from primary
headache, classifying the data, as gathered by clinical interview,
according to IHS classification and DSM-IV diagnostic criteria.
Results We found: 58% of the patients with migraine, 25% with
episodic tension-type headache, 13% with chronic daily headache, and
4% with idiopathic cluster headache.
In the entire sample population we found the following mental dis-
orders: 43% with anxiety and depression, 7% with immature per-
sonality, 3% with identity disorders, 0.8% with schizophrenic disor-
ders, 4.8% with learning problems, and 4.6% with low intellectual
function.
Conclusions These findings suggest that anxiety, depression and
headache are often present at the same time, whereas there are few cor-
relations regarding comorbidity between headache and schizophrenic
disorders. This poor correlation is to be viewed in the context of an
integrated clinical model that considers not only genetic predisposition,
different neuronal transmission systems, and neuronal plasticity, but
also different patterns of relationships, which are found in the young
patients’ environment. Headache and psychosis result when the psy-
chological suffering is no longer tolerable. 
JUVENILE HEADACHE II
A TOOL TO DISCRIMINATE YOUNG HEADACHE SUFFER-
ERS FROM OTHERS: THE FAB-C
D. Moscato, A. Regine, F. Ribaudo
Childhood Headache Centre, Saint Charles Hospital IDI, Roma, Italy;
e-mail: dmoscat@tin.it
The psychological characteristics of young headache sufferers (YHS)
have a decisive weight in the evolution of a headache. Psychometric
instruments must be researched to distinguish YHS from others.
The FAB-C (Feelings, Attitudes, and Behaviours Scale for Children), a
test that measures the various emotional and behavioural problems in
children and adolescents aged 6–14 years, administered together with
CDI (Children’s Depression Inventory), in one of our previous studies,
enabled us to discriminate YHS from others, thus identifying their spe-
cific characteristics (more introverted headache sufferers, those with
major behavioural problems, etc.).
In this study, we intended to assess the structure of the tools applied
(FAB-C and CDI), through the statistical technique of the Stepwise
Discriminant Analysis, that can identify the “model” which better pre-
dicts to which group (normal vs. YHS) each individual group belongs.
How accurate are the two tools in distinguishing normal subjects from
pathological ones? 
The FAB-C and the CDI were administered to a sample of 320 subjects
(47% M, 53% F, aged 8 to 14 years), of whom 160 were “normal” and
160 suffering from MwoA (80), ETTH (51), and CTTH (29).
Results showed that 73% of those apparently well were classified in the
headache sufferer group and 68.7% in the control group. In all, the
entire sample (n=320), appearing to be well, were classified in 70.9%
of the cases.
Based on these results we suggest that both tests provide a good dis-
crimination between YHS and others. We believe, therefore, that as
these tests are easy to administer, they may be useful tools for the iden-
tification of the YHS psychological characteristics.
ASSOCIATION BETWEEN DIFFERENT TYPES OF HEADACHE
AND NOCTURNAL ENURESIS
L. Mazzone, D. Mugno, L. Ruta, D. Mazzone
Division of Child Neurology and Psychiatry, Department of Paediatrics,
University of Catania, Catania, Italy; e-mail: mazzone@unict.it
Objective Headache is a common disorder during the paediatric age.
Previous studies suggest that nocturnal enuresis (NE) can be associat-
ed with headache in childhood. Aim of our study is to evaluate associ-
ation between different types of headache and NE.
Materials and methods Two-hundred children (M/F: 1.1), aged 6 to
15 years (mean 10.66±3.79), were divided into 4 groups: (A) n=50,
affected by tension-type headache (TTH); (B) n=52 affected by
migraine without aura (MWA); (C) n=45 affected by migraine with
aura (MA); and (D) n=53, the control group (CC). The diagnosis of
headache was made according to International Headache Society (IHS)
criteria. Statistical analysis was performed by Anova and Bonferroni
test. A P value of <0.05 was used as the cutoff point of significance.
Results Twelve children (24%) from Group A, 11 (21.1%) from Group
B, 2 (4.4%) from Group C, and 5 (9.43%) from Group D had a history
of or were affected by NE.
Statistical analysis showed a significant association between NE and
TTH and between NE and MwA. No significant association between
NE and MA was present; no statistical differences were present
between TTH and MwA and between MA e CC.
Conclusions Our data indicate that TTH and MwA are more frequent-
ly associated with NE. In contrast, the prevalence of NE in children
affected by MA is comparable to that in control subjects.
RECURRENT AND CHRONIC HEADACHES IN CHILDREN
YOUNGER THAN 6 YEARS OF AGE
1V. Raieli, 2G. Santangelo, 1D. Ragusa, 1E. Pandolfi, 1M. La Vecchia,
1D. Puma, 1G. La Franca, 1M. Eliseo
1NPI Division, “G.F. Ingrassia” Hospital, AUSL 6, Palermo, Italy;
2ARNAS, Civico, Palermo, Italy; e-mail: vinzi.raielk@inwind.it
Objectives To determine the frequency of headache subtypes, accord-
ing to IHS criteria, in a population of children under 6 years of age who
were visited in a Center for the diagnosis and treatment of headache in
youth.
Methods The medical records of the children younger than 6 years at
their first visit, admitted for headache between 1997 and 2003, were
studied. Headache was classified according to IHS criteria. Children
with less than three headache attacks or less than 15 days of daily
headache per month were excluded, with the exception of migraine
with aura (MwA) when one attack is sufficient to classify it.
Results We examined 1598 medical records of children visited at our
Headache Centre during the study period. One hundred and five (6.5%)
were children younger than 6 years of age. The mean age at first med-
ical control was 4.8 years±1.3 (range 17–71 months). Males were 59
(56.1%), females were 46 (43.9%). The mean age at onset of
headaches was 4.3 years (range 14–69 months). According to IHS cri-
teria we found 37 cases (35.2%) with migraine, 19 cases (18%) with
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episodic tension-type headache, 9 cases (8.5%) with chronic daily
headache, 17 cases (16.1%) with idiopathic stabbing headache, 18
cases (17.1%) with post-traumatic headache, 7 cases (6.6%) with other
non dangerous secondary headaches (O.R.L. disease, post-infectious
headache), 3 cases with (2.85 %) dangerous headaches (Arnold-Chiari
type 1 malformation, brain tumor) and 1 case (0.95 %) with unclassifi-
able headache. Six children (5.7%) reported more than one headache
subtype. The prevalence of dangerous headaches was higher in our
patients than in school-aged children (χ2 4.70, p<0.05).
Discussion Our study showed some differences with regard to
headache distribution in this population versus school-aged children. In
fact, in this age group, migraine was the more common headache. In
our study population the clinical picture of migraine attacks at an early
age differs from that in the older age group by the very infrequent aura,
the rare unilaterality, not infrequent gravative pain quality, and the dif-
ficulty to describe the quality of pain, while the frequent brief duration
of attacks (<2h) was also witnessed at this age. However, we also found
an increase of secondary causes among the chronic/recurrent and daily
headaches, especially post-traumatic disorders, and potentially danger-
ous headaches. Finally, our study showed the most prevalence of the
idiopathic stabbing headache in preschool children in comparison with
other age groups.
CHRONIC DAILY HEADACHES IN THE JUVENILE POPULA-
TION: A MULTICENTRE STUDY. PRELIMINARY DATA AND
METHODOLOGICAL ISSUES
1D. Ragusa, 1S. Brucato, 1S. Marchese, 1I. Todaro, 1A. Tassella, 
2P. Parisi, 3G. Santangelo, 4A. Vecchio, 1V. Raieli
1NPI Division, “G.F. Ingrassia” Hospital, AUSL 6, Palermo, Italy;
2Paediatric Division, “S. Andrea” Hospital, Rome, Italy; 3NPI Service,
Civic Hospital, Palermo, Italy; 4NPI Division, “Aiuto Materno”
Hospital, AUSL 6, Palermo, Italy; e-mail: donatellaragusa@inwind.it
Introduction Chronic daily headaches (CDH) are becoming a com-
mon problem in the juvenile population. However, there is no well-
defined classification for these patients and most information comes
from studies conducted in adult populations.
Objective Our aim was to study a group of CDH patients and to
observe the possible presence of psychological, neurophysiological
and biological markers.
Methods We included in the study the first 100 consecutive CDH
patients (25 patients from each of the four centres involved in the
study), the first 50 migraine patients, the first 50 patients with episod-
ic tension-type headache, and 50 control subjects admitted to our cen-
tres from 1 April 2004. The inclusion age was from 6 to 14 years. The
headache was categorized according to the classification of the
International Headache Society (IHS). Every child underwent neuro-
logical and general objective examination, EEG, auditory and visual
evoked potentials, blood tests and a battery of psychological tests
including: TAD test, TMA short form, PSQI, McGill Pain
Questionnaire and Visual Retention test.
Results Our present population consisted of 7 CDH patients (3 females
and 4 males), mean age 9.7 years. Four patients were classified chronic
migraine, and 3 chronic tension-type headache. Almost 43% (3 children)
presented pathological scores in one of the psychological tests. No
abnormalities were observed in the neurophysiological examinations.
Discussion Our data are preliminary and it is not possible at the moment
to reach a definite conclusion. However, the presence of psychological
abnormalities in the CDH group was also evident in a small group.
A QUESTIONNAIRE-BASED STUDY ON PREVALENCE AND
TREATMENTS OF HEADACHE IN SECONDARY SCHOOL
STUDENTS OF CATANZARO
1L. Gallelli, 2R. Iannacchero, 2F. Peltrone, 2A. La Vitola, 2E. De Caro,
1R. Citraro, 1M. Colosimo, 1G. De Sarro
1Clinical Pharmacology and Pharmacovigilance Unit, Department of
Experimental and Clinical Medicine, University “Magna Graecia” of
Catanzaro, Regional Pharmacovigilance Center, “Mater Domini”
University Hospital, Catanzaro, Italy; 2Centre for Headache Study,
Regional Hospital “Pugliese-Ciaccio”, Catanzaro, Italy; e-mail:
luca_gallelli@hotmail.com
Introduction Headaches and migraines occur in a large proportion of
young students. The prevalence of headache increases with age, recur-
rent headache occurs in 3% to 5.9% of 3- to 4-year-old children, where-
as the prevalence of 1-year headache in 13-year-old children was 82%.
Aim In this study, we evaluated the incidence of headache in young
students of secondary schools, examining associated factors and the
drug therapy used.
Methods A detailed questionnaire was directly administered to 1,800
students between the ages of 14 and 18 belonging to secondary schools
of Catanzaro. The questionnaire sought information concerning demo-
graphic characteristics, school years, occurrence and frequency of
headache, and risk factors for onset of headache. 
Results We recorded that headache symptoms started between 10 and
12 years of age without any significant difference in the sex ratio. In
contrast, we found a significant difference in family history of
headache or environmental-related factors among students with
headache respect to healthy students (p<0.01). The incidence density
of recurrent headache was higher in students living in cities (82%) than
in those who lived in the countryside (28%), in smokers or drinkers
compared to non-smokers and non-drinkers (p<0.01). Self-medication
was reported by 51.8% of the students with headache. The most com-
monly used drugs were anti-inflammatory drugs (nimesulide and
acetylsalicylic acid; 50% and 42%, respectively). In 75% of the stu-
dents this treatment resolved the acute manifestations but in 5–10% it
induced the development of chronic headache.
Discussion Starting secondary school appears to increase significantly
the incidence density of overall headache. The increase is almost exclu-
sively attributable to occasional headache. Subsequently, it is important
to develop preventive intervention methods and to prepare people to
cope with the life changes that are caused by starting secondary school.
Moreover, the risk for chronic headache associated with medication
overuse was more than six times higher than the risk for chronic
headache without medication overuse. These results are in agreement
with previous studies, that report that analgesic overuse predicted the
persistence of chronic daily headache.
Conclusions Results of our study suggest that a better management of
headache symptoms and therapy could reduce the frequency of headache
episodes, with a reduction of drug-drug and drug-food interactions. This
study could confirm the findings of other population groups that mor-
bidity from headache is often unrecognised and under treated.
ENDPOINTS FOR THE ASSESSMENT OF SYMPTOMATIC
DRUG EFFICACY IN JUVENILE MIGRAINE: WHAT DO
PATIENTS WANT?
1F. De Cesaris, 1U. Pietrini, 2A. Del Bene, 3A. Becucci, 1E. Del Bene
1Headache Centre, Department of Internal Medicine, University
of Florence, Florence, Italy; 2Department of Neurology, University
of Florence, Florence, Italy; 3Department of Internal Medicine,
University of Florence, Florence, Italy; e-mail: f.decesaris@
dmi.unifi.it
Primary headaches, and particularly migraine, cause serious disabili-
ty in young subjects, with loss of social activities and worsening of
scholastic results. For these reasons, symptomatic treatment is impor-
tant as well as prophylactic treatment (when indicated), but clinical
trials for the assessment of its action are very difficult to carry out.
Symptomatic drugs do not show real efficacy, because the migraine
attack in children and adolescents is of brief duration (1–2 hours),
and there is a typical tendency to fall asleep. A great response can be
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observed to placebo (up to 50%). To identify the characteristics of an
ideal symptomatic drug for migraine required by young patients (<18
years old), we administered a questionnaire to those subjects exam-
ined in our Headache Centre, where they had to attribute a value,
ranging from 0 (not important) to 3 (very important), to 8 parameters:
absence of pain at 2 hours after taking the drug, reduction of pain
from strong to light or medium, total efficacy during the 24 hours
after taking the drug, absence of side effects, partially or totally
recovering the capacity of performing normal activities, disappear-
ance of symptoms accompanying migraine (nausea, vomiting, phono-
and photophobia), desired pain-free interval after taking the drug.
The study was conducted on 24 subjects, 14 females and 10 males,
aged between 10 and 17 years (mean age 14.3). According to IHS
2004 criteria, 3 were affected by migraine with and without aura, 2
by migraine with aura, and 19 by migraine without aura. Results
showed that young patients attributed most importance to recovery of
normal capacities (mean 2.75), followed by absence of side effects
and disappearance of phono- and photophobia (2.33), total efficacy in
the 24 hours after taking the drug (2.25), absence of pain at 2 hours
after drug intake (2.16), reduction of pain from strong to light or
medium (2.00) and disappearance of nausea and vomiting (1.83). The
mean desired pain-free interval after taking the drug was 28.75 min-
utes. We concluded that the characteristics of an ideal symptomatic
drug required by young patients suffering from migraine were obtain-
able for the most part with triptans, so it is to be hoped that these
drugs will soon have the scientific evidence for their approval for use
in patients under 18 years old.
CASE REPORTS I
A PARTICULAR CASE OF PRIMARY STABBING HEADACHE
WITH “SENSITIVE AURA”
G. Capo, A. Esposito
Headache Centre, Neurology Unit, Hospital of “San Giovanni di Dio and
Ruggi D’Aragona”, Salerno, Italy; e-mail: giuseppecapo1@virgilio.it
We describe the case of a 26-year-old woman who, about 8 months
ago, presented with acute stabbing pains, lasting 10 to 15 seconds,
located unilaterally in various parts of the head (anterior and posterior
regions). The particular nature of this disturbance was due to the fact
that the stabbing pain was always preceded by a sense of pins and nee-
dles in the centre of the back of the head, of 5 to 6 seconds duration,
followed by a pain-free period lasting about 1 minute. Immediately
thereafter, the pain returned localized in various regions unilaterally,
with a right-sided preference. Early on, the attack frequency was very
sporadic, but with time the frequency increased from weekly to almost
daily after 50 days of attacks. The daily attacks consisted of 3 episodes
at no particular time of the day. Pain intensity was scored at 8 on a scale
of 1 to 10. The neurological and clinical records were normal. An MR
angiography of the intracranial vessels showed reduced visibility of the
right posterior cerebral artery; the ipsilateral anterior cerebral artery
appeared reduced in diameter.
The administration of indomethacin (75 mg/die) for 5 days resulted
in no improvement. More recently, the patient has been taking flu-
narizine, 5 mg tablet, for 30 days, and has noted during these last
weeks a reduction in the number of episodes and in the intensity of
pain.
This case is an example of a primary stabbing headache, with the
exception that there were also stabs of pain in the posterior regions of
the head. A characteristic of this case was the paresthesis present in the
centre of the back of the head, which constantly preceded the stabs of
pain; another unique feature was that for 50 days the stabbing pains
presented almost daily.
Until now, this type of headache has been attributed, for its peculiarity,
to a trigeminal neuralgia with neuronal stabbing. This singular case,
with a “sensitive aura” invariably the same, which precedes the pain,
could not only confirm this interpretation but also foresee the involve-
ment of vascular structures.
KARTAGENER’S SYNDROME AND MIGRAINE: A CASE
REPORT AND REVIEW OF THE LITERATURE
1G. Santangelo, 1F. Consolo, 1E. Trapolino, 1F. Vanadia, 1R.M. Iannitto,
1D. Pandolfo, 2M. Collura, 2G. Traverso, 2F. Pardo
1Division of Child Neuropsychiatry, “Civic Hospital”, Azienda di
Rilievo Nazionale ed Alta Specializzazione “Civico - Ascoli - Di
Cristina” of Palermo, Palermo, Italy; 2Division of Paediatric
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Primary ciliary dyskinesia (PCD), also known as Kartagener’s syn-
drome, is a human syndrome that results from ciliary dysfunction. This
syndrome is characterized by recurrent respiratory infections, situs
inversus and infertility. In some cases, neurological complications are
also observed. The pathogenesis is a possible channelopathy.
Rapid progress in the complementary fields of molecular genetics and
cellular electrophysiology has led to a better understanding of many
disorders which are caused by ion channel dysfunction. These chan-
nelopathies may manifest in a multitude of ways depending on the tis-
sue specificity of the channel that is affected. Several important gener-
al medical conditions are now known to be channelopathies but the
neurological aspects are amongst the best characterized.
One such case is that of a young woman who presented with attacks of
headache with visual aura and catamenial headache for some years.
The evaluations of the diagnostic flow-chart for headaches were nega-
tive. The possible relationship between headache and Kartagener’s
syndrome with a common channelopathy-based pathogenesis is
hypothesised.
Suggested readings
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HEMIPLEGIC MIGRAINE AND FAMILIAL EPISODIC ATAXIA
TYPE 2
F. Consolo, F. Vanadia, G. Santangelo, E. Trapolino, R.M. Iannitto, 
D. Pandolfo
Division of Paediatric Neuropsychiatry, ARNAS, Palermo, Italy; e-
mail: flaviaconsolo@inwind.it
Introduction Familial episodic ataxia is an unusual hereditary disorder
caused by mutations in the gene encoding the Ca2+ channel subunits
(gene CACNA1A) on chromosome 19 p 13.
Recently, different types of this mutation were shown to be involved in
three human disorders: familial hemiplegic migraine, episodic ataxia,
and chronic spinocerebellar ataxia type 6.
In addition, more evidence is showing that the same gene is also
involved in the common form of migraine with and without aura.
Patients We describe the case of a 13-year-old female, with a sympto-
matology characterized by migraine without aura, right-sided hemiple-
gia and paraesthesia, gastralgia, vomiting, and aphasia lasting for 5
hours.
Materials and methods Haematologic tests were normal (including
homocysteinemia); magnetic resonance imaging of the brain was normal.
Discussion We report this case because the mother and other members of
her family are affected by familial episodic ataxia type 2. It is likely that
our patient presents with different symptoms of the same channelopathy.
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NUMMULAR HEADACHE: CASE REPORT AND FIRST
THERAPEUTIC PROPOSAL
1M. Trucco, 2F. Mainardi, 1G. Perego, 1R. Badino, 2G. Zanchin
1Headache Centre, Department of Neurology, S. Corona Hospital,
Pietra Ligure, Italy; 2Headache Centre, Department of Neurosciences,
University of Padua, Padua, Italy; e-mail: marco.trucco@
ospedalesantacorona.it
Nummular headache (or coin-shaped cephalgia) is a distinctive type of
head pain, first described by Pareja et al. in 2002. It is reported in the
new IHS Classification (ICHD, 2004) in the Appendix (A13.7.1),
which is intended to present research criteria for some novel headache
entities that have not been sufficiently validated by scientific evidence.
Nummular headache is described as pain in a small circumscribed area
of the head in the absence of any lesion of the underlying structures.
No therapy until now was reported as effective in this pain syndrome.
We describe a case of a 55-year-old woman suffering for 1 year from
continuous pain of moderate intensity, without autonomic associated
symptoms, strictly localized to a small area of the left parietal region,
partly responsive to NSAIDs, in accordance with previous observations
of nummular headache. Cerebral MRI with contrast enhancement was
essentially normal, showing only minimal unspecific alterations of
deep white matter and asymmetry of the vertebral arteries. Gabapentin
at the dose of 300 mg t.i.d. led to total disappearance of pain.
HEMICRANIA CONTINUA EVOLVING FROM MIGRAINE
WITH AURA: A CASE REPORT
1A. Palmieri, 2F. Mainardi, 2F. Maggioni, 2F. Dainese, 2G. Zanchin
1Headache Unit, Hospital of San Donà di Piave, Venice, Italy;
2Headache Centre, Department of Neurosciences, University of Padua,
Padua, Italy; e-mail: giorgio.zanchin@unipd.it
Introduction Hemicrania continua (HC) is an uncommon primary
headache disorder originally described in 1984 by Sjaastad and
Spierings and characterised by a continuous, strictly unilateral
headache of fluctuating intensity with exacerbations of more severe
pain usually accompanied by autonomic disturbances, and with com-
plete response to indomethacin. Even though migrainous features can
be part of HC, its relationship with migraine with or without aura has
not been clarified.
We report a case of remitting HC with absolute response to
indomethacin evolving from migraine with aura.
Case report A 40-year-old woman had suffered from migraine with
typical aura from the age of fifteen, with a range of attacks of three to
six per year. The headaches, almost exclusively localised on the left
side, were regularly preceded by ipsilateral visual scotoma and numb-
ness and tingling in the left upper limb. Three months earlier the patient
began to complain of daily, continuous, left-sided headache with super-
imposed exacerbations of more severe pain. These exacerbations were
always preceded by paresthesias over the left hand and the left side of
the mouth and tongue, lasting 5 to 15 minutes, and associated with nau-
sea, eye redness and nasal congestion. Frequent short-lasting ipsilater-
al jabs and jolts were also reported. Common analgesics and NSAID
administration resulted in little or no effect. Medical history and phys-
ical examination were normal. Brain magnetic resonance imaging
(MRI) was normal as were blood cell count, ESR, autoimmunity, and
coagulation tests.
A diagnosis of possible HC was made and the patient was administered
indomethacin 75 mg daily, with a disappearance of symptoms by the
third day. Indomethacin was gradually tapered after one month without
recurrence of symptoms. The patient was still asymptomatic at the six
month follow-up, with the exclusion of a single spell of usual migraine
with aura.
Discussion The coexistence of HC with another form of primary
headache is rarely reported in the literature. The clinical and patho-
genic relationships between HC and migraine are poorly understood.
The exact prevalence of migraine in patients suffering from HC is still
unknown. The two clinical entities share common aspects such as
migraine-like exacerbations associated with vegetative symptoms.
Conversely, aura does not seem to be an exclusively migraine-depen-
dent phenomenon.
Our patient’s headache could represent a clinical and pathogenic con-
tinuum between migraine and HC. Further descriptions and more care-
ful analysis of migraine aspects in HC patients are needed to better
clarify the relationship between migraine and HC.
NEUROVASCULAR HEADACHE: EVIDENCE FOR A ROLE OF
MIDBRAIN VASCULAR MALFORMATION IN ACUTE
MIGRAINE-LIKE HEADACHE
V. Villani, C. Mostardini, G. Bruti, V. Rondelli, F. Di Stani, G.L. Lenzi,
R. Cerbo
Pain Centre “Enzo Borzomati”, Headache Unit, Azienda Policlinico
Umberto I Rome, Department of Neurological Science, University of Rome
“La Sapienza”, Rome, Italy; e-mail: claudio.mostardini@uniroma1.it
After the vascular theory, migraine seems to be increasingly a neu-
rovascular disorder with a primary involvement of central subcortical
sensitive structures, with a secondary neurovascular response.
Functional neuroimaging techniques, confirm this hypothesis rein-
forced by the human model of secondary migraine-like symptoms
related to brainstem pathology (Goadsby PJ et al., Cephalalgia, 2002;
Afridi S et al., J Neurol Neurosurg Psychiatry, 2003).
We present the case of a young patient who came to our Emergency
Department affected by a second-time headache, which started one
week before, of moderate/severe intensity, described like a continuous
throbbing right-sided pain, with severe aggravation by physical activi-
ty but without photophobia.
Following the pain, slight neurological symptoms appeared, such as
allodynia in the area of the right greater occipital nerve, hypesthesia on
the right side of the face, and hiccups. MRI scan of the midbrain and
of the cervical medulla demonstrated a medial voluminous cavernous
angioma that had recently bled, ranging from the distal part of the
trigeminal nucleus to the level of C2. Resolution of part of the neuro-
logical symptoms (hypesthesia and hiccups) in the following days
reduced the necessity of neurosurgical intervention. At follow-up vis-
its 1, 3, and 6 months later, the patient presented with a continous
reduction of headache and allodynia but with persistence in the right
C2 dermatome of paroxysmal, jabbing electric-like pain (4–5/days)
that disappeared with amitriptyline therapy. Neurophysiological tests
(BAERS, Blink Reflexes, AEP, and ESP) were normal. No other
episodes of migraine-like headache were registered during the follow-
up period, confirming the secondary nature of these migraine-like
symptoms.
CASE REPORTS II
MIGRAINE AND EPILEPSY: FOLLOW-UP OF A CHILD SUF-
FERING FROM CORTICAL DYSPLASIA
E. Tozzi, E. Cicconi, R. Savini, R. De Colli
Paediatric Clinic, University of L’Aquila, L’Aquila, Italy; e-mail:
etozzi@univaq.it
Migraine and epilepsy are two different syndromes, which often show
an overlapping of symptoms in childhood.
MS aged 16 years came to our observation affected by West syndrome
since the age of 10 months. A familiarity with mental and language retar-
dation was present in the maternal relatives. Therapy with synacthen and
valproic acid resulted in remission of the crises after 3 months.
Brain magnetic resonance imaging (MRI) revealed polymicrogyric
dysplasia of the left frontal parietal region, EEG revealed left-sided
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temporal and occipital OP discharges until the age of 6. Antiepileptic
therapy (valproate) was stopped at age 6. Neuropsychological assess-
ment showed mental retardation (QI=70) with dyslexia and dyscalcu-
lia present until now. Neurological examination revealed motor clum-
siness and incoordination of the right hand. At 7 years of age the boy
suffered from headache diagnosed as migraine without aura (5 crises
per year).
A new MRI showed the same cortical dysplasia and SPECT showed
modification of the frontal and occipital areas. At age 15, he experi-
enced an abrupt onset of two generalized tonic-clonic crises. EEG
revealed OP discharges during light stimulation and hyperpnea.
Therapy was started with oxcarbazepine stopping the seizures and
migraine.
A relationship between epilepsy and migraine has been postulated.
Migraine and epilepsy are highly comorbid, but the nature of their
association remains unclear. ICHD-II codes in point 7.6 for headache
attributed to epileptic seizure and defines migralepsy as epileptic
seizures occurring between the migrainous aura and the headache
phase of migraine. Exceptionally, reversible brain MRI abnormalities
following migraine and seizures have been reported. There are few
descriptions, however, of patients with brain MRI changes.
ASSOCIATION BETWEEN HYPNIC HEADACHE AND REM
SLEEP: CASE REPORT
P. Meineri, F. Mondino, P.C. Gerbino Promis, E. Torre, E. Rota, 
E. Grasso
Division of Neurology, Department of Neurorehabilitation, A.S.O. “S.
Croce and Carle”, Cuneo, Italy; e-mail: pieromeineri@hotmail.com
A 68-year-old man presented a 3-month history of frontal, bilateral,
dull, and sometimes pulsating headache, of mild severity, not associat-
ed with other symptoms, occurring exclusively during nocturnal sleep.
These attacks occurred almost every night and awakened the patient an
hour after he fell asleep and lasted about sixty minutes. The attacks
usually recurred once or twice during the night. CT and NMR were
negative, as was neurological examination.
A diagnosis of hypnic headache (HH) was made based on the above
data.
Before starting prophylactic treatment, we performed a full-night
polysomnography (PSG), using a portable device. EEG traces were
acquired with electrodes positioned in accordance with the
International 10–20 System. Other channels recorded ocular move-
ments, EMG activity from mylohyoid and tibialis muscles, measure-
ment of thoracic and abdominal efforts (by means of piezoelectric
strain gauges), airflow (by means of thermocouples located at nostrils
and mouth), snoring sounds (by means of a microphone), oxygen sat-
uration level (pulse oxymeter with finger probe), body position, and
heart rate.
The patient reported two headache attacks during that night. Both
attacks aroused him from the rapid eye movement (REM) phase of
sleep, respectively 15 and 14 minutes after REM onset. During that
night we recorded another short REM phase (about 5 minutes), with-
out any attack. No apnoeas or hypopnoeas were recorded.
After PSG, the patient started treatment with lithium carbonate 600 mg
at bedtime, but we could not observe any beneficial effect; moreover
the patient experienced typical lithium side effects (tremor and thyroid
dysfunction). Then he was treated with flunarizine 5 mg at bedtime and
the attacks completely disappeared within 60 days.
Although the first PSG analysis of a case of HH documented a rela-
tionship with REM sleep, subsequent studies did not always confirm
this association. Until now, 17 HH attacks in 11 patients have been
studied with PSG. Twelve of them occurred during REM phases and 5
started during non-REM period.
Our case suggests a relationship between HH and REM sleep.
Moreover, HH attacks seem to not start immediately after REM sleep
has begun, but rather when this period has lasted for some minutes.
CLINICAL AND RADIOLOGICAL FINDINGS IN A CASE OF
PROBABLE CLUSTER-LIKE SYNDROME
G.M. Patruno, A. Romorini, G. Alberti
Neurology Unit, Magenta Hospital, Milan, Italy; e-mail: alessan-
dro.romorini@ao-legnano.it
Cluster headache (CH) is the most frequent primary trigeminal auto-
nomic cephalalgia.
Among the hypotheses, activation of the trigeminovascular system [1]
and the role of the hypothalamus and brainstem are well established [2].
Furthermore, deep brain stimulation of the hypothalamus (inferior-poste-
rior area) with successfully operated intractable chronic cluster headache
patients [3] and biogenic amine metabolism alterations [4] supported the
hypothesis that the pain of CH is generated directly from the brain.
In the literature few observations have been reported as cluster-like
syndrome or symptomatic cluster headache associated with another
neurological disease, such as pituitary adenoma, vascular loops, fungal
sinusitis, or even a tumor.
The relationship between the two diseases is debated.
We describe a 48-year-old man who since June 2003 developed week-
ly episodic right-side periorbital headache with ipsilateral nasal con-
gestion, lacrimation, and conjunctival injection. The pain occurred
once a day around 9 a.m. and lasted 20–40 minutes. No nausea, vom-
iting, photophobia or phonophobia were reported.
For one month he was treated with verapamil 120 mg twice a day with
improvement. When four months after the beginning of therapy, he
stopped taking verapamil, the attacks immediately reappeared but dis-
appeared after resuming verapamil.
In October 2003 and February 2004 magnetic resonance imaging was
performed and revealed, on both occasions, a mild suprasellar mass with
possible compression of the right paramedian hypothalamic region.
Serum hormone assays showed slightly elevated levels of growth hor-
mone (GH).
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SUPERIOR SAGITTAL SINUS THROMBOSIS AND
HEADACHE: CASE REPORT
R. Nardello, A. Barbagallo, S. Mangano, A. Vecchio
Mother-Child Department, Division of Paediatric Neuropsychiatry,
University of Palermo, Palermo, Italy; e-mail: r.nardello@virgilio.it
Introduction Cerebral venous thrombosis (CVT) is a rare disease
associated with many etiological factors. At onset the clinical picture is
characterized by a wide spectrum of non specific symptoms often lead-
ing to a delay in diagnosis. Headache may be, often, the only symptom
in the early stage of the disease. We present a case of superior sagittal
sinus thrombosis in a girl with headache, ethmoid sinusitis, and posi-
tive for lupus anticoagulant antibodies (LAC).
Patients and methods The patient was an 11-year-old girl with an
uneventful personal history but with a family history of migraine. She
was admitted to our department complaining of headache characterized
by pulsating pain of severe intensity associated with vomiting, photo-
and phonophobia, refractory to oral analgesics, lasting 4 days. Clinical
examination revealed unsteady gait, dizziness, and ethmoid sinusitis;
thus antibiotic and anti-inflammatory therapy was started. CT scan was
unremarkable. Since the patient worsened 5 days later, an additional
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CT scan was performed, showing thrombosis of the posterior and mid-
dle third of the superior sagittal sinus. Laboratory investigations
regarding the hypercoagulable state detected lupus anticoagulant anti-
bodies. The patient was placed on anticoagulant drugs which induced
a slow and progressive improvement. 
Discussion CVT is an uncommon cause of headache that is character-
ized by an equilibrium disturbance between endogenous, thrombo-
genic, and fibrinolytic factors. The causes and/or the predisposing con-
ditions for CVT have been classified as infectious and non-infectious.
It has been reported that congenital thrombophilia, autoimmune disor-
ders, head injury, cardiac disease, cirrhosis, Crohn’s disease, and ulcer-
ative colitis may be non-infectious causes of CVT. The clinical features
and the time course of CVT are usually related to the efficiency of
venous collaterals. CVT may develop in association with a single risk
factor for thrombosis, but additional risk factors should be sought,
especially when thrombosis occurs in very young individuals. Our clin-
ical data point out that a hypercoagulability disorder, masked by sinusi-
tis, may be an unusual cause of CVT in children. Moreover, in our
patient the first CT scan did not show any abnormality, suggesting that
in the early stage of the disease it may be less sensitive than MRI.
Therefore, the progressive clinical impairment should lead to more
specific neuroradiological investigations because early recognition
linked with appropriate treatment of CVT may result in improvement
of awareness needs in symptomatic headache. Therefore, we believe
that the hypercoagulable state be examined in the evaluation of chil-
dren with severe and persistent headache.
INTERMITTENT ANGLE-CLOSURE GLAUCOMA IN THE
PRESENCE OF A WHITE EYE, POSING AS VISUAL AURA
1F. Mainardi, 1F. Dainese, 1F. Maggioni, 1C. Perin, 2C. Lisotto, 1G. Zanchin
1Headache Centre, Department of Neurosciences, University of Padua,
Padua, Italy; 2Headache Unit, Hospital of San Vito al Tagliamento,
Italy; e-mail: fmainardi@iol.it
We report a case of a 58-year-old woman with a history of migraine with-
out aura since she was 18. The attacks were always located in the right
periorbital region extending to the parietal-temporal zone. The intensity
was moderate or severe; the pain pulsating, accompanied by nausea
and/or vomiting, phono- and photophobia, and increased with physical
activity. The frequency was of 2–3 attacks per month, the duration 12
hours. Followed elsewhere, the response to NSAID’s was partially satis-
factory, the use of oral sumatriptan 50 mg improved most of the attacks.
Cranial and cervical column x-ray, EEG, and cerebral CT scan with con-
trast, all resulted normal. After the onset of menopause, the attacks
became sporadic. At the age of 55, the patient was visited at the
Emergency Room for a migraine attack with characteristics matching
those described above, but preceded by a new visual disorder, referred as
the sudden appearance of a “white flashing cloth in front of the right eye”;
the duration of this visual disorder was approximately 20 minutes, with
the painful attack beginning before its end. The patient’s clinical exami-
nation by the Emergency Room doctor and later by the neurologist on call
was normal; the painful symptomatology had a good response to the
administration of indomethacin 1 fl i.m.. She was released with a diagno-
sis of migraine with aura. The attacks repeated with no variations in the
following months, with an average frequency of two episodes per month.
The only modification that evolved over time was the duration of the visu-
al disorder that increased to approximately three hours, maintaining the
same relationship with the onset of pain. One year later, following an
attack of particular intensity and of visual disturbance in the right eye for
approximately 8 hours, the patient went to the Emergency Room with a
noticeable conjunctival injection. After a general and neurological exam-
ination, she was given an ophthalmologic examination with tonometry,
which recorded an intraocular pressure of 60 mmHg. Iridectomy in the
right eye for intermittent angle-closure glaucoma was performed. Since
then, the patient has reported a complete resolution of the visual and
painful symptomatology. This case underlines the necessity to carefully
study the visual symptoms to establish a correct differential diagnosis, at
times not simple, between a secondary or primary headache, especially
when atypical features are present, such as the increasing duration of the
supposed aura, exceeding the IHS diagnostic criteria.
A NEW CASE OF OPHTHALMOPLEGIC MIGRAINE SUG-
GESTING AN INFLAMMATORY CONDITION
L. Pierguidi, A. Alberti, A. Baldi, G. Mazzotta, P. Sarchielli, 
G. Capocchi
Neurologic Clinic, Department of Neurosciences, University of
Perugia, Perugia, Italy; e-mail: headache@unipg.it
Ophthalmoplegic migraine is a rare headache disorder characterized by
repeated attacks of headache associated with paresis of one or more
ocular cranial nerves in the absence of a demonstrable intracranial
lesion. The pathophysiology underlying this disorder may be due to an
epiphenomenon of trigeminovascular activation, which is dependent on
the unique oculomotor nerve anatomy and porous blood-nerve barrier
at the emergence of the oculomotor nerves from the brainstem and on
the sequelae of demyelination. The IHS classification 2004 includes it
in chapter 13 (cranial neuralgias and central causes of facial pain)
because of different hypotheses supporting the secondary nature of this
rare headache disorder. 
We describe the case of a 28-year-old male patient with recurrent
episodes of headache associated with paresis of the third cranial nerve.
The headache, of pulsating quality and moderate to severe intensity,
located in the left frontal-temporal region, and associated with nausea
and photo- and phonophobia, preceded the onset of fixed left-sided pto-
sis, associated with convergent strabismus and diplopia on central and
right-sided gaze. Such episodes receded after steroidal therapy. The
IgG-index (index of Link) was increased. Brain magnetic resonance
imaging scan and angio-MRI were normal, and there was no contrast
enhancement of the oculomotor nerves at their exit from the midbrain.
Recently, M.D. Ferrari [1] has described the case of a patient with oph-
thalmoplegic migraine with paresis of the third and fourth cranial
nerves. MRI of the patient showed enhancement only of the fourth cra-
nial nerve and an increased IgG-index. An inflammatory etiopathogen-
esis was hypothesized. In our case no alterations on MRI were noted as
was reported in the case of a patient with ophthalmoplegic migraine in
whom neurological deficits persisted [2].
The increase in the index of Link and the resolution of the symptoms
after steroid treatment in our case supports the inflammatory nature of
this disorder, whereas, the absence of alterations on MRI in our case
confirms its peculiar nature and phenotypic variability.
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HEADACHE PATIENT DIAGNOSIS AND
MANAGEMENT
HEADACHE MANAGEMENT IN PATIENTS REFERRING TO A
HEADACHE CENTRE
S. Sacco, L. Olivieri, I. Ciancarelli, R. Della Cagna, C. Marini, A.
Carolei
Department of Neurology, University of L’Aquila, L’Aquila, Italy; e-
mail: simona_sa@yahoo.com
Objective Despite the progress in knowledge and treatment of
headache disorders, their social burden is still high. We evaluated fac-
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tors influencing headache treatment compliance in patients referring
for a first visit to our Headache Centre.
Patients and methods Patients referring for a first visit to the L’Aquila
Headache Centre, during the year 2002 were included in the study.
Headache disorders were classified according to the International
Headache Society Classification, first edition.
Results Data from 421 patients (328 women and 93 men; mean age
36.4±14.9 years) were available. One hundred and twenty-seven
(30%) patients were from L’Aquila, 115 (27%) from the L’Aquila dis-
trict, and 179 (43%) were from other districts. Three hundred and ten
(74%) patients suffered from migraine without aura, 50 (12%) from
migraine with aura, 13 (3%) from episodic tension-type headache, 21
(5%) from chronic tension-type headache, 1 (0.2%) from cluster
headache, 13 (3%) from other headaches, and in 13 (3%) patients the
diagnosis could not be performed during the first visit. In 155 (37%)
patients an association of migraine without aura with episodic (19%)
or chronic tension-type headache (16%) was found. Two hundred and
forty (57%) patients were prescribed two or more preventive drugs,
122 (29%) were prescribed a single preventive drug, and 59 (14%)
were not prescribed any drug; 349 (83%) were prescribed an acute
treatment, while the remaining 72 (17%) were not prescribed any
acute treatment. One or more paraclinical examinations were request-
ed for 143 (34%) patients. One hundred and twenty-seven (30%)
patients came back to the Headache Centre for follow-up within a
year. One hundred and seven (85%) patients who underwent follow-
up were compliant to the prescribed treatment. Factors predicting the
request of a control visit were the lack of any prescribed preventive
treatment (p<0.0001), the presence of two different headache types
(p=0.004), and the request of a paraclinical examination (p=0.021);
sex, headache type, prescription of acute treatment, and living outside
of town did not favour a control visit.
Conclusions Although a low percentage of patients came to the
Headache Centre for a second visit, compliance to treatment in patients
who had a second visit was high. The second visit was mostly related
to non adequate treatment of the headache disorder.
HEADACHE CENTRE IN AN EMERGENCY DEPARTMENT:
THE EXPERIENCE OF A THREE-MONTH COLLABORATION
C. Mostardini, G. Bruti, V. Villani, F. Di Stani, V. Rondelli, R. Cerbo
Pain Center “Enzo Borzomati”, Headache Unit, Azienda Policlinico
Umberto I Rome, Department of Neurological Science, University of
Rome “La Sapienza”, Rome, Italy; e-mail: claudio.mostardini@ 
uniroma1.it
Headache symptoms account for 1–3% of Emergency Department
(ED) admissions. The overwhelming majority of patients who present
to an ED with acute primary headache (PH) have migraine and very
few of them until then have received a specific diagnosis and an appro-
priate treatment. Ten percent of patients who visit an ED for PH are
repeaters [1] i.e., they have already been admitted for the same reason
in the past. The aim of this study was to evaluate the epidemiological-
clinical and economic impact on the collaboration between a headache
centre (HC) and an ED regarding the diagnosis and treatment of
migraine.
Patients with a discharge diagnosis of headache were visited immedi-
ately or within a maximum of 36h at our pain clinic where a headache
specialist of the headache clinic section made a diagnosis of headache
according to 1998 and 2004 IHS criteria.
In agreement with MIDAS we started specific therapy using a stratified
approach.
Out of 237 patients admitted to our HC with a diagnosis of PH made
in our ED, 190 (63M/127F; age 35±14 years) met IHS criteria for
migraine or its complications (e.g. status migrainosus and/or chronic
migraine), whereas 18 subjects were affected by cluster headache.
Twenty patients, (8%) of the total, were affected by secondary
headaches, and of these 9 patients were classified with psychiatric dis-
orders. Only 14% of migraineurs reported having previously seen a
headache specialist before the ED visit and 90% were triptan naïve
prior to coming to the ED. The percentage of ED repeaters in the pop-
ulation was 10%, exclusively migraineurs.
Our data confirmed that migraine represents the most frequent PH
observed in an ED and that it is an under-diagnosed and under-treated
pathology. A strict collaboration between the HC and the ED, would
improve health care of migraineurs and reduce direct and indirect cost
of migraine. 
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HEADACHE IN THE EMERGENCY DEPARTMENT: THE
MOST APPROPRIATE MANAGEMENT
1A. Giorgetti, 1M.V. Calloni, 1R. Freschi, 1C. Guaita, 1G. Mariani, 
1P. Perrone, 1P. Secchi, 2M. Conti
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In most cases, patients coming to the Emergency Department (ED) com-
plain of headache. Headache has many potential causes but in 85% of the
cases the physician can correctly diagnose primary headache disorder.
However, even if less frequent, the remaining 15% of headaches may
represent a potential life-threatening pathology, particularly, when
headache is attributed to a cranial vascular disorder such as subarachnoid
haemorrhage (SAH), resulting from a ruptured saccular aneurysm [1].
We report the case of a patient with SAH who went to the ED after suf-
fering initially from acute retroorbital headache with brain CT that
excluded the presence of bleeding. Neurological examination showed
no abnormalities. The patient was dismissed even though she returned
to the ED the day after, presenting ptosis in her right eye. This case
illustrates how inadequate management might cause serious medical
and legal consequences. It also proves that the presence of a first acute,
unusual headache must always lead the physician to exclude secondary
headaches [2]. In particular, we should always consider the possibility
of SAH, which represents the most frequent cause of acute headache
with abrupt onset, though the neurological examination and CT scan
may not always reveal any abnormalities [3].
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HEADACHE IN THE PAEDIATRIC EMERGENCY DEPART-
MENT
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Headache in the Emergency Department is the most frequently report-
ed phenomenon of young children involving considerable economic
loss, as well as an important worsening of the quality of life of those
who suffer from it. Many tests are performed and a variety of therapies
are used.
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In the present study with the objective of evaluating the quality of pri-
mary care for acute headaches and the therapies utilized, we examined,
retrospectively, 55000 patients with a complaint of headache who
sought the Emergency Room of a paediatric hospital. Of these, 1.3%
presented with headache.
The etiologies of the headaches secondary to neurological disorders
corresponded to less than 10% of the cases of headache that did not
require patient hospitalization and even in these cases the etiology was
relatively benign. Of the hospitalized patients, 51.5% had headaches
secondary to neurological disorders.
HEADACHE IN CHILDREN IN THE EMERGENCY DEPART-
MENT
E. Tozzi, R. Savini, E. Cicconi, R. De Colli, S. Di Mauro
Paediatric Clinic, University of L’Aquila; L’Aquila, Italy; e-mail:
etozzi@univaq.it
Introduction The medical information of the family paediatrician and
the collaboration between the hospital specialist physician and family
physician represent the first approach to headache in children. In fact,
the family physician should identify, at first consultation, a severe
headache.
Objective The aim of this study was to investigate the rate of acute
headache in children presenting to the Emergency Department of a
general hospital, where there was a headache department dedicated to
adults and children. The period of observation was one year, from April
2003 to April 2004. Among 1532 paediatric consultations in the
Emergency Department of L’Aquila Hospital, headache was diagnosed
in 31 patients. After paediatric consultation, 25 patients were treated in
the hospital, 4 were hospitalised, and 2 were observed for 4 hours in
the Emergency Room. The causes of hospital consultation were: fever
(5 cases), vomiting (2), apistaxis (1), abdominal pain (2), sinusitis (2),
loss of consciousness (2), and blurred vision (1). Three patients suffer-
ing from gastroesophageal reflux, haemophilia B, and ventriculoperi-
toneal shunt malfunction presented to the hospital because of headache
and were admitted. Three children presented headache associated with
head injury. Six children were evaluated by laboratory investigations,
ophthalmologic and neurosurgical consultation. CT scan was per-
formed on 1 child and EEG on another 2 children. The causes of
headache were upper viral respiratory infection (11 children), strepto-
coccal pharyngitis (4), meningitis (1), migraine (3), ventriculoperi-
toneal shunt infection (1), epileptic seizures (1), and posttraumatic
headache (4). Etiological diagnosis of headache was made in 80.6% of
the patients, while in 19.3%, the etiology remained unknown.
Conclusions The abrupt onset of headache represents 2% of all con-
sultations in the Emergency Department of a general hospital, 12.8%
of all headaches observed in one year in the Neuropaediatrics
Department, and of these, 0.2% of hospitalisations. The correct
approach to headache in children can be determined in only 3.9% of
investigations and in only 1 case by neuroradiological examination.
HEADACHES IN THE EMERGENCY DEPARTMENT OF A
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Objective To describe and analyse the patients observed for headache
in the Emergency Department of a paediatric hospital.
Methods We retrospectively evaluated the medical records of all chil-
dren attending the Emergency Department with the symptom
“headache” during a period of one year (1 May 2002 – 30 April 2003).
We considered age, gender, associated symptoms, physical evaluation
(in particular neurological examination), use of complementary diag-
nostic techniques, treatment received, and outcome. Patients with pre-
vious head trauma were excluded.
Results Two hundred and fifty-six patients (1.46% of all paediatric
Emergency Department visits – total number 17488) presented to the
Emergency Department with headache. Mean age was 7.9 years, range
between 2 and 16 years with a distribution male / female=136 / 120
(52.5% vs 47.5%). In 81 subjects (31.6%) headache was the only com-
plaint. Fever was associated in 100 patients, vomiting in 63, nausea in
28, abdominal pain in 15, and neurological symptoms in 15 (i.e., visu-
al symptoms, vertigo, dysarthria, paraesthesia). Others symptoms (i.e.,
diarrhea, abdominal pain, otitis, etc.) were less frequent. Neurological
evaluation was abnormal in 5 patients. Diagnostic techniques used
were ophthalmoscopic examination in 20 patients, CT scan in 6, X-ray
in 4, and MRI in 1. Ninety-four patients (36.7%) were treated with
analgesic medications, including acetaminophen, ibuprofen, and aceta-
minophen plus codeine. Fifteen patients were admitted to the hospital
for further evaluation and treatment: 5 of these patients had primary
headache (i.e., migraine, tension-type headache, paroxysmal benign
vertigo, abdominal migraine), 8 patients secondary headache (i.e., ven-
triculoperitoneal shunt malfunction in brain tumor, aseptic meningitis,
systemic viral or bacterial infections, hypertension in nephropathy),
and 2 patients unclassifiable headache. Of the total of 256 patients, 30
patients underwent further evaluation in the headache centre of our
hospital. The headache type according to ICHD-II, 2004 was tension-
type headache in 9 patients, migraine in 16 patients, abdominal
migraine in 2, secondary headache in 2 (i.e., ventriculoperitoneal shunt
malfunction in brain tumor, ocular disorder), and unclassifiable
headache in 1 patient.
Conclusions Clinical diagnosis plays a key role in the evaluation of
headache disorders in a paediatric Emergency Department. The major-
ity of the headaches are secondary to concurrent illness, and are treat-
ed with minor analgesics and no diagnostic tests are required. In a
small minority of patients hospitalisation is required to perform diag-
nostic tests to exclude serious diagnosis (i.e., intracranial
space–occupying lesion, meningitis, and vascular abnormalities).
THERAPEUTIC ASPECTS I
MULTIPLE-ATTACK STUDY ON THE TRIPTANS AVAILABLE
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Objective The aim of the study was to evaluate the efficacy and toler-
ability of the 5 triptans commercially available in Italy (Zolmitriptan
2.5 mg, Rizatriptan 10 mg, Sumatriptan 100 mg, Almotriptan 12.5 mg
and Eletriptan 40 mg) and compare them to one another and to place-
bo.
Materials and methods The study was conducted in single-blind and
of 18 months duration. At the Headache Centre of the “Agostino
Gemelli Polyclinic” in Rome we selected 42 patients, suffering from
headache with and without aura (IHS, 1988), whose headache fre-
quency was between 1 and 4 monthly crises. A different triptan and
placebo were taken for every 5 consecutive crises up to a total of 30
crises. After 2 hours patients could take a rescue medication if they
wished to do so. The study end-points were as follows: response at 2
hours, “pain free” at 2 hours and “sustained pain free” (at 24 hours).
The intra-patient consistency and tolerability were also evaluated.
Results Thirty patients completed the study and statistical analysis was
only applied to these patients. No substantial differences as regards to
the efficacy of the triptans were noted (some of the differences could
be due to pharmacokinetics); the 5 triptans resulted superior to place-
bo, also in the intra-patient treatment; all triptans were well tolerated.
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Conclusions These results suggest the possibility of testing different
triptans in the same patient in order to identify the ideal drug for every
patient.
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The use of complementary and alternative medicine (CAM) for
migraine is a growing phenomenon about which little is known. This
study was undertaken to evaluate the rates, pattern, and presence of
predictors of CAM use in a clinical population of patients with differ-
ent migraine subtypes. Four hundred and eighty-one migraineurs
attending a headache clinic were asked to complete a questionnaire
designed to gather information on CAM use. Past use of CAM thera-
pies was reported by 30.9% of the patients surveyed, with 17.1% hav-
ing used CAM in the previous year. CAM therapies were perceived as
being beneficial by 39% of the patients who had used them. The most
common source of recommendation for CAM was a friend or relative
(52.9%). Most migraineurs used CAM treatment specifically for
headache (89.3%). Approximately 61% of CAM users had not
informed their medical doctors of CAM use. The most common reason
for choosing to use a CAM therapy was “potential improvement in
headache” (48.3%). The patients who used CAM treatments were:
those with a diagnosis of transformed migraine; those who had con-
sulted a large number of specialists and had completed a higher num-
ber of conventional lifetime visits; those with a psychiatric comorbid
disorder; those with a high income; and those in whom the headache
had been either misdiagnosed or not diagnosed at all. Our findings sug-
gest that migraine patients, in their need and search for care, seek and
explore both conventional and CAM therapies. Physicians should be
made aware of this patient-induced climate change in medicine so as to
prevent health-care resource misuse and better meet patients’ needs.
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Objective The joint effect on serotonin and norepinephrine has been
considered the major reason for the effectiveness of amitriptyline (a tri-
cyclic antidepressant: TCA) in the prophylactic treatment of migraine.
Venlafaxine is a selective serotonin-norepinephrine reuptake inhibitor
but is better tolerated than TCA. A retrospective study by Adelman et
al. [1] showed the efficacy of venlafaxine extended release in the pre-
ventive treatment of migraine.
On this basis, we planned an open-label prospective trial to investigate
the efficacy and tolerability of Venlafaxine as preventive treatment for
migraine.
Materials and methods The study was designed as a multicentre
open-label prospective trial involving 10 Clinical Outpatient Centres in
Sicily. We planned to include 100 patients meeting the following crite-
ria: age range, 12 to 65 years; the diagnosis of migraine according to
the International Headache Society criteria; and 3 to 12 migraine
attacks per month, but with 15 or fewer headache days per month dur-
ing a 4 week prospective baseline phase (run-in). Depressed patients
with scores greater than 15 using the Hamilton Depression Rating
Scale (HDRS) were excluded.
After run-in, patients (following 7 days titration at 37.5 mg/day) were
treated with 75 mg/day of venlafaxine extended release for 12 weeks. The
primary outcome measure was the change in attack frequency per month
as compared to baseline (run-in). Secondary efficacy measures were
responder rate (proportion of patients with 50% or more reduction in
monthly migraine frequency) and reductions in mean number of month-
ly migraine days. Effects on mood and disability were assessed by HDRS
and Impact Test (IT) given after run-in and at the end of treatment.
Results Twenty-five patients have now completed the study. Amongst
which, venlafaxine treatment significantly reduced attack frequency per
month and mean number of monthly migraine days, with a responder
rate of about 75%. IT and HDRS scores were also significantly reduced.
Treatment was well tolerated and no patient dropped out; the most fre-
quently reported side-effects were loss of weight, nausea, and dizziness.
Conclusions If confirmed, these preliminary results could support the
potential efficacy of venlafaxine in preventing migraine, which is
worth exploring in further controlled trials.
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Objective Migraine with aura with high frequency of attacks could
represent a very demanding therapeutic problem. D’Andrea et al. [1]
reported efficacy of the antiepileptic drug lamotrigine for treatment of
this form of migraine. Levetiracetam is a new antiepileptic drug with
an excellent tolerability profile. Mechanisms of action of this drug
remain largely unknown, but quite recently Lukyanetz et al. [2] showed
that levetiracetam is able to exert inhibitory effects on N-type calcium
channels. Inhibition of N-type calcium channels in experimental ani-
mals have been shown to block propagation of cortical spreading
depression in experimental animals [3].
On such grounds we evaluated the efficacy of levetiracetam as prophy-
lactic treatment for migraine with aura in patients with high frequency
of attacks.
Materials and methods We carried out a small open-label trial treat-
ing 15 patients affected by migraine with aura with a high frequency of
attacks (4 or more per month). Ten patients had previously undergone
other preventive treatments that proved completely ineffective. A run-
in period of 1 month preceded the treatment with levetiracetam that
was given for 3 months at the dosage of 1000 mg/die. The number of
attacks per month was considered the major outcome measure.
Results Levetiracetam was generally well tolerated and no relevant
adverse effects or dropping out were recorded. Mean number of attacks
per month was reduced from 7.1±5 during the run-in period to 2±1 at
S43
the 3rd month of treatment (p<0.00001). In 7 out of 15 patients, the
attacks were completely abolished after 3 months of treatment.
Discussion Our results show that Levetiracetam is well tolerated and
could be effective in preventive treatment of migraine with aura.
Conclusion Levetiracetam could represent a new therapeutical option in
migraine with aura. Controlled trials are needed to confirm the results.
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Antiepileptic drugs are used in the prevention of migraine and other
head pains, whereas their mechanisms of action are not still complete-
ly understood. Levetiracetam seems to affect nociception by modulat-
ing GABA-mediated neurotransmission.
This drug interferes with GABA metabolism and possibly inhibits
sodium ion channels and modulates activity of the N-Type calcium ion
channels. The prevention of migraine could be exerted through such
mechanisms as modulating the biochemical phenomena of aura or act-
ing on the nociceptive system.
Levetiracetam has been used for a variety of pain conditions, such as
trigeminal neuralgia, migraine without aura (Drake, 2001; Kursz,
2002), and chronic daily migraine.
In an open-label study on 26 cases of migraine according to IHS
(International Headache Society), patients were initially treated with
levetiracetam at a dosage of 500 mg/die for seven days, then dosages
were titrated up by 500 mg per week to a final dosage of 2000 mg/die.
The therapy took three months.
The aims of treatment were the reduction in number of migraine
attacks and of analgesic consumption.
These studies indicate that levetiracetam is well tolerated by patients,
reduces migraine frequency and intensity, and use of symptomatic
drugs. Levetiracetam seems to have a therapeutic action in the prophy-
lactic treatment of migraine, but more clinical trials are necessary to
prove the effectiveness of the drug in these indications.
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Objectives The calcium-channel antagonist flunarizine is largely used
in migraine prophylaxis because of its effectiveness in long-term
reduction of frequency, severity, and duration of the migraine attack.
The prophylactic action of flunarizine is linked to the modulation of
cerebral vessel tone related to nitric oxide (NO) and oxygen free radi-
cals activity and to its powerful antioxidant properties. In this study, we
investigated the prophylactic efficacy of flunarizine and whether its
anti-migraine action might be ascribed to its influence on NO and
oxidative markers. 
Materials and methods Twenty-five subjects suffering from migraine
without aura were examined. Urine samples collected 24 h before and
after 6-month treatment with flunarizine (5 mg orally per day) were
assayed for NO stable metabolites (NOx) and thiobarbituric acid reac-
tive substances (TBARS). Migraine frequency, expressed as number of
attacks per month, and mean pain severity score (0: no pain; 1: mild
pain; 2: moderate pain; 3: severe pain) were counted and evaluated
according to past medical history during the 6 months preceding pro-
phylactic treatment and at the end of treatment. 
Results Frequency (6.84±2.43 vs 3.36±1.96, p<0.005) and severity
(2.03±0.40 vs 1.47±0.67, p=0.001) of migraine attacks during flunar-
izine prophylactic treatment decreased when compared to those
observed before treatment. Urinary TBARS were decreased after flu-
narizine treatment with respect to levels measured before prophylaxis
(0.35±0.07 vs 0.43±0.12 µmol/mmol creatinine; p<0.05). No differ-
ences were observed in NOx values in migraine sufferers before and
after treatment with flunarizine (0.72±0.15 vs 0.75±0.10 mmol/mmol
creatinine; p=0.413).
Conclusions Our results suggest that flunarizine is clinically helpful in
migraine prophylaxis and in decreasing the frequency and pain severi-
ty of attacks. Flunarizine is effective in limiting oxidative reactions in
migraine sufferers although useless in preventing NO-mediated vasodi-
lation. 
THERAPEUTIC ASPECTS II
DEXAMETHASONE AND AMITRIPTYLINE IN THE DETOXI-
FICATION OF PATIENTS WITH CHRONIC DAILY HEADACHE
AND MEDICATION OVERUSE
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Introduction Chronic daily headache (CDH) is a highly invalidating
pathology which affects 4–5% of the general population and which sig-
nificantly interferes with the professional activity, the social life and
the family life of the people affected by it. Up to 80% of patients affect-
ed by CDH excessively overuse analgesic medication.
Methods Twenty-five patients affected by “chronic daily headache
with medication overuse” (Silberstein and Lipton, 1996) were admitted
to the “Agostino Gemelli” Hospital in Rome for 15 days to undergo a
detoxification/“wash-out” period before starting prophylactic medica-
tion. During this period, we suspended the abused medication and
administered dexamethasone i.v. and amitriptyline daily.
Results The headache frequency, which was daily, or near-daily, in all
patients decreased significantly during the hospital stay.
Conclusions This therapeutic scheme has proven to be useful in inter-
rupting the chronic pattern of daily headache and in offering patients
immediate relief from pain.
Discussion The efficacy of this therapeutic scheme is probably due to
the effect these drugs have on the mechanisms implicated in the gene-
sis of acute and chronic pain.
GREATER OCCIPITAL NERVE BLOCKADE IN CHRONIC
MIGRAINE WITH CERVICO-OCCIPITAL LOCALIZATION:
PRELIMINARY RESULTS
F. Di Stani, G. Bruti, C. Mostardini, V. Villani, V. Rondelli, R. Cerbo
Pain Center “Enzo Borzomati”, Headache Unit, Azienda Policlinico
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Introduction Physiological and pathophysiological data showed the
convergence of trigeminal and cervical afferents on neurons in the
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trigeminocervical complex of the brain stem. Convergence along with
sensitization of central trigeminal neurons provides a physiologic
basis for the clinical phenomenon of spread and referred pain by
which pain originating from an affected tissue is perceived as origi-
nating from a distant receptive field. After strong noxious inputs, noci-
ceptive second-order neurons in the spinal cord can be subjected to a
transient or long-lasting hyperexcitability to afferent stimulation.
Greater occipital nerve (GON) infiltration with local anesthetics and
steroids was successfully used for diagnostic and therapeutic purpose
in cervicogenic headache.
Objective The aim of the study was to evaluate in chronic migraine
with cervico-occipital localization the efficacy of GON blockade in
stopping pain and in incrementing efficacy of preventive therapy.
Materials and methods We enrolled consecutively 10 patients affect-
ed with chronic migraine according to IHS criteria 2004. These
patients were refractory to principal preventive therapies for migraine.
All patients suffered from bilateral cervico-occipital distribution of
pain and were submitted, at T=0, to bilateral GON blockade using lido-
caine 2% (8–10 ml) and betamethasone (4 mg). Follow-up visits were
done at 1 (T=1), 3 (T=2) and 6 (T=3) months. Clinical data, numeric
pain intensity scale (NPIS) and Migraine Disability Assessment Scale
(MIDAS) were collected and administered at every step. Informed con-
sent was obtained from all patients.
Results At baseline our patients showed the following characteristics:
(1) headache frequency (days per month): 22±7; (2) pain-killer use:
35±10; (3) NPIS score: 8±1; (4) MIDAS score: 55±9. At T=1 follow-
up visit we observed a significant reduction in all clinical parameters
considered (p<0.05). At T=3 follow-up visit we did not observe any
significant reduction of headache frequency, pain-killer use, NPIS or
MIDAS score.
Conclusions These preliminary results pointed out that bilateral GON
blockade in chronic migraine with cervico-occipital localization is
strongly effective in reducing pain intensity, pain-killer use, disability,
and headache frequency up to one month after injection. Otherwise,
this positive effect disappears at the 6 month follow-up visit. A greater
number of subjects and the homogeneity of the preventive therapy
started after the bilateral GON blockade will be indispensable for an
accurate evaluation of the efficacy of this technique.
TIME TO DAILY HEADACHE RESOLUTION IN MEDICATION
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Objective Controlled trials and guidelines for the treatment of med-
ication overuse headache are currently not available. The aim of the
present study was the evaluation of the efficacy of a therapeutic regi-
men of detoxification to stop the daily headache in a large sample of
medication overuse headache patients.
Methods One hundred and five daily analgesic abusers (P) admitted
to an inpatient Headache Unit were treated by abrupt discontinuation
of overused medication and intravenous hydrating and sedative ther-
apy with benzodiazepines for an average of 10 days [SD 3].
Symptomatic and antiemetic drugs were used only in case of severe
rebound headaches. The efficacy measure of the therapeutic regimen
used was the time to daily headache resolution. Follow-up lasted
three months.
Results The study included 93 females (88,6%), mean age 55 years
[SD 12], and 12 males (11,4%), mean age 58 years [SD 16]. The ini-
tial headaches were migraine without aura (78 P), migraine without
aura and tension-type headache (12 P), migraine with aura and
migraine without aura (10 P), and tension-type headache (5 P).
Medication overused were: combination analgesics, 43 cases
(40,9%); simple analgesics, 39 cases (37,2%); triptans, 13 cases
(12,4%); and ergotamine, 10 cases (9,5%). Average time to daily
headache resolution was 8 days [SD 5]. Daily headache stopped more
rapidly in triptan abusers (5 days [SD 2]) than in abusers of other
medications (simple analgesics 10 days [SD 6], ergotamine 10 days
[SD 4], or combination analgesics 8 days [SD 5]). No correlation was
found between the time to daily headache resolution, the type of ini-
tial headache, the daily drug intake duration, and the number of daily
drugs taken. At 3-month follow-up all patients had reverted to a pat-
tern of less than 15 attacks/month.
Conclusion The time to daily headache resolution in medication
abusers treated with detoxification as in-patients was remarkably
shorter than that indicated by IHS (≤ two months). Positive results
were obtained also in patients with a prolonged overuse period and
high daily drug intake. A comparison among different therapeutic
strategies for the treatment of medication overuse headache is war-
ranted.
COMBINATION OF TIZANIDINE AND AMITRIPTYLINE IN
THE PROPHYLAXIS OF CHRONIC TENSION-TYPE
HEADACHE: EVALUATION OF EFFICACY AND IMPACT ON
QUALITY OF LIFE
D. Bettucci, L. Testa, F. Monaco
Neurologic Clinic, University of Piemonte Orientale “A. Avogadro”,
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Chronic tension-type headache (CTTH) is one of the most widespread
types of chronic headache. It has a particularly strong impact in terms
of the individual’s “Quality of Life” (QOL) and socio-economic costs.
We carried out an open-label randomized clinical trial on 20 adult
patients with CTTH (diagnostic criteria IHC 2004), divided them into
two groups of treatment, each of 10 patients, in order to compare the
effectiveness and impact on QOL of two different schemes of pharma-
cological prophylaxis. The first consisted in the use of amitriptyline 20
mg/d over a 3 month period, while the second proposed to combine
amitriptyline with tizanidine (4 mg/d), a molecule with a faster phar-
macological effect, that recent studies have shown as a promising pro-
phylactic adjunct for different forms of chronic headache in the first 3
weeks of treatment.
In our opinion, the in-combination therapy could guarantee an
improvement in QOL even in the early stages of treatment, com-
pared with the usual utilization of only amitriptyline. In fact, as is
well-known, the efficacy of amitriptyline in the prophylaxis of
CTTH may be observed only after 2–3 weeks of treatment, with con-
sequent persistency, in the first phases of therapy, of the cephalalgia
and its correlated negative impact on the individual’s psycho-physi-
cal condition.
Outcome measures included frequency, pain intensity, duration of
headache, and the Headache Impact Test (HIT) used as QOL measures.
The in-combination therapy was effective from the first month of
treatment, with a significant reduction (>50%), greater than the
results obtained with amitriptyline alone, in terms of frequency
(-52,3% vs. -40,7%; p<0,05), intensity (-59,51% vs. -20,39%;
p<0,02), and duration (-53,17% vs. -36,16%; p<0,05) of the
headache. This trend was confirmed by the pattern of HIT scores
which are indicators of the impact on QOL (1st month: -18,6%vs.
-12,8%; p<0,05/ 3rd month -22,10 vs. -23,20; p>0,05). At the end of
the 90-day treatment period, however, there were no significant dif-
ferences. Further, subjective reporting by the patients showed a
total degree of satisfaction, higher on average, for the group treated
with both medicines. Our data suggest that the combination of
tizanidine and amitriptyline is effective in guaranteeing a more
rapid improvement in the headache pattern and correlated QOL
rather than the use of amitriptyline alone. We therefore propose it
as a possible therapeutic option in the preventive treatment of
CTTH.
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STEROID TREATMENT AND NEUROIMAGING CORRELA-
TIONS IN FIVE CASES OF PAINFUL OPHTHALMOPLEGIA
(TOLOSA-HUNT SYNDROME)
1E. Ferrante, 3A. Brioschi, 2A. Savino
1Neuroscience and 2Emergency Departments, Niguarda Hospital, Milan,
Italy; 3IRCCS - Italian-Piacavallo Auxology Institute, Verbania, Italy; e-
mail: enricoferrante@libero.it
Objective To evaluate the correlations between clinical evolution,
neuroimaging and steroid treatment in patients (pts) affected by
Tolosa-Hunt syndrome (THS).
Materials and methods We report 5 pts (3 males, 2 females, age
range: 35–65 years) affected by THS according to International
Headache Society (IHS) inclusion criteria. All pts underwent gener-
al, neurological, and ophthalmologic examinations, routine blood
tests, serum inflammatory and infectious disease tests, autoantibod-
ies, angiotensin converting enzyme, tumor markers and gadolinium
enhancement brain MRI. Cerebral angiography and cavernous sinus
biopsy were performed in 1 pt, CSF examination was performed in
1 pt.
Results In 3 pts laboratory data and neuroimaging were normal at
symptom onset; high dose steroid therapy was promptly started
(deamethasone, 16 mg bid i.m., tapered over 4 weeks) within 5 days
from onset of symptoms. Pain disappeared within 60 hours, ocular
palsies within 5 days from onset of therapy. Two other pts had cav-
ernous soft-tissue masses on gadolinium-enhanced brain MRI and
slightly increased erythrocyte sedimentation rate. Cavernous sinus
mass biopsy was performed in 1 case showing non-specific inflam-
matory abnormalities. These 2 pts underwent high dose steroid ther-
apy after only 1 month from the onset of symptoms and showed slow
improvement with complete recovery within 2 mouths. The cav-
ernous sinus mass disappeared after 6 months on brain MRI. All pts
did not show any clinical relapse during follow-up (from 3 to 10
years, mean 6 years).
Discussion THS is a rare painful ophthalmoplegia often due to non-
specific granulomatous inflammation in the cavernous sinus or supe-
rior orbital fissure. Diagnostic criteria are based on oculomotor
nerve involvement, steroid responsiveness and/or demonstration of
granuloma by MRI or biopsy and exclusion of other causes (tumors,
vasculitis, basal meningitis, sarcoidosis, aneurysm, diabetes, and
ophthalmoplegic migraine), according to IHS 2004.
Conclusions Our report confirms that steroid treatment has to be
started early during the course of the disease to obtain a more rapid
resolution of symptoms and signs, possibly preventing anatomical
damage. MRI could have a positive prognostic value predicting
steroid efficacy and clinical outcome.
HEADACHES AND THE MARFAN SYNDROME
P. Hermes, C. Porciani, V. Letri, M. Attanasio
University of Florence, Careggi Hospital, Marfan Centre, Florence,
Italy; e-mail: neuropfo@hotmail.com
Marfan syndrome is a genetically transmitted disease affecting 1
person in 5000–10000 people.
Two hundred twenty-four patients’ charts with a confirmed diagno-
sis of Marfan were reviewed at the Centre for Marfan syndrome at
the University of Florence, Careggi Hospital. The diagnosis of these
patients was clinically positive and corroborated by echocardiogram,
MRI, eye consultation and when in doubt, by genetic studies.
Twenty-one patients were interviewed in depth by a neurologist
(PH). Ninety (40%) of the patients were found to have headaches, of
these 75% were consistent with a migraine syndrome and the rest
were of tension-type, 75% had common migraine, and 25% suffered
from classic migraine with visual auras.
None had a TIA or stroke-like accompanying syndrome. The course
of headaches was essentially benign over the years with gradual
improvement in most patients. Mitral valve prolapse was present in
90% of Marfan patients. This high association may partly explain
the impressive frequency of migraine in this syndrome. Other fea-
tures affecting the Marfan patients, such as dural cysts of the sacral
spinal cord, visual impairment (dislocated lenses, high myopia, etc.),
and dissection of the aorta may also contribute to and\or aggravate
the headaches in these patients.
The presence of migraine in morphologically characteristic patients
should alert the neurologist and the headache specialist to proceed to
a complete neurovascular check-up, since an early diagnosis of this
condition may avert fatal complications, such as sudden dissection
of the aorta (fatal in 50% of the cases).
Genetic counselling is indicated in all patients.
SOME NEW FINDINGS IN THE PATENT FORAMEN OVALE
MIGRAINE SYNDROME
P. Hermes, G. Santoro
University of Florence, Careggi Hospital, San Lucca Cardiology
Clinic, Florence, Italy; e-mail: neuropfo@hotmail.com
This syndrome should be of great interest to neurologists since 20%
of the general population is affected with patent foramen ovale
(PFO) and 15% with migraine. An unknown number of this com-
bined group has a right-to-left cardiac shunt.
A significant percentage of this group has psychiatric disturbances,
general fatigue, lack of energy, and mild continuous headaches, in
addition to the well known cerebrovascular accident (CVA)-
migraine complications. The response of these symptoms to conven-
tional medical treatment or after PFO closure has not been
described.
The objective of this study was to review the response of migraine
and related symptoms in patients following placement of the
"Amplatzer" prosthesis, which closes the PFO and arrests the right-
to-left shunt.
Patients and methods Thirty-two patients underwent the tran-
scatheter endovenous "Amplatzer" procedure for closure of the PFO.
The age range was 17–70 years; mean age 40 years, and 14 were
females. Assessment of their post intervention condition was made
by direct interview and/or telephone follow-up.
The original reason for referral was TIA/CVA in 88%. Seventy-five
percent of the patients had headaches, 58% lack of energy and chron-
ic fatigue, and 48% psychiatric symptoms. All patients had a trans-
esophageal echocardiography (TEE) prior to prosthesis placement,
which showed a right-to-left shunt in most, after Valsalva procedure.
Results Length of follow-up was one month to five years and mean
follow-up was 26 months. There was improvement or disappearance
of headaches in 50% of the patients, and of psychiatric symptoms
in 36%. Fifty-five percent reported improvement in general fatigue
and well-being. Except for one patient none reported worsening of
symptoms. One-third did not experience any changes. There was no
recurrent CVA/TIA after the "Amplatzer" procedure, A subgroup of
5 patients reported "miraculous" improvement. Transient atrial fib-
rillation occurring during PFO closure responded to medication in
one and to cardioversion in two patients. About 65% of patients
were still taking medications after PFO closure mostly for related
conditions. The reason for improvement in headaches, psychiatric
symptoms, and decrease of fatigue is conjectural and includes con-
trol of hyperradrenalism and improvement in cerebral
ischemia/hypoxemia.
Conclusion PFO closure may join the therapeutic armamentarium
for management of severe migraine, with right-to-left shunt, with
additional benefits to the classical ones.
